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Abstract 
This thesis concerns gene 176R from camelpox virus (CMLV) that encodes a protein 
known as viral schlafen (v-slfn).  v-slfn has an N-terminal domain related to the p26 
protein from baculovirus and a C-terminal domain related to mammalian schlafen 
proteins.  A full length v-slfn is expressed by all sequenced orthopoxviruses except 
vaccinia virus (VACV) and variola virus.  The baculovirus p26 proteins are poorly 
characterised, with no known function.  In contrast, murine schlafen (m-slfn) proteins 
are upregulated in response to infection and the promoter for m-slfn2 has NF-κB and 
AP-1 binding sites.  The prototypic slfn, m-slfn1, halts cellular proliferation by 
inhibition of cyclin D1 expression in vitro and both m-slfn1 and m-slfn8 reduce 
thymocyte proliferation in vivo. 
v-slfn is a predominantly cytoplasmic protein of 57 kDa that is expressed both early 
and late during CMLV infection.  Expression of v-slfn reverses the growth arrest 
resulting from m-slfn1 expression, and this is a result of a reversal of the inhibition of 
cyclin D1 expression.  This effect can be seen following overexpression of various 
transcription factors that upregulate cyclin D1 expression. 
Recombinant VACV expressing enhanced levels of v-slfn replicated and spread at a 
comparable rate to control viruses in vitro, but was less virulent than controls in the 
intranasal model of infection in vivo.  A group of viruses based on VACV WR were 
constructed, which lack the gene fragments (B2R and B3R) corresponding to CMLV 
176R.  The undisrupted sequence for 176R was also re-inserted at this locus, 
resulting in a virus that expresses v-slfn from its natural promoter.  In vitro 
characterisation showed no differences in replication or spread when compared to 
controls. 
Thus, v-slfn is an orthologue of mammalian slfn proteins, and may exert its effect by 
reversing their inhibition of cellular proliferation. 
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CARD caspase recruitment domain 
CD cluster of differentiation antigen 
CD4+ CD4-positive/CD8-negative T lymphocyte 
CD8+ CD8-positive/CD4-negative T lymphocyte 
cDNA complementary DNA 
CEV cell-associated enveloped virus 
CLP committed lymphoid progenitor 
CMC carboxymethylcellulose 
CMLV Camelpox virus 
CMV cytomegalovirus 
COP Copenhagen 
CPE cytopathic effect 
CPXV Cowpox virus 
CRE cyclin AMP response element 
CREB CRE binding protein 
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CTL cytotoxic T lymphocyte 
CVA Chorioallantois virus Ankara 
DAI DNA-dependent activator of IFN-regulatory factors  
DAPI 4’,6’-diamidino-2-phenylindole 
DC dendritic cell 
DDX DEAD box protein 
DEAD Asp-Glu-Ala-Asp  
DEEM deep etch electron microscopy 
DMEM Dulbecco’s modified Eagle’s medium 
DN CD4/CD8 double-negative 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
DP CD4/CD8 double-positive 
DPXV Deerpox virus 
ds double-stranded 
DTT dithiothreitol 
E.coli Escherichia coli 
EBNA Epstein-Barr virus nuclear antigen 
EBV Epstein-Barr virus 
ECL enhanced chemiluminescence 
EcoGPT E. coli guanine xanthine phosphoribosyltransferase 
ECTV Ectromelia virus 
EDTA ethylene diamine tetraacetic acid 
EEV extracellular enveloped virus 
eGFP enhanced GFP 
eIF eukaryotic initiation factor 
EM electron microscopy 
ER endoplasmic reticulum 
ERK extracellular signal regulated kinase 
EST expressed sequence tag 
EtBr ethidium bromide 
EV extracellular virion 
FACS flow assisted cell sorting 
FBS foetal bovine serum 
FITC fluorescein isothiocyanate 
FPLC fast protein liquid chromatography 
FPV Fowlpox virus 
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GAG glycosaminoglycan 
GBLV Taterapox virus 
GFP green fluorescent protein 
GM-CSF granulocyte-macrophage colony-stimulating factor 
GMP guanosine monophosphate 
GTP guanosine triphosphate 
HA haemaglutinin 
HAT histone acetyltransferase 
HeLa Henrietta Lacks (uterine carcinoma) cell lines 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGPRT hypoxanthine guanine phosphoribosyltransferase 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
hpi hours post infection 
HRP horseradish peroxidase 
HSP heat shock protein 
HSPV Horsepox virus 
IEV intracellular enveloped virus 
IFN interferon 
Ig immunoglobulin 
IKK inhibitor of nuclear factor-κB kinase 
IL interleukin 
IMV intracellular immature virus 
IP immunoprecipitation 
IPTG b-D-thiogalactopyranoside 
IRAK IL-1 receptor associated kinase 
IRF IFN regulatory factor 
ITR inverted terminal repeat 
IV immature virion 
IκB inhibitor of NF-κB 
JAK Janus activated kinase 
JNK cJun N-terminal kinase 
Kan kanamycin 
kb kilobases 
KIR killer-cell immunoglobulin-like receptor 
LB Luria-Bertani broth 
LPS lipopolysaccharide 
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LRR leucine rich repeat 
luc luciferase 
mAb monoclonal antibody 
MAL MyD88 adaptor like 
MAPK mitogen activated protein kinase 
MDA5 melanoma-differentiation associated gene 5 
MEM minimal essential medium 
MHC major histocompatibility complex 
MKK MAPK kinase 
MOCV Molluscum contagiosum virus 
MOI multiplicity of infection 
MPA mycophenolic acid 
MPXV Monkeypox virus 
mRNA messenger RNA 
MTOC microtubule organising centre  
MV mature virion 
MVA modified vaccinia Ankara 
MyD88 myeloid differentiation factor 88 
MYXV Myxoma virus 
NALP nacht domain-, LRR-, and PYD-containing protein 
NF-κB nuclear factor κB 
NIH3T3 National Institutes of Health 3T3 murine fibroblast cell line 
NK natural killer 
NLR NOD-like receptor 
NO nitric oxide 
NOD nuclear oligomerization domain 
NOS NO synthase 
NP-40 nonidet-P 40 
OAS 2’-5’-oligoadenylate synthetase 
OD optical density 
OPV Orthopoxvirus 
ORF open reading frame 
ORFV Orf virus 
Pam3Cys tripalmitoyl-S-glycerylcysteine 
PAMP pattern-associated molecular pattern 
PBR Poxvirus Bioinformatics Resource 
PBS phosphate buffered saline 
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PCR polymerase chain reaction 
PEI polyethylinimine 
PFA paraformaldehyde 
PFU plaque forming unit 
pi post infection 
PKA protein kinase A 
PKR protein kinase R 
poly(i:c) polyinosinic-polycytidylic acid 
PRR pathogen recognition receptor 
RAW RAW264.7 murine macrophage cell line 
RCA regulator of complement activation 
REV reticuloendotheliosis virus 
RIG-I retinoic-acid-inducible protein I 
RIPA radio immunoprecipitation analysis buffer 
RK-13 rabbit kidney-13 cells  
RLH RIG-like helicase 
RLU relative light units 
RNA ribonucleic acid 
RNase ribonuclease 
rpm rotations per minute 
RPMI Royal Park Memorial Institute medium 
RPXV Rabbitpox virus 
RSV Respiratory cyncitial virus 
RT room temperature 
SARM sterile α and HEAT-armadillo motif protein 
SARS severe acute respiratory syndrome 
SD standard deviation 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
sE/L synthetic early/late promoter 
Serpin serine protease inhibitor 
SFV Shope fibroma virus 
slfn schlafen 
SOC super optimal catabolite 
SP single-positive 
ss single-stranded 
STAT signal transducers and activators of transcription 
SWPV Swinepox virus 
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TAB TAK-binding protein 
TAE Tris Acetate EDTA 
TAK TNF-associated kinase 
TANK TRAF-associated NF-κB activator 
TANV Tanapox virus 
TBK  TRAF-associated NF-κB activator binding kinase 
TCEP tris(2-carboxyethyl)phosphine 
TCF T cell factor 
TE Tris-EDTA 
TEMED N,N,N,N-tetramethylethylenediamine 
TH T helper 
TIR Toll/IL-1 receptor 
TK-143 thymidine kinase-deficient osteosarcoma cell line strain 143  
TLR Toll-like receptor 
TNF tumour necrosis factor 
TRAF TNF receptor associated factor 
TRAM TRIF-related adaptor molecule 
TRIF TIR-domain containing adaptor inducing IFN-β 
TRITC tetramethyl rhodamine isothiocyanate 
TSA trichostatin A 
UV ultraviolet 
v/v volume/volume 
VACV Vaccinia virus 
VARV Variola virus 
VCP virus complement control protein 
VETF viral early transcription factors 
VGF viral growth factor 
VITF viral intermediate transcription factor 
vXRev revertant virus with re-insertion of ORF X 
v∆X deletion virus lacking ORF X 
w/v weight/volume  
WHO World Health Organisation 
WR Western Reserve 
WT wildtype 
WV wrapped virion 
XGPRT xanthine guanine phosphoribosyltransferase 
YLDV Yaba-like disease virus 
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1 Chapter 1
Introduction 
1.1 An introduction to orthopoxviruses 
Poxviruses are a family of large double stranded (ds)DNA viruses that replicate in the 
cytoplasm of infected cells (Moss, 2007).  The family Poxviridae is subdivided into 
two subfamilies, Chordopoxvirinae and Entomopoxvirinae, which infect vertebrates 
and arthropods, respectively.  Chordopoxvirinae are sub-divided into eight genera: 
Avipoxvirus, Capripoxvirus, Leporipoxvirus, Molluscipoxvirus, Orthopoxvirus (OPV), 
Parapoxvirus, Suipoxvirus and Yatapoxvirus. 
Variola virus (VARV) and molluscum contagiosum virus (MOCV) are obligate human 
pathogens, meaning that they only infect humans, but other poxviruses can infect 
humans as zoonoses (McFadden, 2005).  A noteable example of this was a small 
outbreak of monkeypox virus (MPXV) in the mid-western United States in 2003 (Di 
Giulio & Eckburg, 2004; Reed et al., 2004).  The virus had been imported from West 
Africa in rodents and had infected prairie dogs before being passed to 37 humans.  
Other poxviruses that can infect humans include cowpox virus (CPXV), orf virus 
(ORFV) (a parapoxvirus), and tanapoxvirus (TANV) and Yaba-like disease virus 
(YLDV) (yatapoxviruses) (McFadden, 2005). 
1.1.1 Variola virus 
The most notorious poxvirus is VARV, an OPV and the causative agent of smallpox.  
The first recorded use of the term variola was in 570 AD by Bishop Marius of 
Avenches (near Lausanne, Switzerland).  It comes from either the Latin term varius, 
meaning stained, or varus, meaning mark on the skin.  The term smallpox (or small 
pockes, pocke meaning sac) was first used in England in the 15th century, the prefix 
“small” being used to differentiate it from great pockes, which is now known as 
syphilis (Barquet & Domingo, 1997).  To date it is the only human pathogen to be 
eradicated through vaccination.  In fact, the term vaccination was coined from the 
practice of inoculating people with fluid from pustules of CPXV-infected milkmaids, as 
the Latin for cow is vacca.  Edward Jenner was the first to publish data on the 
efficacy of this method based on observations that 13 people who had contracted 
cowpox were resistant to challenge with VARV, and based on a vaccination and 
subsequent VARV challenge of a child, James Phipps (Baxby, 1996; Jenner, 1798).  
Vaccination of this sort was carried out as early as early as 1774 (Barquet & 
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Domingo, 1997), and was a modification of variolation, a similar method using fluid or 
ground scabs from smallpox pustules.  Variolation was practiced as early as the 11th 
century in China (Needham, 1980).  Variolation was effective at immunising people 
against natural infection, but the process was dangerous: 1 to 3 % of variolated 
individuals died from smallpox, caused a new epidemic, or became susceptible to 
secondary infections such as tuberculosis and syphilis (Fenner et al., 1988). 
1.1.2 Vaccinia virus 
In 1967 the World Health Organisation (WHO) intensified their global smallpox 
eradication plan, for which a resolution had been passed in 1959 following a 
recommendation by the Soviet Union (Fenner et al., 1988).  At this point, the disease 
was endemic in 31 countries and caused 2 million deaths per year.  The last natural 
occurrence of VARV infection was in 1977 and the virus was declared eradicated by 
the WHO in May 1980 (Fenner, 1980; 1993; Fenner et al., 1988).  The eradication 
campaign used live VACV (Henderson, 1976), which by this point had been identified 
as a distinct virus to CPXV (Downie, 1939).  The publication of the horsepox virus 
(HSPV) genome suggests that VACV is intermediate between HSPV and CPXV 
(Tulman et al., 2006).  Further attention will be given in later sections to the many 
studies over the last few decades on VACV (sections 1.1.7 to 1.1.10). 
1.1.3 Camelpox virus 
The discovery of CMLV in 1972 caused concern because it caused a disease in 
camels similar to smallpox in man, and CMLV and VARV share some biological 
properties (Baxby, 1972).  Genome sequencing later confirmed the close relationship 
of these viruses, and CMLV and VARV were shown to be more closely related to 
each other than any other virus (Gubser & Smith, 2002).  However, CMLV does not 
cause disease in man (Jezek et al., 1983).  CMLV strain CMS has 206 predicted 
open reading frames (ORFs) (Gubser & Smith, 2002) and CMLV strain M96 has 211 
predicted ORFs (Afonso et al., 2002).  Bioinformatic analysis of the CMLV genome 
identified several potential novel immunomodulators encoded within the variable 
regions of the genome (Afonso et al., 2002; Gubser & Smith, 2002). One of these, 
CMLV CMS protein 176, is the subject of this study. 
1.1.4 Continuing interest in poxviruses 
Despite the eradication of smallpox, poxviruses are still studied intensively.  There 
are several reasons for this, the most important being the use of VACV and other 
poxviruses as a tool for furthering our knowledge of host-pathogen interactions, the 
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response of host immune systems to infection and anti-viral immunity.  There is also 
a strong focus on developing VACV as a vaccine vector to vaccinate against other 
pathogens (section 1.1.7.1) or as an oncolytic virus (section 1.1.7.2).  There is also 
the risk that VARV or another poxvirus will be a threat to humans in the future, either 
through bioterrorist attacks (Fenner et al., 1988; Mayers, 1999), release of VARV 
from bodies frozen in the permafrost as global temperatures increase (Ewart, 1983), 
or outbreak of adapted zoonotic virus in humans (Fenner et al., 1988).  For this 
reason, different strains of VACV, recombinant VACVs and attenuated VACVs are 
still being studied as vaccines against VARV to improve their safety whilst 
maintaining their efficacy.  In response to the terrorist attacks of September 11th 2001 
and the potential threat of a bioterrorist attack, the US Department of Defense (DoD) 
vaccinated 753,226 military personnel and civilian DoD workers between December 
2002 and December 2004 (Grabenstein & Winkenwerder, 2003; Lewis et al., 2006). 
1.1.5 The genomic structure of OPVs 
The genome of poxviruses comprises linear dsDNA, ranging in size from 134 kilo 
base pairs (kbp) in parapoxviruses to over 300 kbp in some avipoxviruses.  All 
sequenced poxviruses have oppositely orientated repeated sequences at either end 
of the genome, known as inverted terminal repeats (ITRs) (Baroudy et al., 1982; 
Goebel et al., 1990), with covalently closed incompletely base-paired hairpin termini 
that are important for DNA replication (DeLange et al., 1986). 
All poxviruses have tandem repeats of varying length (Wittek & Moss, 1980) within 
the ITRs.  These repeats in VACV strain Western Reserve (WR) begin 87 bp from the 
proximal end of the terminal loop, and comprise 13 tandem 70-bp repeats followed by 
a spacer region of 325 bp and then a further 18 tandem repeats (Baroudy et al., 
1982).  In addition to these sequences there is a highly conserved region of less than 
100 bp within the ITR, which is required for the resolution of concatemeric genomes 
into single copies during DNA replication (DeLange & McFadden, 1987; Merchlinsky, 
1990). 
ORFs are present on both strands of the genome (i.e. running in both directions) and 
are for the most part non-overlapping.  The OPV genome can be loosely divided 
between a highly conserved central region and more variable terminal regions 
(Wittek, 1982).  The ITRs are genetically the most unstable regions of the genome, 
with a higher frequency of deletions, duplications, inversions and intra-genomic 
recombination (Kriajevska et al., 1994; Shchelkunov & Totmenin, 1995). 
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Forty nine ORFs are conserved in all poxviruses, whereas chordopoxviruses have 
about 90 conserved ORFs (Gubser et al., 2004; Upton et al., 2003).  The 90 
conserved ORFs of chordopoxviruses can therefore be considered as the minimal 
poxvirus genome (Gubser et al., 2004; Upton et al., 2003).  The ORFs in this region 
code for proteins involved in RNA and DNA synthesis, protein processing, virion 
assembly and structural proteins (Gubser et al., 2004).  The genes are orientated in 
both directions in this region (Gubser et al., 2004) and there is a higher concentration 
of ORFs expressed late during infection compared to the rest of the genome 
(Assarsson et al., 2008; Rubins et al., 2008). 
However, these 90 conserved genes would not be sufficient for effective replication 
and spread in vivo, because they do not include the immunomodulatory and host 
range proteins expressed from the genes present near the termini of the genome 
(Gubser et al., 2004).  These genes tend to be transcribed towards the terminus 
whereas in the central region of the virus there is a mix of left- and right-transcribed 
genes. 
1.1.6 Annotation of poxvirus genes and proteins 
The first poxvirus genome sequence was from VACV strain Copenhagen (Goebel et 
al., 1990; Johnson et al., 1993) and genes were named according to the HindIII 
restriction fragment in which they reside.  Genes are numbered from left to right 
followed by L or R to indicate the direction of transcription (Rosel et al., 1986).  An 
exception was the left-most fragment (HindIII C) where genes were numbered from 
right to left. 
Although complete genome sequences from poxviruses sequenced more recently 
such as CMLV (Gubser et al., 2002) have numbered genes from left to right across 
the entire genome, the original nomenclature from VACV Cop remains a valuable 
reference for poxvirologists. 
Poxviral proteins are named according to the gene name but the L or R is omitted.  
The proteins coded for by the K7R and F1L genes are therefore referred to as K7 and 
F1, respectively.  Some proteins are commonly referred to by names based on 
function, such as thymidine kinase (TK) (Weir & Moss, 1983) and viral intermediate 
transcription factor (VITF 1) (Rosales et al., 1994a; Rosales et al., 1994b), coded for 
by VACV Cop J2R and E4L, respectively. 
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1.1.7 Production and uses of recombinant poxviruses 
Much of the knowledge about poxvirus protein function and details of the virus life 
cycle stems from work with VACV, and this has been aided by the ability to easily 
insert, delete or mutate genes and construct recombinant VACVs.  There are several 
methods for construction of recombinant viruses.  These include deletion of specific 
genes of interest (Falkner & Moss, 1988; 1990), expression of exogenous genes 
(Mackett et al., 1982) and expression of essential genes under inducible promoters to 
create conditional lethal mutants (Rodriguez & Smith, 1990).  Expression of 
exogenous genes from the TK locus and deletion of regions of poxvirus genomic 
DNA will be discussed in more detail in sections 6.2.1 and 6.4, respectively. 
Manipulation of the viral genome is usually accomplished by homologous 
recombination within infected cells.  After virus infection, linear or circular DNA 
fragments are transfected into the cells and these recombine with homologous 
sequences in the virus genome.  Recombinant viruses can also be made using 
bacterial artificial chromosomes (BACs) using another poxvirus as a rescue virus 
(Cottingham et al., 2008; Domi & Moss, 2002). 
1.1.7.1 Poxvirus-based vaccines against other pathogens 
The use of viruses as vaccine vectors has been studied since 1983 (Panicali et al., 
1983; Smith et al., 1983c; Smith et al., 1983d).  The use of recombinant viruses 
expressing exogenous proteins can result in immunity against a pathogen with no risk 
of infection from the target pathogen.  In addition to this, viruses act as natural 
adjuvants as they have the attributes recognised by the innate immune system.  The 
use of VACV as a vector for immunisation against hepatitis B virus (Smith et al., 
1983c) and influenza virus (Panicali et al., 1983; Smith et al., 1983d) were the first 
reports on the efficacy of this approach.  
VACV has been of particular interest as a vector because of its ability to 
accommodate large amounts of exogenous DNA (Smith & Moss, 1983), to express 
multiple foreign antigens simultaneously (Perkus et al., 1985), its broad host range, 
and ability to express high levels of protein (Moss, 2007).  One example of the 
successful application of VACV as a vaccine is against rabies in Western Europe, 
which caused a drastic reduction in the rabies incidence in foxes when delivered 
orally via inoculated bait (Brochier & Pastoret, 1993; Brochier et al., 1990). 
Other examples of the use of poxviruses as vaccine vectors include fowlpox virus 
(FPV)-based vaccines for chickens against highly virulent H5N1 and H7N1 strains of 
influenza virus (Qiao et al., 2003), VACV-based vaccine candidates against influenza 
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virus (Bender et al., 1996; Meitin et al., 1994), respiratory syncitial virus (RSV) 
(Kanesaki et al., 1991) and HIV (Harari et al., 2008; Huang et al., 2009; Peters et al., 
2007).  Notably, an MVA-based severe acute respiratory syndrome (SARS) vaccine 
candidate was developed and tested in vivo (Bisht et al., 2004) within months of the 
initial identification of this novel virus (Ksiazek et al., 2003). 
One problem with the use of viruses as vaccine vectors is the phenomenon known as 
‘original antigenic sin’, which was first described for influenza virus infections 
(Fazekas de St & Webster, 1966a; b).  Secondary infection with a similar but 
antigenically distinct virus results in an asymmetric pattern of adaptive immunity, with 
the vast majority of the protective antibodies and cytotoxic T lymphocytes directed 
against epitopes from the primary infection (Klenerman & Zinkernagel, 1998).  In the 
case of an individual who had been vaccinated previously against smallpox using 
VACV, the majority of the adaptive immunity against a recombinant VACV vaccine 
would be against VACV rather than the exogenous antigen (Harrer et al., 2005).  
Similarly, more than one attempt to use VACV as a vaccine vector using different 
exogenous antigens may be less successful at each attempt. 
1.1.7.2 Viral oncotherapy 
Viral oncotherapy is the use of viruses to selectively target cancerous cells. This can 
either be through exploitation of the lytic ability of viruses (oncolytic virotherapy) or 
through exogenous expression of proteins that stimulate anti-cancer immunity. 
Several approaches have been taken to make VACV more oncolytic (Kirn & Thorne, 
2009).  One method involves combined insertion of granulocyte-macrophage colony 
stimulating factor (GM-CSF), which is a potent stimulator of cell-mediated (Dranoff, 
2002; 2003) and virus-mediated (Mastrangelo et al., 1999) anti-tumour immunity.  A 
second is the deletion of either the VACV TK gene (Kim et al., 2006) or VACV growth 
factor (VGF) gene (Kirn & Thorne, 2009; Puhlmann et al., 2000) or both together 
(McCart et al., 2001).  TK-negative VACVs replicate more efficiently in tumours (Naik 
et al., 2006; Puhlmann et al., 2000) because cancerous cells often constitutively 
express the normally transient S-phase cellular TK (Hengstschlager et al., 1994) 
whereas resting non-cancerous cells do not, and expression of TK enhances pools of 
pre-cursors for DNA synthesis that aid virus replication.  As VGF normally acts as a 
mitogen to prime surrounding resting cells for VACV infection, deletion of VGF 
reduces the replication of VACV in non cancerous cells but does not affect replication 
in dividing cancerous cells, and it also decreases the virulence of the virus (Buller et 
al., 1988a).  Expression from VACV of a single-chain antibody against a host growth 
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factor, vascular endothelial growth factor (VEGF), also increased the efficacy of the 
virus as an oncolytic agent (Frentzen et al., 2009). 
Another approach was to generate a VACV strain that expresses p53 from the TK 
locus (Blaszczyk-Thurin et al., 2002; Fodor et al., 2005; Timiryasova et al., 1999), 
resulting in a tumour-targeted virus (Naik et al., 2006; Puhlmann et al., 2000) that 
causes a re-instatement of p53-mediated apoptosis of previously p53-negative cells. 
VACV has also been used to increase immunity to heterogeneously expressed 
antigens found naturally on specific tissues.  These include prostate-specific antigen 
(PSA), which is expressed on all prostate tissues including cancerous cells (Eder et 
al., 2000; Hodge et al., 1995), or carcinoembryonic antigen (CEA), which is 
expressed in 90 % of gastrointestinal carcinomas (Kantor et al., 1992). 
1.1.8 Life cycle of VACV 
1.1.8.1 Early gene expression 
Once the virus core has penetrated the cytosol, transcription of VACV genes 
commences using the transcriptional enzymes that are packaged within the virus 
core (Moss, 1990).  Genes are grouped into three classes based on the time of 
expression; early, intermediate and late (Broyles, 2003).  Recently another group of 
genes has been identified, the immediate-early genes, based on the kinetics of 
expression following infection (Assarsson et al., 2008) but genetic evidence for the 
subdivision of the early class of genes is lacking. 
Messenger RNA (mRNA) is sythesised within minutes of the virion entering the cell 
(Shuman & Moss, 1988).  This is made possible by the viral early transcription factors 
contained within the virus core (Kates & McAuslan, 1967) and it leaves the viral core 
through pores in the surface (Kates & McAuslan, 1967; Munyon et al., 1967). 
1.1.8.1.1 Regulation of early transcription 
Initiation of transcription of early genes is controlled by an A-T rich region from -13 to 
-27, with the consensus sequence AAAAAATGAAAAAA/TA (Davison & Moss, 1989a) 
and transcription initiates at a purine.  This promoter sequence is conserved amongst 
poxviruses, explaining “nongenetic reactivation”, in which a heat inactivated poxvirus 
is replicated and forms infectious virions by using the transcriptional machinery of a 
live “helper” poxvirus (Fenner & Woodroofe, 1960).  This is also the basis of the 
reactivation of bacterial artificial chromosome (BAC) containing a VACV genome 
using FPV as the live helper virus (Cottingham et al., 2008; Domi & Moss, 2002). 
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Early gene transcription is terminated 20 to 50 bp downstream of the sequence 
TTTTTNT (where N represents any nucleotide) (Piacente et al., 2008; Yuen & Moss, 
1986; 1987), which is mediated by the UUUUUNU sequence in the nascent RNA 
(Shuman & Moss, 1989).  This termination sequence is not 100 % efficient, and may 
be affected by RNA secondary structure (Earl et al., 1990; Lee-Chen et al., 1988; Luo 
& Shuman, 1991). 
1.1.8.2 DNA replication 
Before VACV DNA replication can occur the core must be uncoated (Zaslavsky, 
1985), and this can be measured by the susceptibility of viral DNA to DNase 
treatment and can be blocked by UV treatment of the virus (Joklik, 1964).  DNA 
replication and assembly of progeny virions occurs in areas of the cytoplasm called 
virus factories (Cairns, 1960; Dales & Siminovitch, 1961).  Each virus factory 
originates from a single virion (Cairns, 1960; Katsafanas & Moss, 2007) and 
transcription and translation occur within the factories (Katsafanas & Moss, 2007).  
Small cavities, or tunnels, are apparent in the factories and contain viral mRNA, 
ribosomes and host translation initiation factors (Katsafanas & Moss, 2007).  Early 
virus factories are surrounded by endoplasmic reticulum (ER)-derived membranes, 
resembling small cytoplasmic nuclei, and are closely associated with mitochondria. At 
later stages of infection as the mature virions become detectable, the ER membrane 
disperses (Tolonen et al., 2001). 
The enzymes required for DNA replication are encoded by early genes.  Each cell 
can produce approximately 10,000 copies of the genome (Joklik & Becker, 1964; 
Salzman, 1960). Replication of genomic DNA initiates after a nick has been 
introduced near the end of the genome (Fig. 1-1a) (Pogo, 1980; Pogo et al., 1981; 
Pogo & O'Shea, 1978).  This allows the DNA replication machinery access to single- 
stranded DNA as the genomic DNA opens up from the nick (Fig. 1-1b).  This is 
known as the “self-priming model”.  The genome replicates to the terminus, and the 
newly-formed DNA folds back on itself (Fig. 1-1c).  This allows the DNA replication 
machinery to continue until the viral genome is replicated in its entirety (Fig. 1-1d).  
Transient intermediate concatemeric DNA is thus formed (Baroudy et al., 1983; 
DeLange, 1989; Moyer & Graves, 1981), and is subsequently resolved into single 
copy genomic DNA by a late gene product (Fig. 1-1e) (Merchlinsky & Moss, 1989).  
The requirement for late gene expression before concatemers resolve distinguishes 
replication and resolution as different stages. 
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Fig. 1-1.  Poxvirus genomic DNA replication. 
Schematic representation of the self-priming model for replication of VACV DNA.  Parental 
and daughter genomes are shown in blue and red, respectively.  Direction of replication is 
indicated by an arrow head on the replicating DNA strand.  Complementary DNA strands are 
represented by upper and lower case letters.  Adapted from (Moss et al., 1983).  
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1.1.8.3 Intermediate and late gene expression 
For transcription of intermediate and late genes to occur the template DNA must be 
‘naked’ rather than contained within the virion core (Baldick & Moss, 1993).  DNA 
replication results in ‘naked’ DNA within the viral factories, allowing intermediate and 
late transcription factors, which are under the control of early promoters and are 
therefore produced early in infection, access to the viral promoters and ORFs (Keck 
et al., 1990).    Transfected genes under the control of an intermediate promoter can 
be transcribed in the absence of DNA replication (Vos & Stunnenberg, 1988). 
Intermediate gene transcription is initiated from within the AAA sequence in the 
sequence TAAA, and is regulated by a core element 10 or 11 bp upstream with the 
consensus sequence AAAA/TAA (in the A1L, A2L, and G8R promoters).  There are 
also additional promoter-dependent T residues upstream (Baldick et al., 1992).  No 
transcriptional termination sequence is known for intermediate transcripts, and 
transcription is not terminated at the TTTTTNT early termination sequence (Baldick & 
Moss, 1993). 
As with early and intermediate promoters, late promoters consist of a core and an 
initiation site.  The initiation site for late genes is TAAAT, and any mutation of this 
regions causes a drastic reduction in transcription (Davison & Moss, 1989b).  The 
core region is A-T rich, but there is some variability in core sequence between 
promoters.  Replacement of the 25 nucleotides upstream with T residues increased 
the activity of one promoter almost 50 fold (Davison & Moss, 1989b).  As with 
intermediate genes, there is no known termination sequence for late transcripts and 
late gene transcription is not terminated at the TTTTTNT early termination sequence 
(Baldick & Moss, 1993). 
1.1.8.4 Homologous recombination 
Recombination can occur in poxvirus-infected cells between homologous regions of 
DNA.  This can happen between two different viral genomes (Fenner & Comben, 
1958) or between a viral genome and transfected DNA.  Poxvirus DNA replication 
and recombination are linked, hence inhibitors of DNA replication suppress 
recombination (Colinas et al., 1990).  Recombination has occurred naturally between 
two leporipoxviruses, Shope fibroma virus (SFV), which causes benign tumours in 
rabbits, and myxoma virus (MYXV), the causative agent of myxomatosis.  The 
resultant virus, called malignant rabbit virus (MRV), is a tumorigenic poxvirus that 
infects rabbits (Block et al., 1985) and contains regions in which the MYXV genomic 
DNA has been replaced with the corresponding regions of the SFV genome. 
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Recombination has been the primary tool used to generate recombinant poxviruses, 
owing to the high frequency elimination of homologous regions of DNA (Ball, 1987).  
The regions flanking the area to be genetically manipulated are cloned into a transfer 
vector, and can either be transfected in circular or linearised form.  For generation of 
clean deletion viruses, the flanking regions are joined together in a transfer vector 
expressing a selection marker (Fig. 1-2a).  The target region of the genome can also 
be replaced by exogenous DNA to create a “dirty” knockout (Fig. 1-2b).  For 
generation of knock-in (or insertion) viruses, the exogenous DNA is inserted between 
the flanks of the target region in a transfer vector.  Selection of recombinant viruses 
can either use genetic selection, for example selection of TK-negative viruses when 
inserting into the TK locus, or the strategy may require use of a selection marker 
(either within the flanks or at a distal site, Fig. 1-2c).  These strategies are discussed 
in more detail in sections 6.2.1 and 6.4. 
 
Fig. 1-2.  Plasmids used for generation of recombinant poxviruses. 
Schematic representation of (a) the plasmid used for transient dominant selection, (b) the 
plasmid used for replacement of the target area of the genome to create a dirty knockout, (c) 
the plasmid used for inserting exogenous DNA into genomic DNA.  F1, left flanking region; F2, 
right flanking region; P, promoter sequence for transcription of exongenous DNA (if 
necessary).  
1.1.8.5 Poxvirus virion nomenclature 
There are two systems of nomenclature in use for poxvirus virions.  The original 
system, which is still used by many laboratories, refers to intracellular mature virus 
(IMV), intracellular enveloped virus (IEV), extracellular enveloped virus (EEV) and 
cell-associated enveloped virus (CEV).  The alternative system refers to IMV as 
mature virion (MV), IEV as wrapped virion (WV) and both EEV and CEV as 
extracellular virion (EV).  The first of these two systems will be used throughout this 
thesis. 
1.1.8.6 Morphogenesis 
The first visible evidence of new virion synthesis is the formation of rigid cupules 
(known as crescents) with a single lipid bilayer on the inside, which is synthesised de 
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novo (Dales & Mosbach, 1968; Dales & Pogo, 1981), and regular projections or 
spicules on the outside composed of the D13 protein (Dales & Mosbach, 1968; Risco 
et al., 2002) (Fig. 1-3a). However, deep etch electron microscopy (DEEM) showed 
that the outer layer is in fact a confluent honeycomb lattice rather than a 
discontinuous layer of spikes (Heuser, 2005; Hung et al., 1980).  Crescents continue 
to grow until they form spheres called immature virions (IV) (Ericsson et al., 1995) 
(Fig. 1-3b).  Viral DNA and transcriptional enzymes are inserted into the IV before it 
seals (Cassetti et al., 1998). 
The maturation from IV to IMV results in morphological and functional changes.  The 
loss of the structural D13 protein occurs during the maturation process (Heuser, 
2005; Sodeik et al., 1994) (Fig. 1-3c) and the core proteins A3, A10 and L4 are 
cleaved, most probably by the product of the I7 gene (Kane & Shuman, 1993).  
IMV particles may remain in the cytoplasm until they are released following cell lysis, 
or they may move on microtubules to near the microtubule organising centre (MTOC) 
(Sanderson et al., 2000; Ward, 2005).  Here they are wrapped in 2 more membranes 
to form the IEV, which is surrounded by three membranes (Fig. 1-3d).  Most virions 
produced early in infection are wrapped to form IEV, whereas later in infection most 
virions remain as IMV (Ulaeto et al., 1996).  The extra membrane is derived from 
early endosomes (Tooze et al., 1993) or the trans-Golgi network (Schmelz et al., 
1994). 
The presence of cellular organelles, coupled with protein density of up to 300 mg/ml 
(which includes cytoskeleton) makes passive diffusion of anything over ~500 kDa 
very slow (Luby-Phelps, 2000).  Intracellular virion movement is faster than this (0.34 
µm/s (Ward & Moss, 2001b)).  VACV particles are actively shuttled in the cell on 
microtubules through their interaction with the molecular motor kinesin via the F12 
and A36 proteins (Herrero-Martinez et al., 2005; Hollinshead et al., 2001; Rietdorf et 
al., 2001; van Eijl et al., 2002; Ward & Moss, 2001a; 2004). 
Once the IEV virions reach the cell periphery, the outer membrane fuses with the 
plasma membrane exposing a two-membraned virion to the extracellular environment 
(named CEV if they remain attached to the cell surface or EEV if they do not) (Fig. 
1-3e).  EEV particles contribute to longer distance virus spread within the host (Moss, 
2007).  CEV can be propelled some distance away from the main cell body by actin 
tails formed from the surface of the infected cell (Hiller et al., 1979) (Fig. 1-3f). 
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Fig. 1-3.  VACV morphogenesis. 
Schematic diagram showing VACV morphogenesis.  (a) De novo formation of single-lipid 
bilayer cupules, (b) formation of IV from cupules, (c) maturation of IV to IMV, (d) wrapping of 
IMV to generate IEV particles, (e) egress of virions from the cell through fusion of the outer 
viral membrane with the cellular plasma membrane, (f) formation of actin tails from the surface 
of the infected cell.  Adapted from (Roberts & Smith, 2008). 
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1.1.9 Virus dissemination in cell culture 
In cell culture extracellular virions can spread to other cells either as CEV projected 
on actin tails or as free EEV.  CEV are the principal virions involved in plaque 
formation in both liquid and semi-solid overlays.  The use of actin tails to project CEV 
towards other cells may be a method through which poxviruses are spread locally in 
vivo (Smith et al., 2003).  In addition, poxvirus-infected cells have increased motility 
(Sanderson et al., 1998), which may lead to an increase in virus spread through 
direct cell to cell contact.   
1.1.10 The immune response to poxvirus infection 
Viruses and their hosts have adapted extensively over millennia to cope with 
evolutionary pressure put on them.  The ability of poxviruses to incorporate large 
amounts of exogenous DNA into their genomes (section 1.1.8.4) has resulted in 
expression of proteins specifically aimed at controlling aspects of the immune 
response. 
1.1.10.1 Innate immune system recognition of poxviruses: pattern 
recognition receptors 
Pattern recognition receptors (PRRs), both intracellular and membrane-associated 
extracellular forms, are an early component of the innate immunity that are essential 
for effective function of both the innate and the adaptive immune responses.  They 
are activated by signature elements found in invading pathogens, but not in 
uninfected hosts, known as pattern-associated molecular patterns (PAMPs). 
1.1.10.1.1 Cell surface PRRs – the Toll-like receptors 
The cell surface receptors that sense extracellular or endocytosed PAMPs form part 
of a large family known as the Toll-like receptors (TLR), based on their similarity to 
Drosophila melanogaster Toll protein (Medzhitov et al., 1997).  The various TLRs 
form dimers, either homo- or hetero-dimers, and the resulting combination of 
extracellular leucine-rich repeats (LRRs) sense different PAMPs (Ozinsky et al., 
2000).  The first step in the intracellular signalling pathway downstream of TLR ligand 
binding is via recruitment of different combinations of five adaptor proteins, MyD88, 
TRIF, Mal, TRAM and SARM, which contain TIR domains.  Broadly speaking, the two 
main consequences of TLR stimulation are activation of the MyD88-dependent or the 
MyD88-independent pathways.  TLR4 directly activates both pathways via two 
different adaptor proteins (O'Neill, 2002). 
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Live or UV-inactivated VACV can stimulate cells to produce the pro-inflammatory 
cytokines IL-6, IL-1 and IL-12 through stimulation of TLRs (Zhu et al., 2007).  Pro-
inflammatory cytokine induction occurs in cells derived from TRIF-knockout mice, but 
not in cells derived from MyD88-knockout mice, suggesting that the MyD88-
dependent pathway is involved.  This is mediated by stimulation of TLR2, and TLR2-
knockout mice elicit a greatly reduced innate and adaptive immune response in 
response to VACV challenge (Zhu et al., 2007). 
In contrast to the phenotype of TLR2-knockout mice, TLR3-knockout mice infected 
intranasally with VACV showed reduced virus replication at the primary site of 
infection, diminished virus spread to secondary sites, decreased signs of illness and 
improved survival rates (Hutchens et al., 2008a).  This seems counter-intuitive based 
on the fact that poxviruses have developed mechanisms of evading TLR-mediated 
immunity (Hutchens et al., 2008a).  However, the majority of the TLR-evasion 
strategies are targeted at NF-κB rather than IRF3 activation.  TLR3 expression has a 
detrimental effect on the outcome of other virus infections (Le Goffic et al., 2006; 
Wang et al., 2004), and it was suggested that this is through recruitment of immune 
effector cells and the release of pro-inflammatory cytokines (Hutchens et al., 2008a). 
Interestingly, mice lacking TRIF, the only adaptor molecule known to be involved in 
transducing the signal from TLR3, are more susceptible to VACV infection (Hutchens 
et al., 2008b).  The only other TLR to use TRIF as an adaptor molecule is TLR4, 
which also signals through MyD88.  Mice lacking TLR4 are more susceptible to 
VACV infection, the virus spreads more rapidly and there is a higher rate of mortality 
in VACV-infected mice (Hutchens et al., 2008b).  This could be a result of activation 
of the MyD88-dependent pathway by TLR4, which is important for VACV clearance 
(Zhu et al., 2007). 
TLR9 is also important for the detection and clearance of some poxviruses, including 
most strains of VACV and ECTV, but not for the detection of the attenuated VACV 
MVA (Samuelsson et al., 2008).  Dendritic cells (DCs) were not activated by ECTV in 
vitro in the absence of TLR9, and TLR9 knockout mice were more susceptible to 
ECTV infection (Samuelsson et al., 2008). 
1.1.10.1.2 Poxvirus defences against TLRs 
The importance of TLR signalling in the immune response against poxvirus infection 
is underscored by the increasing numbers of TLR signalling regulators being 
discovered.  The first of these, A46, was discovered through its sequence similarity  
 
Chapter 1 - Introduction 
37 
 
 
 
Fig. 1-4.  Proteins encoded by VACV for evasion of TLR-mediated responses. 
Schematic representatation of each of the signalling pathways activated by TLRs.  Signalling 
pathways are indicated by black arrows and the inhibitory effect of VACV proteins is indicated 
by red arrows. 
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with TIR domains of TLRs and their adaptors (Bowie et al., 2000).  A46 and a closely 
related protein, A52, block NF-κB activation induced by both IL-1 receptor and TLRs 
(Fig. 1-4) (Bowie et al., 2000).  However, they are non-redundant in the evasion of 
TLR responses as they act at different levels in the TLR signalling pathway (Fig. 1-4). 
N1 was initially characterised as an extracellular (Kotwal et al., 1989) and later as an 
intracellular (Bartlett et al., 2002) virulence factor, and was later suggested to be 
involved in modulation of TLR signalling (DiPerna et al., 2004).  Further studies 
revealed that N1 did not affect NF-κB activation in infected cells, as compared to cells 
infected with N1 knockout virus, and the important function of the protein is more 
likely to be as an anti-apoptotic protein (Cooray et al., 2007).  N1 has a Bcl-2-like 
structure (Cooray et al., 2007), which is similar to that of B14 and A52 (Graham et al., 
2008).  B14 is also an intracellular virulence factor (Chen et al., 2006), and it inhibits 
NF-κB activation by binding to and preventing phosphorylation of IKKβ (Fig. 1-4) 
(Chen et al., 2008).  Other poxvirus proteins involved in regulation of MyD88-
dependent TLR signalling include K1 (Shisler & Jin, 2004) and M2 (Hinthong et al., 
2008) (Fig. 1-4). 
While most poxvirus regulators of TLR signalling are directed at the MyD88-
dependent pathway, K7 targets the activation of IRF3 through the MyD88-
independent pathway via an interaction with DDX3, which itself can associate with 
IKKε (Fig. 1-4) (Schroder et al., 2008).  Interestingly, K7 has structural similarity to the 
Bcl-2-like N1 and B14 (Kalverda et al., 2009). 
1.1.10.2 Complement 
Complement is a component of the innate immune system, involving a binding 
cascade of specific protein complexes to the surface of invading pathogens or cellular 
debris, resulting in phagocyte and granulocyte recruitment, opsonisation and 
subsequent phagocytosis, and membrane rupture (Roozendaal & Carroll, 2006).  IMV 
is susceptible to complement, however, EEV is not (Vanderplasschen et al., 1998).  
Wrapping of the IMV to create IEV particles incorporates cellular proteins, including 
CD46, CD55, CD59, CD71, CD81, and MHC class I, which prevent complement 
binding (Vanderplasschen et al., 1998).  Species-specific CD55 and CD59 
incorporation into IEV are critical for protection against complement  when the virus 
exits the cell as EEV (Vanderplasschen et al., 1998).  The incorporation of host 
proteins into the membrane rather than expression of a mimic has been suggested to 
be important for host range due to the species-specific nature of regulator of 
complement activation (RCA) proteins.  In addition to the incorporation of cellular 
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proteins, the VACV complement control protein (VCP, encoded by VACV Cop C21L) 
(Isaacs et al., 1992; Kotwal & Moss, 1988) is essential for evasion of complement 
(Vanderplasschen et al., 1998).  Thus, EEV dissemination within the host is not 
inhibited by complement. 
1.1.10.3 Cell-mediated immunity 
During the inflammatory response to infection there is an increase in the number of 
immune cells present at the site of infection.  The predominant lymphocyte population 
for the first few days after VACV infection of mice by intraperitoneal (Selin et al., 
2001) or intradermal (Jacobs et al., 2006) routes is γδ T lymphocytes.  γδ T 
lymphocytes are innate immune rather than adaptive immune cells and exert their 
effect on infected tissues through the production of IFN-γ, which induces specific 
cytotoxicity against VACV-infected cells (Selin et al., 2001).  Activation of some 
subsets of γδ T lymphocytes is dependent on IL-18 and IL-12 (Johnson et al., 2008; 
Sugaya et al., 1999).  Some poxviruses encode a protein that can bind and block IL-
18 activity, which would result in a lower activation of the recruited γδ T lymphocytes 
(Reading & Smith, 2003; Smith et al., 2000; Symons et al., 2002a). 
Natural killer (NK) cells are important for VACV clearance and cellular depletion 
results in a drastic increase in viral load within infected tissues and a delayed viral 
clearance (Bukowski et al., 1983; Kennedy et al., 2000).  NK cells are, like γδ T 
lymphocytes, lymphocytes involved in the innate immune response, and respond to 
infection through release of IFN-γ in response to IL-12 and IL-18 produced by other 
cells (Orange & Biron, 1996).  NK cells recognise cells expressing low or abnormal 
MHC class I through their killer cell immunoglobulin-like receptors (KIR) (Malnati et 
al., 1995; O'Connor et al., 2006; Yusa & Campbell, 2003) and CD94/NKG2 receptors 
(Lee et al., 1998; O'Connor et al., 2006; Winter et al., 1998).  Type I IFN stimulation is 
required for activation of NK cells in response to VACV infection (Martinez et al., 
2008).  However, VACV and other poxviruses express proteins that prevent type I 
IFN binding to cell surface IFN receptors and thereby inhibit signalling (Alcami et al., 
2000; Symons et al., 1995; Waibler et al., 2009). 
Macrophages and DCs are critical for the immune response to poxvirus infection, and 
mice depleted of macrophages are unable to clear virus or elicit a CTL response to 
infection, resulting in an increased mortality rate (Karupiah et al., 1996).  A major 
function of macrophages (Unanue, 1984; Unanue et al., 1969) and DCs (Cella et al., 
1997) is as antigen presenting cells (APCs).  They can present via both MHC class I, 
on which the presented antigen is dervived from within the cell, and MHC class II, on 
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with the presented antigen is derived from an endocytosed foreign antigen (Morrison 
et al., 1986; Song & Harding, 1996).  Importantly, in the case of a VACV infection, 
uninfected macrophages and DCs can acquire antigen from infected cells through 
cross-presentation, and present the antigen on MHC class I within 1 h of the 
encounter between the APC and the infected antigen-donor cell (ADC) (Ramirez & 
Sigal, 2002).  Antigen presentation could also occur from infected macrophages and 
DCs, however replication of viral particles within activated macrophages (Buchmeier 
et al., 1979; McLaren et al., 1976; Natuk & Holowczak, 1985)  and DCs (Drillien et al., 
2000; Engelmayer et al., 1999) is abortive after early gene expression but before 
DNA replication.  The secreted VACV semaphorin protein (A39) prevents APC 
phagocytosis of virions (Walzer et al., 2005), highlighting the importance of cross-
presentation for effective APC function in the context of a VACV infection. 
Neutrophils are recruited to the site of infection by CXC chemokines (Haelens et al., 
1996).  They are capable of phagocytosing VACV (West et al., 1987), and the rate at 
which they do so is increased by VACV-specific antibody opsonisation (Jones, 1982).  
Complement would also aid the uptake of VACV, but EEV is resistant to complement 
(section 1.1.10.2).  In addition, the viral semaphorin that prevents uptake by DCs also 
prevents uptake of virus by neutrophils (Walzer et al., 2005). 
1.1.10.4 Cytokines 
Cytokines are small proteins that carry signals between cells, and carry out functions 
as diverse as cell recruitment, inflammation, lymphocyte differentiation cell growth 
and development.  Cytokine inhibitors take the form of soluble orthologues of 
cytokine receptors, and the first to be discovered was a soluble TNF receptor 
expressed by Shope fibroma virus (Smith et al., 1991).  Shortly after this, a soluble 
receptor for IL-1β, expressed from VACV Cop B15R, was discovered (Alcami & 
Smith, 1992; Spriggs et al., 1992).  While the host IL-1 receptor binds IL-1α, IL-1β 
and IL-1 receptor antagonist (IL-1ra), B15 only binds IL-1β (Alcami & Smith, 1992).  
This is intriguing, but later work showed that IL-1β is the major pyrogen in a VACV 
infection, and a fever induced by VACV lacking B15R could be prevented using anti-
IL-1β antibody (Alcami & Smith, 1996). 
A soluble IFN gamma receptor (IFNγR) was discovered in MYXV (Upton et al., 1992), 
with an orthologue encoded by B8R in VACV (Alcami & Smith, 1995; Mossman et al., 
1995; Symons et al., 2002b).  The IFNγRs expressed from VACV and ECTV have 
species specificity (Mossman et al., 1995), and deletion of B8R from VACV does not 
change the virulence in the mouse model, but insertion of a soluble form of the 
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murine IFN-γ receptor under the control of the B8R promoter increased virulence 
(Symons et al., 2002b).  VACV B8 protein can bind human, cow, rabbit, rat and 
chicken, but not mouse, IFN-γ (Alcami & Smith, 1995; Mossman et al., 1995; Upton 
et al., 1992).  This is a useful safety measure for generation of potentially dangerous 
VACV, as use of the ∆B8R parental virus does not alter virulence in the murine 
models but is predicted to attenuate the virus in humans (Symons et al., 2002b). 
A soluble type I IFNR with little or no primary sequence similarity to its cellular 
counterpart (encoded by VACV Cop B19R but commonly referred to as B18 as the 
VACV WR orthologue is encoded by B18R) was discovered (Symons et al., 1995).  
B18 also has a broad species specificity, binding human, rabbit, cow, rat and mouse 
type I IFNs (Symons et al., 1995).  B18 then binds to the cell surface, sequestering 
the IFNs away from any cellular receptors (Alcami et al., 2000). 
Poxviruses express an IL-18 binding protein, encoded by VACV Cop C12L.  IL-18, a 
member of the IL-1 superfamily (Bowie & O'Neill, 2000), stimulates the production of 
IFN-γ by NK and γδ T lymphocytes (Reading & Smith, 2003; Smith et al., 2000; 
Symons et al., 2002a).  C12 has very little similarity with its cellular IL-18 receptors, 
but it does have sequence similarity with cellular IL-18 binding proteins, which 
negatively regulate IL-18 function (Aizawa et al., 1999; Novick et al., 1999).  
1.1.10.5 Adaptive immunity 
Effective clearance of poxvirus infections and lasting immunity is dependent on both 
cellular and humoral immunity (Belyakov et al., 2003).  For the immediate response 
against poxvirus infection in vaccinated individuals, antibodies are important for 
survival and virus clearance (Belyakov et al., 2003; Edghill-Smith et al., 2005).  Long-
lasting immunity against poxviruses requires the establishment of lymphocytes 
directed against virus-specific epitopes, and results in a TH1-skewed cellular profile 
with lasting CD4+ and CD8+ cells (Amara et al., 2004; Calvo-Calle et al., 2007). 
1.1.10.5.1 Helper T lymphocytes 
The cytokines released during infection will determine whether an immune response 
is predominantly cellular or humoral (Bradley et al., 2000; Swain et al., 2006), as a 
result of the priming of helper T lymphocytes (O'Garra & Arai, 2000).  Helper T 
lymphocytes are CD4+CD8- (CD4+) and can be broken down into two categories 
based on the type of response they elicit: TH1 cells are important for priming the 
cytotoxic CD4-CD8+ (CD8+) cellular response (Janssen et al., 2003; Sun & Bevan, 
2003), while TH2 cells are important for the priming of B lymphocytes and subsequent 
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antigen-specific antibody release (Bradley et al., 2000).  CD4+ cells can also aid in 
the anti-viral response through the release of cytokines such as IFNγ (Swain et al., 
2006). 
The majority of poxvirus epitopes recognised by CD4+ cells are expressed late in 
infection and are from virion core or membrane proteins (Jing et al., 2008; Moutaftsi 
et al., 2007).  None of the epitopes recognised come from immunomodulatory 
proteins (Moutaftsi et al., 2007), in contrast to the pattern of epitopes recognised by 
CD8+ cells.  
1.1.10.5.2 Cytotoxic T lymphocytes 
Poxvirus infection elicits a CTL response (Harrington et al., 2002) but this is neither 
required nor sufficient for virus clearance (Belyakov et al., 2003; Xu et al., 2004).  
However, the CTL response appears to be important late in infection to reduce the 
severity of the disease and prevent mortality (Belyakov et al., 2003; Xu et al., 2004). 
Poxvirus epitopes recognised by CD8+ cytotoxic T lymphocytes (CTLs) are very 
diverse, and include early- and late-expressed proteins from a range of different 
protein types (Jing et al., 2005; Mathew et al., 2005; Moutaftsi et al., 2006; Tscharke 
et al., 2005).  These include structural proteins, transcription factors, 
immunomodulators and other poxvirus enzymes (Jing et al., 2005; Tscharke et al., 
2005), and the immunodominance of specific epitopes is determined by the strain 
used and route of infection (Tscharke et al., 2005). 
1.1.10.5.3 Humoral immunity 
The humoral response is sufficient for poxvirus clearance in the absence of CTLs 
(Belyakov et al., 2003).  Virus entry into cells can be prevented using neutralising 
antibodies (Chang et al., 1995), and IMV and EEV have different neutralising 
epitopes because of the different compositions of their surface membranes (Boulter & 
Appleyard, 1973; Law et al., 2005; Putz et al., 2006).  A27 (Hooper et al., 2004; 
Pulford et al., 2004), L1 (Fogg et al., 2004; Hooper et al., 2000), H3 (Davies et al., 
2005; Pulford et al., 2004), D8 (Pulford et al., 2004) and A17 (Wallengren et al., 
2001) are the targets of IMV-neutralising antibodies. B5 is the only neutralising 
antibody target found on the surface of EEV (Law & Smith, 2001), although 
antibodies against A33 and A56 are also raised following infection both in animal 
models (Fogg et al., 2004; Hooper et al., 2000; Law & Smith, 2001) and in vaccinated 
humans (Putz et al., 2006). 
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1.2 Proteins related to CMLV v-slfn 
CMLV v-slfn has two domains.  The N-terminal domain has sequence similarity to 
baculovirus p26 proteins and the C-terminal domain has sequence similarity to 
mammalian slfn proteins. 
1.2.1 Discovery of mammalian slfn proteins 
1.2.1.1 Initial identification of murine short and intermediate slfns 
Murine slfn (m-slfn) proteins are divided into three groups based on their size; short 
(m-slfns 1 and 2), intermediate (m-slfns 3 and 4 and LOC435271) and long (m-slfns 
5, 8, 9, 10 and 14) (Fig. 1-5).  The prototypic member of the slfn family, m-slfn1, was 
discovered by a subtractive hybridisation between transgenic mice in which T cell 
maturation was halted at the CD4+8+ double positive (DP) stage, and mice in which 
maturation was skewed toward CD4 single positive (SP) selection (Schwarz et al., 
1998).  m-slfn1 expression was increased in thymocytes skewed towards 
differentiation into CD4+ cells as compared to those in earlier stages of development 
(Schwarz et al., 1998).  BLAST searches of the expressed sequence tag (EST) 
database identified 3 more m-slfn genes, which were named m-slfns 2, 3 and 4.  m-
slfns 1-4 contain a common conserved N-terminal region, whereas m-slfns 3 and 4 
contain a C-terminal extension (Fig. 1-5).  The conserved region of slfn proteins 
contains a putative ‘ATPases associated with diverse cellular activities’ (AAA) domain 
(Erdmann et al., 1991), which are found in families of proteins from mammals to 
bacteria and archea (Frickey & Lupas, 2004).  As the name suggests, these proteins 
have a diverse range of activities, although their unifying function is unfolding and 
remodelling of proteins and nucleic acids. 
1.2.1.2 Identification of a further sub-family of schlafen proteins 
A subtractive hybridisation of a cDNA library obtained from the spleens of mice 
infected with Listeria monocytogenes versus uninfected mice identified a further four 
members of the slfn family (Geserick et al., 2004), named m-slfn 5, 8, 9 and 10.  
Compared to m-slfns 1 to 4, m-slfns 5, 8, 9 and 10 contain a further extension at the 
C terminus that includes an ATP/GTP binding domain and Walker A and B motifs, 
indicating that these proteins may have ATPase activity (Geserick et al., 2004) (Fig. 
1-5). In addition, these proteins may have RNA/DNA helicase activity due to the 
presence of both the AAA domain and Walker A and B motifs (Geserick et al., 2004; 
Walker et al., 1982) (Fig. 1-5).  These proteins were also discovered independently 
through BLAST analysis of the murine genome, as were two further slfn-like proteins, 
Chapter 1 - Introduction 
44 
novel slfn A (NSA) and NSB (Brady, 2004), which are annotated as LOC435271 
(XP_918759) and Slfn14 (XP_899217), respectively. 
 
Fig. 1-5.  Mammalian slfn proteins. 
Schematic representatation of each of the short (m-slfn1), intermediate (m-slfn3) and long (m-
slfn8) m-slfns.  Dark grey indicates sequences shared by all sub-families, light grey for those 
shared by intermediate and long slfns and black for those found in long slfns only.  The 
divergent AAA, Walker A (W-A) and Walker B (W-B) motifs are indicated by hatched boxes. 
1.2.1.3 Identification of mammalian slfn-like proteins 
Further annotation of mammalian genomes has revealed another sub-family of slfn-
like proteins, known as the slfn1-like proteins (Fig. 1-6).  The genes encoding these 
proteins are found on different chromosomes to the slfn cluster (section 1.2.2), and 
code for proteins with broken regions of conservation.  m-slfn1 shares 13 % identity 
and 29 % similarity with both the murine (chromosome 4) and human (chromosome 
1) slfn1-like proteins, and the majority of the conservation is scattered over a central 
section of the proteins corresponding to aa 193-234 of m-slfn1.  The 
VXAFXNTXGGXL motif, where X is any amino acid (aa), is well conserved in all 
murine slfns and slfn-like proteins and may be important for function. 
 
Fig. 1-6.  Sequence alignment of.m-slfn1 and schlafen-like proteins. 
ClustalW aa alignment of m-slfn1, murine slfn-like protein 1 (m-slfnlike) and human slfn-like 
protein 1 (h-slfnlike).  Identical or similar residues found in all analysed proteins are shown in 
black, residues found in 2 sequences are shown in grey.  Red boxes indicate areas of the 
sequence that are highly conserved in all m-slfn proteins. 
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1.2.2 Mammalian slfn proteins – bioinformatic analysis 
1.2.2.1 Murine slfn proteins 
The short murine slfns (m-slfns 1 and 2) share 47 % identity and 63 % similarity 
(Table 1-1).  The first 27 aa of m-slfn1 are required for its function as a negative 
regulator of cell division (Geserick et al., 2004). 
The intermediate form m-slfn 3 and 4 are closely related to each other (74 % identity, 
77 % similarity, Table 1-1), and differ most significantly in the N-terminal region: m-
slfn4 has an additional N-terminal extension not found in any other slfns, while m-
slfn3 has a deletion from the N-terminal region that removes all aa with similarity to 
the essential first 27 aa of m-slfn1.  If the N-terminal extension of m-slfn4 is ignored, 
the level of identity and similarity between the two proteins is increased to 87 % and 
91 %, respectively.  The newly-identified intermediate-length m-slfn, LOC435271, has 
high sequence identity with m-slfns 3 and 4 (67 % and 70 %, respectively, Table 1-1) 
but lower identity with intermediate-length human slfns 12 and 12L (39 % and 37 %, 
respectively), suggesting that it is a gene duplication from within the murine slfn locus 
rather than an orthologue of the human intermediate slfn proteins.  Indeed, 
phylogenetic analysis of slfns from several species, which separated the proteins into 
four groups, placed all intermediate-length slfns (and all short slfns) in the same 
group, but the divergence of intermediate m- and h-slfns early in evolution is evident 
(Bustos et al., 2009). 
There is some divergence in the long m-slfns: m-slfns 8-10 are more similar to each 
other than they are to the other long m-slfns (85-87 % identity, 90-92 % similarity, 
Table 1-1).  m-slfns 5 and 14 have higher sequence identity with their human 
counterparts (58 % and 66 %, respectively, Table 1-1) than they do with the other 
long form m-slfns (34-39 % and 34-37 %, respectively).  m-slfn14 lacks both the 
GXXXXGKT/S Walker A and the DEAQ Walker B motif, which is conserved in all 
other long form slfns (Geserick et al., 2004; Walker et al., 1982) (Fig. 1-5).  The 
division of slfns into four different groups split long m-slfns into three groups; m-slfn5 
(Group 2), m-slfn14 (Group 3) and m-slfns 8-10 (Group 4) (Bustos et al., 2009). 
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m‐slfn1 m‐slfn2 m‐slfn3 m‐slfn4 m‐slfn5 m‐slfn8 m‐slfn9 m‐slfn10 m‐slfn14 LOC435271
m‐slfn1 47 (63) 27 (37) 27 (35) 11 (19) 11 (19) 12 (19) 11 (19) 12 (20) 28 (37)
m‐slfn2 47 (63) 33 (40) 33 (41) 11 (19) 11 (19) 11 (19) 11 (19) 13 (21) 35 (43)
m‐slfn3 27 (37) 33 (40) 74 (77) 16 (26) 15 (27) 16 (27) 15 (27) 16 (27) 67 (72)
m‐slfn4 27 (35) 33 (41) 74 (77) 16 (27) 15 (27) 16 (27) 15 (27) 16 (27) 70 (74)
m‐slfn5 11 (19) 11 (19) 16 (26) 16 (27) 39 (59) 39 (60) 40 (60) 33 (51) 16 (27)
m‐slfn8 11 (19) 11 (19) 15 (27) 15 (27) 39 (59) 85 (91) 85 (90) 36 (58) 16 (28)
m‐slfn9 12 (19) 11 (19) 16 (27) 16 (27) 39 (60) 85 (91) 87 (92) 37 (59) 17 (28)
m‐slfn10 11 (19) 11 (19) 15 (27) 15 (27) 40 (60) 85 (90) 87 (92) 37 (58) 16 (28)
m‐slfn14 12 (20) 13 (21) 16 (27) 16 (27) 33 (51) 36 (58) 37 (59) 37 (58) 17 (28)
LOC435271 28 (37) 35 (43) 67 (72) 70 (40) 16 (27) 16 (28) 17 (28) 16 (28) 17 (28)  
Table 1-1.  Amino acid conservation in m-slfns. 
Data from ClustalW aa alignment of the entire length of all predicted murine slfn proteins.  
Expressed as % identity (normal text) and similarity (brackets).  Short m-slfns are unshaded 
horizontally, intermediate m-slfns are shaded in light grey and long m-slfns are shaded in dark 
grey. 
1.2.2.2 Human slfn proteins 
Murine slfns are clustered in a single locus on chromosome 11, and similarly human 
slfn genes are all clustered in a single locus on chromosome 17q12.  While originally 
the human slfn (h-slfn) annotation included four members (all of which were long 
form), compared to at least eight m-slfns, there are now six h-slfns predicted, two of 
which are intermediate length (h-slfn 12 and 12L) and four of which are long (h-slfn 5, 
8-10).  It is possible that alternative splicing of the h-slfn genes could lead to 
truncations, possibly compensating for the fact that no short form h-slfns are 
expressed.  An example of alternative splicing is the differentially spliced isoforms of 
the IRAK2 gene, which leads to expression of proteins with opposing effects (Hardy & 
O'Neill, 2004). 
The intermediate h-slfns have many of the residues from long h-slfns that are absent 
in intermediate m-slfns, and lack many sequences from intermediate m-slfns that are 
also absent in long h-slfns.  This suggests that the intermediate h-slfns are in fact 
truncations of the long h-slfns rather than direct counterparts of the intermediate m-
slfns.  It is interesting that this truncation has occurred in a region of the intermediate 
h-slfns that is comparable to the intermediate m-slfns.  This suggests that the C-
terminal extenstion found in long slfns forms a distinct domain, which can be removed 
at a specific point without disrupting the rest of the protein. 
Like m-slfns 8, 9 and 10, h-slfns 11 and 13 share a high level of identity and similarity 
(76 % and 84 %, respectively), while h-slfns 5 and 14 are less similar to the other two 
two long h-slfns and to each other. 
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1.2.2.3 Comparison of mammalian slfn loci 
Comparison of the relative position and orientation of the slfn genes in Homo 
sapiens, Mus musculus, Macaca mulatta, Bos taurus and Equus caballus (human, 
mouse, macaque monkey, cow and horse) shows that they are all located on single 
loci on chromosomes 17, 11, 16, 19 and 11, respectively.  Sequences were viewed in 
graphical format using online software from NCBI, Map Viewer 
(www.ncbi.nlm.nih.gov/projects/mapview/) and Sequence Viewer v.2.1 
(www.ncbi.nlm.nih.gov/projects/sviewer/) (Fig. 1-7).  Proteins related to m-slfns 1, 2, 
3 and 4 in mice are not only absent in humans (Kehrer-Sawatzki et al., 2003), but 
also in macaque monkeys, cows and horses (Fig. 1-7).  This could be caused either 
by a deletion of a section of the slfn locus early in mammalian evolution, or by gene 
duplication in rodents to create these two new gene sub-families.  Flanking genes are 
not affected, as the majority of flanking genes expressed in mice are also found in all 
other species analysed.  Other than VARV, poxviruses for which each of these 
species acts as a natural host, namely ECTV, MPXV, CPXV and HPXV, all have 
undisrupted ORFs that correspond to CMLV 176R. 
1.2.3 Expression profile of m-slfns 
The expression of m-slfn mRNA is highest in circulating lymphocytes and organs 
containing high numbers of lymphocytes (Schwarz et al., 1998), including the thymus, 
lymph nodes and spleen.  Depletion of T lymphocytes resulted in a drastic reduction 
in mRNA coding for m-slfn1 in circulating lymphocytes, suggesting that the majority of 
m-slfn1 is expressed in T lymphocytes or results from T lymphocyte-mediated 
signalling (Schwarz et al., 1998). 
The promoter for m-slfn2 contains both NF-κB and AP-1 binding sites, and the activity 
of the promoter was up-regulated by treatment with LPS or CpG DNA (Sohn et al., 
2007).  Both of these binding sites are necessary for m-slfn2 expression in 
macrophages.  NF-κB and AP-1 are both ‘rapid-acting’ transcription factors, which 
are present in an inactivated state within the cell.  Activation is therefore reliant on 
modification of the proteins that make up the transcription factor or modification of 
their repressors, meaning that activation is faster than for transcription factors under 
transcriptional control.  Toll-like receptors and their downstream signalling pathways 
(section 1.1.10.1.1) are major contributors to the activation of NF-κB, and are 
differentially expressed in some mucosal epithelial cells and leukocytes (McGettrick & 
O'Neill, 2007; Yu & Chen, 2008) 
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Fig. 1-7 
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Fig. 1-7.  Organisation of the human, mouse, rhesus monkey, cow and horse slfn loci. 
The orientation of the genes in the slfn loci in Homo sapiens, Mus musculus, Macaca mulatta, 
Bos taurus and Equus caballus are shown.  Gene size and spacing are not to scale.  Slfn-like 
genes are shown in red, non-slfn genes are shown in blue.  All sequences are shown reading 
along the positive strand (from top to bottom) other than those marked with an asterisk. 
1.2.4 Putative cellular function of m-slfns 
1.2.4.1 Differentiation of T lymphocytes 
As discussed in section 1.2.3, m-slfns are expressed at their highest levels in 
lymphocytes.  Expression of m-slfns changes over the course of thymocyte 
differentiation, from double negative (DN) (CD4-CD8-) to double positive (DP) 
(CD4+CD8+) and then to single positive (SP) CD4+ or CD8+.  Expression of short m-
slfns 1 and 2 is greatly increased on differentiation into SP cells, intermediate m-slfn 
4 is decreased, and intermediate m-slfn3 and long m-slfns 5, 8, 9 and 10 are 
unaltered (Geserick et al., 2004; Schwarz et al., 1998).  This suggests that the 
different m-slfns have distinct functions, which are involved in thymocyte 
differentiation.  Activation of the T cells through TCR stimulation resulted in a reversal 
of the expression profile of m-slfns 1, 2 and 4 observed in unactivated T cells, 
reducing m-slfn1 and 2 levels and increasing m-slfn4 (Geserick et al., 2004).  A 
strong correlation between the decrease in m-slfn1 and an increase in expression of 
cyclin D1 was observed in activated T lymphocytes (Zhang et al., 2008).  This is 
consistent with both the earlier observations that m-slfn1 is decreased in activated T 
lymphocytes (Schwarz et al., 1998), the inhibition of cyclin D1 expression by m-slfn1 
(Brady et al., 2005) and the rapid expansion of T lymphocytes following activation.  
Although no major differences had been observed in long m-slfn expression levels on 
differentiation into SP cells, expression was changed upon T cell activation; 
expression of m-slfns 5 and 8 decreased, m-slfn9 increased and m-slfn10 remained 
constant (Geserick et al., 2004). 
Granulocytes and macrophages proliferate in the absence of growth factors following 
MyD88-dependent TLR signalling (Nagai et al., 2006).  TLR signalling via MyD88 
drives differentiation of haematopoietic stem cells towards committed myeloid 
progenitors and subsequently drives granulocyte/macrophage progenitors by 
stimulating cell cycle progression, whilst concurrently reducing the growth of 
committed lymphoid progenitors (CLPs) (McGettrick & O'Neill, 2007; Nagai et al., 
2006).  CLPs can differentiate into T or B lymphocytes, NK cells or DCs.  Treatment 
of CLPs with TLR ligands for several day results in differentiation of nearly all cells 
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into DCs (Nagai et al., 2006).  This could be attributed to autocrine and paracrine 
cytokine signalling, but antibodies against TNFα and GM-CSF, which could cause 
such a differentiation pattern, did not reverse this effect and the cause of the DC 
skew remains unknown (Nagai et al., 2006).  It is possible that the preferential 
expression of m-slfns in lymphoid cells and their up-regulation by TLR ligands results 
in inhibition of the cell cycle (section 1.2.4.3) in lymphocytes while other leukocytes 
proliferate in response to TLR signalling. 
1.2.4.2 Innate immune response to infection 
Analyses of differential gene regulation have identified m-slfn genes as being 
involved in or affected by the response to infection with various pathogens.  Infection 
with Listeria monocytogenes caused up-regulation of all studied m-slfn genes in the 
splenocytes of infected mice 2 days post-infection (Geserick et al., 2004).  Microarray 
analyses identified changes in the level of m-slfn gene expression resulting from 
various stimuli.  Brucella abortus infection of the murine macrophage cell line 
RAW264.7 resulted in an increase in m-slfn2 expression (Eskra et al., 2003).  Both 
m-slfn2 and m-slfn4 expression levels were increased in the lungs of Klebsiella 
pneumoniae- (experimental pneumonia) infected mice, and this effect was abolished 
in TLR-4 deficient mice, suggesting that slfns can be up-regulated as a result of TLR 
stimulation (Schurr et al., 2005).  Expression of m-slfn3 was increased in the colon of 
Salmonella enteritidis-infected rats (Rodenburg et al., 2007).  As well as being 
regulated differentially in response to infection, m-slfn gene expression may increase 
or decrease under other conditions related to the immune response.  Fibroblasts 
isolated from mice deficient in NF-κB repressing factor (NRF) have a 7.5 fold 
reduction in m-slfn2 levels (Froese et al., 2006).  It was suggested that m-slfn4 may 
be involved in resistance to experimentally-induced cancer (Yamashita et al., 2002). 
1.2.4.3 Inhibition of cellular proliferation 
Stable cell lines expressing m-slfn1 halt cell division at the G1 to S transition 
(Schwarz et al., 1998) by reducing cyclin D1 expression through transcriptional 
inhibition of the cyclinD1 promoter (Brady et al., 2005).  Cyclin D1 regulates cyclin-
dependent kinases (CDKs) that control re-entry from the quiescent G0 phase of the 
cell cycle to G1 and progression to subsequent growth and division phases (section 
1.3).  The mechanism of cyclin D1 suppression by m-slfn1 is unknown, although it 
does not affect phosphorylation of the components of the growth factor signalling 
pathway between Ras and Erk (Brady et al., 2005).  Deletion of the first 27 aa of m-
Chapter 1 - Introduction 
51 
slfn1 resulted in loss of the growth arresting phenotype, showing that this sequence is 
important for m-slfn1 function (Geserick et al., 2004). 
Although some work has been published about the function m-slfn2, the researchers 
were unable to reproduce those data published regarding the function of m-slfn1 and 
therefore concluded that neither protein had an inhibitory effect on cell growth and 
division (Zhao et al., 2008).  It was proposed that this lack of reproducibility may be a 
result of variability between fibroblast cell lines.  However, the fact that this effect was 
shown in stable cell lines expressing m-slfn1 (Schwarz et al., 1998), fibroblasts 
transduced with retroviruses expressing m-slfn1 (Geserick et al., 2004) and m-slfn1-
transfected fibroblasts (Brady et al., 2005; Zhang et al., 2008) and CHO cells (Brady 
et al., 2005) makes this unlikely. 
Constitutive expression of long m-slfns 5, 8, 9 and 10 from retroviral vectors did not 
alter the kinetics of fibroblast proliferation, showing they have different function(s) to 
short slfns (Geserick et al., 2004).  Selection of cell lines stably-expressing long slfns 
was possible, while cells that expressed even small amounts of m-slfn1 were not 
viable (Geserick et al., 2004). 
1.2.4.4 Up-regulation in arthritis 
A study to identify genes that are upregulated in different murine models of arthritis 
found several clusters of up-regulated genes, which included the m-slfn cluster 
(Fujikado et al., 2006).  Other genes up-regulated included MHC class I and II, and 
certain chemokines and complement, all of which contribute to progression of 
rheumatoid arthritis.  Genes are clustered in eukaryotic genomes according to their 
expression profiles (Hurst et al., 2004), and the co-expression of m-slfns with these 
proteins invoved in antigen presentation and leukocyte chemotaxis furthers the 
likelihood that m-slfns are involved in the immune response.  However, the nature of 
their contribution to arthritis is still uncertain. 
1.2.5 m-slfn1 and m-slfn8 constitutive expression in mice 
To determine the function of m-slfn1 in vivo, transgenic mice were made with m-slfn1 
under the control of the human CD2 promoter (Schwarz et al., 1998), resulting in 
expression of the m-slfn1 gene in all thymocyte lineages regardless of their 
differentiation or activation state (Stewart et al., 1993).  Heterozygous expression of 
CD2-m-slfn1 resulted in a 70-90 % reduction in thymocyte numbers, while 
homozygous expression resulted in 97-99 % reduction when compared to littermate 
controls (Schwarz et al., 1998). 
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Homozygous deletion of m-slfn1 from mice resulted in no observable phenotype 
(Schwarz et al., 1998).  It was expected that deletion may lead to hyper-proliferation 
of thymocytes, but this did not occur, and there were no changes in CD4+ or CD8+ T 
lymphocyte levels.  This could be due to other members of the slfn family 
compensating for loss of the gene, which would suggest slfn redundancy. 
Transgenic mice were also made with m-slfn8 under the control of the CD2 promoter 
(Geserick et al., 2004).  These mice had a reduction in thymic cellularity, although the 
results were not as pronounced as the m-slfn1 transgenic mice, with a 60 % drop 
when compared to littermate control mice. 
1.2.6 The p26 proteins expressed from baculoviruses 
The N-terminal domain of v-slfn has sequence similarity to baculovirus p26 proteins.  
Baculoviruses are large, dsDNA viruses that infect invertebrates, primarily insects.  
Baculoviruses can infect mammalian cells under certain conditions, but the virus does 
not replicate (Tjia et al., 1983; Volkman & Goldsmith, 1983).  Of the two genera of 
baculovirus, nucleopolyhedroviruses (NPV) and granuloviruses (GV), only NPVs 
encode p26 (Bicknell et al., 1987; Huh & Weaver, 1990a; b), and then only NPVs that 
infect lepidopteran species (Goenka & Weaver, 2008). 
In a study to investigate the p35 gene, which is directly upstream of p26, the majority 
of the DNA coding for the p26 protein was removed (Rodems & Friesen, 1993).  The 
deletion had no effect on the production of budded viruses or polyhedra, showing that 
the p26 protein is not essential for virus replication.  This was confirmed in later work 
to directly study the function of p26 (Simon et al., 2008).  p26 is expressed early in 
cells infected with Autographa californica multinucleocapsid nucleopolyhedrovirus 
(AcMNPV) and exists as a dimer in the cytoplasm (Goenka & Weaver, 2008). 
1.2.7 Previously reported binding partners for m-slfn1 and v-slfn 
1.2.7.1 DnaJB6 
DnaJB6 (also known as mammalian relative of DnaJ, Mrj) (Hunter et al., 1999) is a 
member of the heat shock protein 40 (Hsp40) family of proteins, which aid protein 
folding and prevent aggregation (Ohtsuka & Hata, 2000; Young et al., 2004).  Hsp40 
proteins can have up to three conserved domains: a J domain, which interacts with 
Hsp70 proteins and regulates its ATPase activity; a glycine/phenylalanine-rich (G/F) 
domain, which may act as a linker; and a cysteine-rich zinc finger-like (C) domain.  
They are divided into three groups depending on the presence of these domains.  
DnaJB6 belongs to the type II subfamily, which contain the J and G/F but not the C 
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domain (Cheetham & Caplan, 1998; Ohtsuka & Hata, 2000).  It interacts with 
transcription factors and recruits class II histone deacetylases (HDACs) (Dai et al., 
2005).  HDACs remove the acetyl groups from histones, resulting in condensation of 
nucleosomes and attached DNA, and a reduction in transcription (Narlikar et al., 
2002). 
Nuclear localisation of m-slfn1 is critical for its function as a negative regulator of 
cellular proliferation, and sequestering the protein in the cytoplasm prevents its 
function (Zhang et al., 2008).  A yeast-2-hybrid screen identified DnaJB6 as a binding 
partner for m-slfn1, and this was confirmed by co-immunoprecipitation (Zhang et al., 
2008).  Expression of DnaJB6 is necessary for m-slfn1 translocation to the nucleus, 
and m-slfn1 does not have any effect on cellular proliferation in low-expressors of 
DnaJB6 or following knockdown by siRNA.  Transgenic mice expressing DnaJB6 
under the same promoter used to study m-slfns 1 and 8 over-expression in 
thymocytes (section 1.2.5) resulted in a decrease in proliferation of activated T 
lymphocytes and a stabilisation and reduction in degradation of m-slfn1 in these cells 
as compared to cells from littermate controls (Zhang et al., 2008). 
1.2.7.2 MESR6 
A yeast-2-hybrid search identified several potential binding partners for v-slfn and m-
slfn1 (Brady, 2004).  Several of these were examined in more detail to determine 
whether they might explain the effects of the slfns.  Some of these were discarded 
because they were identified in many yeast-2-hybrid screens.  Two proteins stood out 
as potential candidates for the control of cellular proliferation: HDAC2 (which turned 
out to be out of frame and was therefore abandoned) and a fragment of a human 
orthologue of the Drosophila melanogaster MESR6 protein (h-MESR6), which was 
identified in D. melanogaster through its ability to suppress Ras signalling (Huang & 
Rubin, 2000).  No further studies have been performed to elucidate the function of the 
protein in either D. melanogaster or in mammals. 
Both v-slfn and m-slfn1 interacted with h-MESR6 in the yeast-2-hybrid system, and 
the interaction was verified for v-slfn with a GST-pulldown (Brady, 2004). 
1.3 Regulation of the cell cycle 
As discussed in section 1.2.4.3, one of the roles of the mammalian slfn family is 
inhibition of cyclin D1 transcription.  This in turn prevents cells from transitioning from 
G0 and therefore halts progression of the cell cycle.  An overview of temporal control 
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of the cell cycle, both in terms transcriptional and protein regulation, is discussed in 
this section. 
1.3.1 Phases of the cell cycle 
The eukaryotic cell cycle is an evolutionarily-conserved process.  It involves tightly-
controlled events leading to replication of all necessary cellular components for 
division into two identical daughter cells.  It consists of five distinct phases: the three 
“gap phases”, G0, in which cells are held in a resting quiescent state, and G1 & G2, in 
which RNA and protein synthesis occur in cells with two copies of each chromosome 
(2n) or four copies (4n), respectively; synthesis (S) phase, in which DNA is replicated; 
and mitosis (M) phase, in which the cell undergoes the processes of mitosis and 
cytokinesis and divides into two identical daughter cells.  Regulation of these 
processes occurs through interactions between constitutively expressed (static) 
proteins and the temporally expressed (dynamic) proteins that regulate the activity of 
protein complexes governing the activity of the cell cycle (Cho et al., 1998; de 
Lichtenberg et al., 2005; Whitfield et al., 2002). 
Most cells will not continue through another round of the cell cycle immediately after 
dividing and will instead halt mid-G1 and enter the quiescent G0 phase (Zetterberg & 
Larsson, 1985).  Those cells that are unable or unlikely to divide again, such as 
neurons, are referred to as terminally differentiated cells.  The point in G1 phase after 
which cells are committed to S phase entry is commonly referred to as the restriction 
point (Pardee, 1974) and there may be an “R-protein”, which is responsible for 
transition beyond this restriction point (Campisi et al., 1982; Rossow et al., 1979).  
This hypothetical protein would be a labile protein essential for G1/S progression, and 
as such it has been suggested that D-type cyclin proteins are likely candidates 
(Blagosklonny & Pardee, 2002).  However, it has also been suggested that the 
restriction point and G0 phase do not in fact exist, but are simply convenient ways to 
describe an elongated (or infinitely long) inter-division period (Cooper, 1998a; b; 
2003).  By this argument, any biochemical changes observed in what would be 
considered as G0 or terminally differentiated cells are a result of cellular stresses or 
reductions in growth factors (Cooper, 2001). 
1.3.2 Downstream of D-type cyclin activation 
D-type cyclin proteins are important regulators of the cell cycle and, together with 
their associated kinases and cyclin E, are a critical element in the G1/S transition.  
Cyclin proteins were named based on the fact that their expression and activation is 
cycled at specific points in the cell cycle, activating stage-specific transcription factors 
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(Evans et al., 1983).  The most intensely studied function of the cyclin D proteins is 
as a regulator of cyclin dependent kinase (Cdk) 4 or 6, with which they form an 
activated holoenzyme that phosphorylates the retinoblastoma protein (pRb) (Kato et 
al., 1993; Lundberg & Weinberg, 1998; Weinberg, 1995).  This activation of Cdk is 
achieved for all cyclin-Cdk complexes through a conformational change in the Cdk, 
which results in access for the substrate to the catalytic core and also allows ATP to 
bind (Jeffrey et al., 1995). 
1.3.2.1 Pocket proteins 
pRb, and the other related ‘pocket proteins’ p107 and p130, bind to and inhibit the 
function of E2F transcription factors (Hurford et al., 1997) through recruitment of 
HDACs and Swi/Snf remodeling complexes (Zhang et al., 2000).  Deacetylation of 
histone octamers facilitates the condensation of nucleosomes, thereby preventing 
transcription factor access to chromosomal DNA (Kingston & Narlikar, 1999; Wolffe & 
Hayes, 1999).  Pocket proteins are only active in non- or hypo-phosphorylated states, 
and phosphorylation leads to disruption of the interactions with both HDACs and E2F 
(Ewen et al., 1993; Lundberg & Weinberg, 1998). 
1.3.2.2 E2F activation 
E2F proteins can be sub-divided into several groups.  E2F1, 2 and 3a interact 
exclusively with pRb, E2F4 can interact with all pocket proteins and E2F5 interacts 
with p130 (Dyson, 1998; Nevins, 1998).  E2F3a and b are encoded by the same 
gene, but transcription of E2F3b is controlled by an intronic promoter and it therefore 
has a different N terminus (He et al., 2000; Leone et al., 2000).  As with E2F3a, 
E2F3b interacts with pRb but not the other pocket proteins (Leone et al., 2000).  E2F 
1, 2 and 3a are strong activators of transcription, while E2F 3b, 4 and 5 act as 
repressors (Gaubatz et al., 2000; Leone et al., 2000).  E2F 1-5 also have a 
transactivation domain, which can recruit histone acetyl transferases (HATs) and 
relieve the chromatin condensation in quiescent cells, leading to up-regulation of 
transcription (Rowland & Bernards, 2006). 
The novel E2F6 (Trimarchi et al., 1998; Trimarchi & Lees, 2002), E2F7 (Kosugi & 
Ohashi, 2002) and E2F8 (Christensen et al., 2005; Maiti et al., 2005) proteins are all 
repressors of E2F transcription.  They all lack the pocket protein and DP protein 
binding domains, and therefore inhibit E2F-dependent transcription in a pRb-
independent manner. 
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Activation of E2F-dependent transcription results in transcriptional upregulation of 
various genes, leading to expression of proteins required for initiation of S phase.  
These include DNA polymerase α, thymidine kinase, thymidylate synthase, cdc2, 
cyclin A, cyclin E and a feedback amplification of cyclin D1 (Jolliff et al., 1991; Ohtani 
et al., 1995; Pearson et al., 1991; Yamamoto et al., 1994). 
There are 16 phosphorylation sites on pRb, and the level of transcriptional repression 
depends on the level of phosphorylation.  Phosphorylation by cyclin D/Cdk4 can 
result in dissociation of HDAC from pRb leading to transcriptional upregulation of 
cyclin E and entry into S phase, but Swi/Snf complexes can retain the repression of 
cyclin A and cdc2 transcription (Zhang et al., 2000).  It has been proposed that an 
increase in cyclin E/Cdk 2 expression is required for hyperphosphorylation of pocket 
proteins, and is therefore required for entry into S phase, but the fact that Cdk2 
knockout mice are viable makes this unlikely (Berthet et al., 2003).  E2F can 
therefore exist in three states: inactive, bound to pocket proteins; repressive, bound 
to chromatin remodelling complexes; active, not bound to either pocket proteins or 
chromatin remodelling complexes.  For activation, E2F must dimerise with DP-1 or 
DP-2 through protein interaction domains (Wu et al., 1996). 
1.3.3 Regulation of D-type cyclins 
The consequences of disregulated D-type cyclin expression can be loss of the control 
mechanisms preventing cell division and this can ultimately lead to development of 
cancer, including breast (Gillett et al., 1996), brain (Molenaar et al., 2008), liver 
(Yamamoto et al., 2006) and lung cancer (Sanchez-Mora et al., 2008).  There are 
several different mechanisms in place that control protein levels and prevent this from 
occurring. 
1.3.3.1 Transcriptional regulation of D-type cyclins 
The cyclin D1 promoter has binding sites for transcription factors NF-κB, E2F, CREB, 
TCF/LEF, Sp1, EtsB, AP-1, STAT3 and STAT5 (reviewed in Klein & Assoian, 2008).  
The first regulation of cyclin expression is at the transcriptional level.  D-type cyclins 
are only expressed when a cell is required to progress beyond G1 phase of the cell 
cycle.  The most intensely studied pathway leading to their upregulation is that 
leading from mitogenic signalling (Lukas et al., 1996).  The signalling cascade is 
initiated by the binding of a growth factor, such as epidermal growth factor (EGF) or 
platelet-derived growth factor (PDGF), to a receptor tyrosine kinase (RTK) at the 
plasma membrane, resulting in homo- or hetero-dimerisation of receptor subunits 
(Heldin et al., 1998).  This dimerisation results in activation of the kinase domains, 
Chapter 1 - Introduction 
57 
resulting in auto- and cross-phosphorylation of the RTK subunits (Heldin et al., 1998).  
Phosphorylated tyrosines act as docking sites for a series of proteins, including Shc, 
Grb2, SOS, and ultimately GDP-bound Ras (Katz et al., 2007).  SOS can then 
exchange GDP for GTP on Ras, thereby activating it (Innocenti et al., 2002), followed 
by recruitment and phosphorylation of Raf (Katz et al., 2007).  This leads to activation 
of MEK1/2 (Huang & Erikson, 1994), followed by ERK1/2 (Crews et al., 1992) and 
subsequently activation of many transcription factors, including NF-κB, AP-1, c-Myc 
and EtsB (Chang et al., 2003). 
Some cytokines can also lead to up-regulation of D-type cyclins.  Janus receptors 
recruit different Janus-activated kinases (JAKs), which phosphorylate signal 
transducers and activators of transcription (STATs).  Activation of STAT3 or STAT5 
through receptor binding of interleukin (IL) 6 (Takeda et al., 1998) or IL-3 (Ihle & Kerr, 
1995), respectively, leads to up-regulation of cyclin D1 transcription (Leslie et al., 
2006; Matsumura et al., 1999). 
In addition to growth factor and cytokine signalling, the extracellular matrix (ECM) can 
influence cyclin D1 expression (Assoian & Klein, 2008; Kothapalli et al., 2008).  
Binding of ECM proteins, including collagen, fibronectin and vitronectin, results in 
clustering of the cell surface receptor integrin.  This lead to activation of focal 
adhesion kinase (FAK), and thereby of ERK and subsequent activation of many 
transcription factors and upregulation of cyclin D1 expression (Zhao et al., 2001). 
1.3.3.2 Degradation of D-type cyclins 
In addition to transcriptional regulation, the levels of cyclin D protein are tightly 
controlled by ubiquitination and subsequent degradation (Diehl et al., 1997).  
Ubiquitination is dependent on phosphorylation of threonine 286 in cyclin D1, and this 
phosphorylation event is not controlled by the Cdks (Diehl et al., 1997) but by 
glycogen synthase kinase- (GSK) 3β (Diehl et al., 1998).  GSK-3β activity is inhibited 
by phosphorylation by Akt (Dudek et al., 1997), which is also activated by Ras 
(section 1.3.3.1) and PI-3 kinase, which itself is activated by Ras (Chiu et al., 2005; 
Yamamoto et al., 1999; Yan et al., 1998).  This means that mitogenic signalling not 
only increases transcription of D-type cyclins, but prevents their degradation.  
Consistent with this, the half life of cyclin D1 was found to be 13 mins in serum-
starved cells, as compared to 24 mins in serum-stimulated cells (Diehl et al., 1998).  
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1.3.3.3 Inhibitors of D-type cyclins 
Several Cdk inhibitors (CKIs) have been discovered, which add an additional level of 
regulation on top of transcriptional and protein degradation.  These can be broken 
down into two groups: the Cip/Kip proteins and the Ink4 proteins (Reynisdottir et al., 
1995). 
The Cdk interacting protein (Cip)/Kinase inhibitor protein (KIP) family consists of 
p21Cip1, p27Kip1 and p57Kip2 (Reynisdottir et al., 1995), which target Cdks coupled with 
cyclins A, D and E (el-Deiry et al., 1993; Gu et al., 1993; Harper et al., 1993; Lee et 
al., 1995; Matsuoka et al., 1995; Polyak et al., 1994; Toyoshima & Hunter, 1994).  
The Cdk binding domain of the Cip/Kip proteins is sufficient for cell cycle arrest when 
overexpressed (Chen et al., 1995; Luo et al., 1995).  However, p21Cip1 and p27Kip1 
have been shown to be critical for the assembly of cyclin D/Cdk complexes and their 
transport into the nucleus, suggesting a dual role for these proteins (Cheng et al., 
1999). 
The inhibitor of Cdk4 (Ink4) family consists of p16Ink4, p15Ink4B, p18Ink4C and p19Ink4D 
(Reynisdottir et al., 1995).  These proteins have no sequence similarity to the CIP/KIP 
proteins, and contain ankyrin repeats (Hannon & Beach, 1994; Hirai et al., 1995; 
Serrano et al., 1993).  They are specific for Cdk 4 and 6, and prevent cyclin D 
proteins from binding. 
1.3.4 Regulation of transcription factors I and III by pRb 
RNA polymerase I (pol I) is required for translation of large ribosomal RNAs (rRNA), 
while pol III is required for synthesis of tRNA and the small 5S rRNA. Active pRb and 
other pocket proteins are capable of preventing both pol I (Cavanaugh et al., 1995) 
and pol III (Sutcliffe et al., 2000; Sutcliffe et al., 1999; White et al., 1996) transcription 
by preventing them from interacting with other proteins necessary for activity.  An 
increase in the machinery required for both ribosome assembly and amino acid 
transfer occurs concurrently with activation of D-type cyclins.  In contrast to the self-
sufficient transcription of poxvirus genes and replication of viral DNA, host machinery 
is required for translation of virus proteins.  Inhibition of pRb results in more efficient 
virus replication by increasing ribosome numbers and the pool of tRNAs. 
. 
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1.4 Project aims 
This introduction shows that poxviruses express many proteins that manipulate 
cellular processes.  Exploration of the mechanisms of these manipulations and their 
impact on virus replication, spread and survival provides invaluable information about 
the viruses and their infected hosts. 
The aim of this project was to characterise v-slfn and determine its function.  This is 
of interest for two reasons: to further our knowledge of mammalian slfn proteins and 
their role in infection and understand the function of the slfn mimic in poxviruses.  
This thesis describes the work carried out to achieve these aims in four parts: 
1) Basic characterisation of v-slfn, including bioinformatic analysis, kinetics of 
expression, subcellular localisation and expression by different OPVs 
2) Recombinant protein production and purification for production of an anti-v-
slfn polyclonal antibody and cystallistion trials 
3) Functional analysis, including determination of the effect of v-slfn on m-slfn1-
induced arrest of cell proliferation and analysis of potential binding partners 
4) Production and characterisation of recombinant VACV expressing full length 
CMLV v-slfn 
These parts are described in four separate results chapters. 
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2 Chapter 2
Materials and Methods 
2.1 Cell culture 
Unless stated otherwise, all culture media were supplemented with 10 % heat treated 
(56 °C, 1 h) foetal bovine serum (FBS, Gibco), 50 units/ml penicillin and 50 µg/ml 
streptomycin (Gibco).  BS-C-1, D98OR, RK-13, NIH3T3 and B7 (NIH3T3 cells stably 
expressing v-slfn, a gift from Dr Gareth Brady, Trinity College Dublin) cells were 
cultured in Dulbecco’s modified Eagles medium (DMEM, Invitrogen).  HeLa cells 
were cultured in minimal essential medium (MEM) supplemented with 5 % non-
essential amino acids.  NIH3T3 cells stably expressing m-slfn1 (18-9 cells), a gift 
from Dr Gareth Brady (Trinity College Dublin), were cultured in RPMI 1640 medium 
supplemented with 100 µg/ml gentamycin to maintain the stable expression of m-
slfn1 and 0.5 µg/ml tetracycline to repress m-slfn1 expression.  m-slfn1 was induced 
using tetracycline-free medium.  All cell types were grown at 37 °C in a 5 % CO2 
atmosphere. 
2.1.1 Expression of exogenous genes 
2.1.1.1 Transient transfection of mammalian cells 
Cells were seeded at a density of 90 % for Lipofectamine 2000 (Invitrogen), or 50 % 
for FuGENE 6 (Roche) or at varying densities for PEI tranfections in antibiotic-free 
medium.  The transfection reagent was added to serum-free medium (OptiMEM, 
Gibco) as recommended by the supplier.  For Lipofectamine 2000, Fugene 6 and 
PEI, ratios of 5 µl of transfection reagent to 2 µg DNA, 3 µl of transfection reagent to 
1 µg of DNA and 3 µl of transfection reagent to 2 µg of DNA was used, respectively. 
2.1.1.2 Extraction of protein from mammalian cell culture 
Cells were lysed in RIPA buffer (50 mM Tris pH 8, 0.1 % SDS, 150 mM NaCl, 1 % 
NP40, 0.5 % sodium deoxycholate), mild lysis buffer 1 (50 mM HEPES, pH 7.5, 100 
mM NaCl, 1 mM EDTA, 10 % glycerol, 0.5  % NP-40), or mild lysis buffer 2 (20 mM 
Tris, pH 8, 100 mM NaCl, 0.5 % Triton-X100, 5 mM EDTA) containing protease 
inhibitor cocktail set III (Calbiochem) or Complete EDTA-free protease inhibitor 
tablets (Roche), and cell debris was removed by centrifugation at 13,000 rpm in a 
benchtop centrifuge (Sanyo Hawk 15/05) for 30 min at 4 °C. 
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2.2 Preparation and use of competent Escherichia coli (E. coli) 
2.2.1 Antibiotics 
Stocks of antibiotics were made up to 1000× concentrations and frozen at -20 °C.  
Ampicillin was made up to 100 mg/ml, kanamycin to 30 mg/ml and tetracycline to 20 
mg/ml. 
2.2.2 Preparation of chemically competent E. coli cells 
A single colony of DH5α (Novagen) cells was used to inoculate 5 ml of antibiotic-free 
Luria-Bertani (LB) medium. This was incubated with shaking for 16 h at 37 °C and 
transferred to 250 ml LB medium.  This was incubated with shaking at 37 °C until the 
bacteria reached an optical density at 595 nm (OD595) of 0.5.  The bacteria were 
collected by centrifugation at 1500 rpm for 15 min at 4 °C and incubated in 100 ml of 
ice cold 100 µM CaCl2 for 20 min on ice.  The bacteria were collected by 
centrifugation, resuspended in 5 ml 100 µM CaCl2 containing 10 % glycerol and 200 
µl aliquots were snap-frozen in methanol cooled with dry ice.  Tubes were stored at -
70 °C until needed. 
2.2.3 Preparation of electro-competent E. coli cells 
A single colony of Rosetta-Gami or B834 (Novagen) was used to inoculate 5 ml of LB 
containing tetracycline (Rosetta-Gami) or antibiotic-free LB medium (B834) and was 
incubated with shaking for 16 h at 37 °C. The sample was then transferred to 1 L of 
LB (tetracycline/antibiotic free).  This was incubated with shaking at 37 °C until the 
bacteria reached an optical density at 595 nm (OD595) of 0.5.  Flasks were then 
incubated on ice for 30 min, the bacteria were transferred into pre-cooled 250 ml 
centrifuge tubes, collected by centrifugation at 1500 rpm for 15 min at 4 °C, and 
resuspended in 500 µl ice-cold H2O.  This was repeated four times, reducing the 
volume of H2O to 250 ml, 100 ml, 50 ml and for the last wash 25 ml of ice-cold 10 % 
glycerol was used.  Cells were collected by centrifugation as before, resuspended in 
5 ml of 10 % glycerol and 200 µl aliquots were snap-frozen and stored as before. 
2.2.4 Transformation of chemically competent E. coli 
Bacteria were thawed on ice and 100 ng of plasmid DNA or 3 µl of ligation mix was 
added to 25 µl aliquots on ice for 5 min.  The tubes were then incubated in a 42 °C 
water bath for 30 s and transferred immediately back to ice for 10 min. 200 µl SOC 
medium was added and tubes were shaken at 37 °C for 1 h to allow for expression of 
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antibiotic resistance.  The bacterial suspension was then spread onto agar plates 
containing antibiotic (ampicillin or kanamycin) and incubated at 37 °C overnight. 
2.2.5 Transformation of electro-competent E. coli 
Bacteria were thawed on ice and 10 ng of plasmid DNA was added to 50 µl aliquots 
in pre-cooled 2-mm electroporation cuvettes (BioRad) for 10 min on ice.  The cuvette 
was pulsed in an electroporator (BioRad Micropulser) using the Ec2 setting (2.5 kV, 1 
pulse) and 200 µl SOC medium was added immediately.  The samples were 
incubated on ice for 10 min and shaken at 37 °C for 1 h.  Finally, 20 µl was spread 
onto an agar plate containing kanamycin and incubated at 37 °C overnight. 
2.3 Cloning 
2.3.1 Vectors and plasmids 
The mammalian expression vector pCI was from Promega.  The bacterial expression 
vectors pET24a and pET28a were from Novagen.  pCI expressing v-slfn without (pCI-
176-WT) or with a HA tag on the N or C terminus (pCI-176-NHA and pCI-176-CHA, 
respectively) were constructed by Dr Caroline Gubser (Imperial College London).  
The mammalian expression vector expressing murine cyclinD1 (pcDNA3.1-cyclinD1) 
or NF-κB p65 subunit (pp65), and the bacterial expression vector expressing 176R 
fused to a GST tag (pGEX-KG-176-GST) were a gift from Dr Gareth Brady (Trinity 
College Dublin).  The mammalian vector pCEFL-KZ-AU5 and pCEFL-KZ-AU5-H-
RasV12, which contains the sequence for a constitutively activated form of H-Ras, 
were a gift from Dr José M. Rojas (Instituto de Salud Carlos III, Spain).  pSTAT5a-
N642H, which expresses a constitutively activated form of STAT5a, was a gift from 
Prof Toshio Kitamura (University of Tokyo).  pSTAT5bCA, which expresses a 
constitutively activated form of STAT5b, was a gift from Prof Peter Rotwein (Oregon 
Health & Science University).  pSTAT3-C, which expresses a constitutively activated 
form of STAT3, was purchased from Addgene (plasmid 8722).  pVP16-CREB, which 
expresses a constitutively activated form of CREB, was a gift from Dr Piruz Nahrein 
(University of Colorado Denver Health Sciences).  Plasmids expressing luciferase 
under the control of the cyclin D1 (-1745CD1LUC), CRE (pCRE-luc), E2F-dependent 
(pE2F-luc), NF-κB-dependent (pNF-κB-luc) and TCF-dependent (p8×TOPFLASH) 
promoters were gifts from Professor Richard Pestell (Boston University), Dr William 
Walker (University of Pittsburgh), Dr Gareth Brady (Trinity College Dublin), Dr 
Andrew Bowie (Trinity College Dublin) and Dr Randall Moon (University of 
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Washington), respectively.  Several constructs were made as part of this project 
(Table 2-1). 
2.3.2 Restriction enzyme digestion and dephosphorylation of DNA 
All restriction digests were performed with enzymes from Roche or New England 
Biolabs using temperature and buffers as recommended.  All digestions were carried 
out in 20 to 50 µl volumes for 1 h except when using SmaI and NheI, when reactions 
were carried out for 4 h.  Vectors digested with SmaI or NheI were dephosphorylated 
with 1 U shrimp alkaline phosphatase (SAP, Amersham Biosciences) in the restriction 
digestion reaction mix to prevent vector self-ligation.  Where a change of buffer was 
required between reactions for a double digest the DNA was purified (section 2.3.6). 
2.3.3 Oligonucleotides 
Oligonucleotide primers (Table 2-1) were synthesised by Sigma-Aldrich.  Lyophilised 
DNA was resuspended in an appropriate volume of ddH2O in obtain a stock of 500 
µM.  Working stocks were made by diluting this stock 1:50 to obtain a stock of 10 µM. 
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Table 2-1 
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Table 2-1 (continued) 
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Table 2-1.  List of cloning primers used in this study. 
The genes or ORFs cloned are presented along with the vector into which they were cloned, 
included tags (if any) and which terminus of the protein they are at, the restriction sites 
included within the primers for cloning, the name of the primers used and the sequence of the 
primer, colour coded to indicate different features. 
2.3.4 Amplification of mammalian and viral genes by PCR 
Murine cDNA was reverse transcribed from RNA extracted from the spleens of 
BALB/c mice using Superscript III RT (Invitrogen) with Oligo(dT) primers (Invitrogen).  
Human cDNA was reverse transcribed from HeLa cell RNA.  RNA was extracted 
using Trizol reagent (Invitrogen) according the manufacturer’s protocol.  Viral DNA 
was extracted from infected cells using proteinase K (section 2.6.6.10).  Platinum Pfx 
DNA polymerase (Invitrogen) was used for DNA amplification for cloning.  A standard 
protocol was used (Table 2-2), and modified if required. 
10 × Pfx buffer 5 μl
MgCl2 (50 mM) 1.5 μl 95 °C 2 min
dNTP (10 mM) 1 μl 95 °C 30 s
Primer 1 (10 μM) 1 μl 55 °C 30 s × 25 cycles
Primer 2 (10 μM) 0.4 μl 68 °C 1‐3 min
(cDNA) 1 μg 68 °C 10 min
(Proteinase K extracted VACV DNA) 2 μl
Platinum Hi‐Fi/Pfx Taq 0.2 μl
dd H2O 38 μl  
Table 2-2.  Conditions used for amplification of DNA for cloning by PCR. 
The reagents used for amplification of target genes by PCR for cloning are indicated, with 
quantities used and the standard programme used. 
2.3.5 Creating blunt ends using the Klenow enzyme 
To create blunt ends from an overhang generated by a restriction digestion the 
Klenow enzyme was used, which has 5’ – 3’ polymerase and 3’ – 5’ exonuclease 
activity.  Purified DNA (section 2.3.6) was incubated for 15 min at 37 °C with 2 µl 10 
mM dNTP, 2 µl 10 × filling buffer (500 mM Tris pH 7.5, 100 mM MgCl2, 10 mM DTT 
and 500 µg/ml BSA), made up to 20 µl in H2O. 
2.3.6 Purification of PCR products 
When different buffers were required for double digests or when several enzyme 
treatments were to be carried out in serial, PCR products were purified using a PCR 
Purification Kit (Qiagen). 
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2.3.7 Agarose gel electrophoresis 
DNA fragments were resolved by agarose gel electrophoresis. Samples were mixed 
at a ratio of 5:1 with 6 × loading buffer (10 mM Tris, pH 7.6, 0.03 % (w/v) 
bromophenol blue, 0.03 % (w/v) xylene cyanol FF, 0.15 % (w/v) orange G, 60 % 
glycerol, 60 mM EDTA) and loaded onto a 1 % (w/v) agarose gel made up in Tris 
acetate EDTA (TAE, 40 mM Tris, pH 8, 20 mM acetic acid, 1 mM EDTA).  As the gel 
was setting, ethidium bromide (10 µg/ml) was added. Electrophoresis of the DNA was 
performed in TAE buffer in a minigel electrophoresis unit (BioRad).  The DNA 
fragments were visualized and photographed using a UV transilluminator (Chemi 
Doc, BioRad). 
2.3.8 Isolation of DNA from agarose gels 
DNA to be gel purified was resolved on a 1 % agarose gel, visualised on a UV 
transillumination box and excised from the gel using a clean scalpel.  DNA was 
purified from the agarose using a Qiaex II Gel Extraction Kit (Qiagen) according to 
the manufacturer’s instructions. 
2.3.9 DNA ligation 
All DNA was purified from agarose gels before ligation (section 2.3.8).  DNA ligations 
were carried out using a Rapid DNA Ligation Kit (Roche) according to the 
manufacturer’s protocol.  Prior to ligation a portion of the digested DNA was resolved 
on an agarose gel, and molar ratios of insert and vector were calculated based on the 
intensity of the bands.  The ratio of insert to vector was 3:1 for all reactions.  Ligated 
DNA was transformed immediately into chemically-competent DH5α. E. coli (section 
2.2.4). 
2.3.10 Screening of colonies 
Ligation of DNA into the vector of interest was confirmed by restriction enzyme 
digestion.  A single colony was isolated using a small micropipette tip from a plate of 
transformed E. coli and used to inoculate 3 ml of LB broth.  The inoculate was 
incubated overnight at 37 °C with shaking at 200 rpm, and plasmid DNA was 
extracted using a miniprep kit (section 2.3.11). Ten µl of the 50 µl purified DNA was 
digested with restriction enzymes appropriate for determination of DNA insertion 
(usually the enzymes used for cloning).  The digested DNA was resolved by agarose 
gel electrophoresis (section 2.3.7) 
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2.3.11 Small scale preparation of plasmid DNA (miniprep) and large scale 
preparation of plasmid DNA (maxiprep) 
For small scale DNA preparations, single colonies of E. coli strain DH5α containing 
plasmid DNA inserts were inoculated in 5 ml of LB medium containing the appropriate 
antibiotic.  Bacterial cultures were shaken overnight at 37 °C, collected by 
centrifugation at 3000 rpm for 10 min, and plasmid DNA was extracted using QIAprep 
Spin Miniprep Kit (Qiagen).  For larger scale, high quality DNA preparations, single 
colonies were inoculated in LB for 8 h as described above and were then transferred 
to 250 ml LB containing appropriate antibiotics.  Bacteria were shaken overnight at 37 
°C and collected by centrifugation at 3000 rpm for 10 min. Plasmid DNA was 
extracted using a HiSpeed Plasmid Maxi Kit (Qiagen). 
2.3.12 Quantification of DNA 
The DNA concentration was determined by measuring the UV absorbance at 260 nm 
and using the equation 1 OD260 = 50 µg/ml dsDNA. The purity of the DNA was 
determined by the ratio of the A260 to A280.  Pure DNA has an A260:A280 ratio of 1.8:1. 
2.3.13 Preparation of glycerol stocks 
A 500 µl aliquot of the overnight culture grown up for restriction enzyme screening of 
colonies (section 2.3.10) was used to store the appropriate bacterial clones for future 
use.  The bacterial suspension was mixed with an equal volume of 30 % (v/v) sterile 
glycerol solution and stored at -80 °C.  When required, the glycerol stock was 
scraped using a 10 µl micropipette tip and used to inoculate 200 µl LB broth.  This 
was immediately streaked out on an agar plate and incubated at 37 °C overnight.  A 
single colony was picked from the plate and used to inoculate 5 ml LB broth, which 
was shaken for 8 h at 37 °C and then transferred to 250 ml LB and shaken overnight 
at 37 °C. 
2.4 Protein detection and analysis 
2.4.1 SDS-polyacrylamide gel electrophoresis (PAGE) 
Protein samples were mixed at a ratio of 5:1 with 6 × Laemmli loading buffer (300 mM 
Tris, pH 6.8, 12 % SDS, 60 % glycerol, 0.6 % bromophenol blue) supplemented with 
100 mM 1,4-dithio- DL-threitol (DTT).  Samples were heated at 95 °C for 5 min.  
Proteins were resolved on a 10 % or 12 % polyacrylamide gel consisting of a stacking 
gel (125 mM Tris, pH 6.8, 4 % (v/v) acrylamide mix (Kimberly Research), 0.1 % (w/v) 
SDS, 0.1 % (w/v) ammonium persulphate and 0.04 % v/v N,N,N’,N’-
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tetramethylethylenediamine (TEMED)) and a resolving gel (10 % or 12 % (v/v) 
acrylamide mix, 375 mM Tris pH 8.8, 0.1 % (w/v) SDS, 0.1 % (w/v) ammonium 
persulphate, 0.04 % (v/v) TEMED) by electrophoresis, in a Tris-glycine running buffer 
(24 mM Tris-Base, 192 mM glycine, 1 % (w/v) SDS) using a Mini-PROTEAN II 
apparatus (BioRad).  A prestained molecular mass marker was run with each sample, 
either Precision-Plus (BioRad) or SeeBlue 2 (Invitrogen). 
2.4.2 Coomassie blue staining 
Gels in coomassie brilliant blue solution (0.25 % (w/v) Coomassie brilliant blue R-250, 
10 % (v/v) acetic acid, 25 % (v/v) methanol) were microwaved on a low power for 2 
min and placed on a rotary shaker for 10 min.  Excess stain solution was removed 
using destain buffer (10 % (v/v) acetic acid, 25 % methanol).  Gels were equilibrated 
in water for 10 min and dried between 2 sheets of pre-wet cellophane membrane 
(Bio-Rad) in a hot air dryer (GelAir drying system, Bio-Rad). 
2.4.3 Electrophoretic transfer of proteins 
SDS-polyacrylamide gels were equilibrated in transfer buffer (24 mM Tris-Base, 192 
mM glycine, 20 % (v/v) methanol) for 30 min.  The proteins were then transferred to a 
nitrocellulose membrane (Hybond ECL, Amersham Pharmacia Biotech) using a semi-
dry electrotransfer cell for 30 min at 18 V. 
2.4.4 Immunoblotting 
Nitrocellulose membranes were incubated with PBS containing 5 % (w/v) dried milk 
powder (Marvel) overnight at 4 °C to block non-specific protein binding sites, and 
were then incubated with primary antibody (Ab) for 1 to 3 h at RT, at a dilution factor 
of 1:100 to 1:2000.  Membranes were washed in PBS/0.1 % Tween 20 (PBS-T) and 
incubated for 1 h with secondary Ab linked to horseradish peroxidase (HRP) at a 
concentration of 1:2000.  Blots were washed vigorously and developed in enhanced 
chemiluminescence (ECL) plus solution for 5 min.  The resulting luminescent signal 
was detected on X-ray film (Kodak). 
2.4.5 Immunofluorescence 
HeLa cells were grown on sterile glass coverslips in 6-well plates.  The cells were 
washed with ice-cold PBS, fixed in 4 % paraformaldehyde in 250 mM HEPES pH 7.6 
for 20 min on ice, and quenched in 20 mM glycine for 15 min at RT.  The samples 
were blocked for 1 h with 0.1 % saponin (Sigma) in PBS containing 10 % FBS, 
incubated with anti-v-slfn antiserum or anti-HA  for 1 h, washed three times in block 
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solution and incubated for 30 min with anti-mouse rhodamine (TRITC)-conjugated or 
anti-rabbit Alexa Fluor 488- (Invitrogen) conjugated secondary Ab. Samples were 
washed three times in block solution, with a final wash in distilled water and mounted 
in mowiol-4’,6-diamidino-2-phenylindole medium. Samples were viewed with a Zeiss 
Pascal laser scanning confocal microscope and images were captured and prepared 
using Zeiss LSM image browser software version 3.2. 
2.4.6 Immunoprecipitation 
HeLa cells were seeded in 10 cm dishes and transfected with 24 µg DNA using 60 µl 
Lipofectamine 2000 according to the manufacturer’s instructions.  Cells were 
harvested 24 h post-transfection in 400 µl lysis buffer (either RIPA, mild lysis buffer 1, 
or mild lysis buffer 2), and the protein concentration was determined by measuring 
the OD595 using Protein Assay solution (BioRad) compared to OD595 of standards.  
Each immunoprecipitation (IP) used 750 µg protein and 50 µg was kept for the input.  
Protein samples were pre-cleared with 30 µl protein G sepharose beads for 2 h at 4 
°C, centrifuged in a benchtop centrifuge at 4 °C, and incubated with either anti-v-slfn 
(1:150) or anti-HA (1:500) Ab overnight at 4 °C.  Forty µl protein G sepharose beads 
were added to each sample and rotated for 2 h at 4 °C.  The beads were collected by 
centrifugation at 4 °C and washed four times in lysis buffer, rotating the samples at 4 
°C for 10 min between each wash.  The beads were collected by centrifugation, 
resuspended in 45 µl 2 × Laemmli loading buffer and boiled for 5 min.  Samples were 
loaded onto a 10 % polyacrylamide gel and analysed by immunoblotting. 
2.5 Expression and purification of recombinant v-slfn protein and generation 
of an anti-v-slfn Ab 
2.5.1 Expression of recombinant protein from E. Coli 
pET28a or pGEX-KG vectors expressing v-slfn or m-slfn1 were transformed into 
electro-competent B834 or Rosetta-Gami E. coli.  Single colonies were used to 
inoculate a 5 ml starter culture and were incubated with shaking overnight. Then an 
appropriate volume (1/100 of the final volume) was transferred to either 5 ml or 500 
ml of LB. At OD595 of 0.6, protein expression was induced for 3 h by addition of IPTG 
to a final concentration of 1 mM. 
2.5.1.1 Small scale protein expression 
The relative quantity of bacteria was determined at OD595 before samples were 
collected by centrifugation at 3000 rpm (Beckman Allegra 6R centrifuge) for 15 min 
and lysed in 200 µl BugBuster (Novagen) per 1 OD595 unit.  Samples were then 
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sonicated four times for 15 s at 20 % power output, with 30 s incubation on ice 
between each sonication, and centrifuged at 13,000 rpm in a benchtop centrifuge for 
30 min at 4 °C.  The supernatant (soluble protein) was transferred to a fresh tube, 
and the pellet (insoluble material) was resuspended in the same volume of lysis 
buffer as used to lyse the sample originally. 
2.5.1.2 Large scale protein expression 
Bacterial cultures (500 ml) were induced to express recombinant protein and were 
collected by centrifugation at 3000 rpm for 15 min at 4 °C.  The pellets were lysed in 
20 ml BugBuster containing protease inhibitors.  Samples were sonicated ten times 
for 30 s at 20 % power output, with a 30 s incubation on ice between sonications.  
The soluble and insoluble fractions were separated by centrifugation at 10,000 × g for 
30 min at 4 °C. 
2.5.1.3 Purification of inclusion bodies from the insoluble fraction 
To purify v-slfn from inclusion bodies, the pellet from the insoluble fraction was 
washed four times in 50 ml inclusion body wash buffer (20 mM Tris, pH 7.5, 10 mM 
EDTA, 1 % Triton-X100), and centrifuged at 10,000 × g for 10 min at 4 °C between 
washes. The final pellet was resuspended in 5 ml PBS.  Protein purity was 
determined by serial dilutions of the suspension followed by SDS-PAGE and 
coomassie blue staining. 
2.5.1.4 Protein denaturation and refolding 
A 1 litre culture was grown and induced to express v-slfn for 3 hours at 37 °C with 1 
mM IPTG.  The bacteria were lysed in BugBuster lysis buffer (Novagen) with 
proteinase inhibitors and the lysates were sonicated.  The inclusion bodies were 
washed as before (section 2.5.1.3) and dissolved in denaturation buffer (6 M GnHCl, 
50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM EDTA, 10 mM DTT) and left at 4 °C 
overnight which allows full denaturation of the proteins.  The insoluble precipitates 
were then removed by centrifugation at 4,000 rpm for 20 min at 4 °C, and the proteins 
were partially refolded by rapid dilution into 100 ml refolding buffer (1 M Arginine, 50 
mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM DTT, 10 mM EDTA, 6.5 mM cysteamine, 
3.7 mM cystimine) and left for 24 hours.  This was then dialised against gel filtration 
buffer (50 mM Tris-HCl pH 7.5, 200 mM NaCl) overnight at 4 °C and finally it was 
concentrated. 
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2.5.2 Production of rabbit polyclonal antiserum to v-slfn 
A polyclonal rabbit antiserum was raised against v-slfn by Harlan Seralabs using 
purified inclusion bodies from bacteria expressing v-slfn.  To reduce cross-reactivity 
of the antiserum with denatured mammalian proteins, an antiserum cleanup was 
performed.  HeLa cells (3 x 108) were collected by centrifugation, lysed with acetone 
and incubated at -20 °C for 30 min.  The precipitated proteins were collected by 
centrifugation and dried overnight at RT.  Antiserum diluted 1:10 in PBS was added 
to the precipitate and incubated with shaking for 48 h.  Protein precipitate was 
removed by centrifugation, and the supernatant was filtered and used for 
immunoblotting. 
2.5.3 Expression of recombinant protein from baculoviruses 
Recombinant baculoviruses expressing v-slfn or m-slfns 1, 3 or 8 were generated 
using the BacVector system (Novagen).  The relevant genes were amplified by PCR 
to include HindIII and XhoI restriction sites at the 5’ and 3’ ends, respectively, and 
cloned into the pBAC-1 plasmid (Novagen) to create plasmids pBACvS (v-slfn), 
pBACS1 (m-slfn1), pBACS3 (m-slfn3) and pBACS8 (m-slfn8). 
2.5.3.1 Generation of recombinant baculoviruses 
Sf9 cells were seeded in a 25 cm2 flask at a density of 2.5 × 106 cells per flask and 
allowed to settle for at least 20 min.  pBACvS, pBACS1, pBACS3 or pBACS8 and 
BacVector-1000 triple-cut virus genomic DNA were transfected into the cells using 
Insect GeneJuice (Novagen).  Cell growth medium was harvested 72 hpi and any 
floating cells were removed by centrifugation.  Recombinant virus was recovered and 
purified from the medium by plaque purification. 
2.5.3.2 Plaque purification of virus 
To isolate individual clones of viruses, Sf9 cells were seeded in a 6 well plate at a 
density of 1.5 × 106 cells per well and allowed to settle for at least 20 min.  Serial 
dilutions of virus stocks were performed and used to infect the monolayers of cells.  
The wells were overlaid with 2 ml Sf900-II containing 5 % FBS and 1 % BacPlaque 
agarose (Novagen).  Plaques were identified 72 hpi and picked using a wide-
bottomed p200 pipette tip.  The entire plug of agarose containing the virus was added 
to 500 µl of Sf900-II containing 5 % FBS and left for at least 2 h to allow diffusion of 
virus out of the agarose plug. 
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2.5.3.3 Amplification of virus stocks 
Sf9 cells were seeded in a 25 cm2 flask at a density of 2.5 × 106 cells per flask and 
allowed to settle for at least 20 min.  Virus isolated by plaque purification (200 µl) was 
used to infect the monolayer of cells.  Cell growth medium was harvested when full 
CPE was observed (usually 72-96 hpi) and floating cells were removed by 
centrifugation.  This medium was stored for future use (master stock).  Sf9 cells were 
seeded in a 75 cm2 flask at a density of 1.25 × 107 cells per flask and allowed to 
settle for at least 20 min.  The monolayer of cells was infected with 200 µl of the 
master stock of virus.  Cell growth medium was harvested when full CPE was 
observed (usually 72 hpi) and floating cells were removed by centrifugation.  This 
medium was titred stored for future use (sub-master stock). 
Sf9 cells in suspension were grown up to a density of 2 × 106 cells per ml in a total of 
500 ml Sf900-II medium.  Cells were infected at an MOI of 0.05 by adding an 
appropriate amount of virus to the suspension to allow infection of 1 cell in 20.  Cell 
growth medium was harvested when full CPE was observed (usually 72-96 hpi) and 
cells were removed by centrifugation.  This medium was titred stored for future use 
(working stock). 
2.5.3.4 Large scale protein production 
Sf9 cells in suspension were grown up to a density of 2 × 106 cells per ml in a total of 
1500 ml Sf900-II medium.  Cells were infected at an MOI of 5 with the appropriate 
virus.  Infected cells were collected by centrifugation 72 hpi and lysed using Sf9 lysis 
buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 1 % Triton X-100, 1 mM TCEP) and 
incubated on ice for 30 min.  Cell debris was collected by centrifugation at 10,000 × g 
for 30 min at 4 °C, and the supernatant was filtered using a 0.45 µm syringe filter. 
2.5.3.5 Affinity chromatography 
A 5 ml HisTrap column (GE Healthcare), which was attached to an ÄKTApurifier fast 
protein liquid chromatography (FPLC) apparatus, was equilibrated using protein 
purification buffer A (500 mM NaCl, 50 mM Tris-HCl, pH 7.5, 20 mM imidazole, 1 mM 
TCEP).  His-tagged proteins were isolated from infected cell lysates by running the 
lysates through the column, utilising the affinity of the recombinant His tags to the Ni2+ 
matrix, and washing any unbound protein off using buffer A.  Protein was eluted using 
an increasing gradient of protein purification buffer B (500 mM NaCl, 50 mM Tris-HCl, 
pH 7.5, 500 mM imidazole, 1 mM TCEP), and eluted protein was collected using a 
Frac-950 fraction collector (GE Healthcare). 
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2.5.3.6 Size-exclusion chromatography 
A Superdex 200 10/300 GL column (GE Healthcare), which was attached to an 
ÄKTApurifier FPLC apparatus, was equilibrated using protein purification buffer C 
(500 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1 mM TCEP).  Concentrated protein from a 
HisTrap purification was applied to the column and eluted with 1.5 column volumes of 
buffer C.  Eluted protein was collected using a Frac-950 fraction collector (GE 
Healthcare). 
2.6 Viruses 
2.6.1 Virus stocks 
The source of VACV strain Western Reserve (WR) v∆B8R and CMLV strain CMS 
were described previously (Gubser & Smith, 2002; Symons et al., 2002b).  
Recombinant v∆B8R viruses expressing v-slfn were made by Andrea Ecker (Gubser 
et al., 2007).  Briefly, the CMLV strain CMS 176R gene was inserted into the 
thymidine kinase (TK) gene locus either in its wild-type state (v176-WT) or with a HA 
tag on the N or C terminus (v176-NHA and v176CHA, respectively). As a control a 
recombinant virus, vH1, expressing the influenza virus A/34/PR/8 HA gene (Smith et 
al., 1987) from the same locus and under the same promoter was made by Dr 
Caroline Gubser (Gubser et al., 2007).  All virus stocks were stored at -70 °C.  Before 
use virus stocks were thawed at 37 °C and sonicated with three 10 s pulses at 20 % 
power output. 
2.6.2 Virus infection of mammalian cells 
Virus was diluted in DMEM containing 2.5 % FBS and was added to cells in 0.5 ml (6-
well plate), 2 ml (25 cm2 flask) or 5 ml (175 cm2 flask).  Cells were rocked every 15 
min for 1.5 h at 37 °C.  The inoculum was removed and the cells were incubated in 
DMEM/2.5 % FBS for the time indicated for each experiment. 
2.6.3 Preparation of crude stocks 
Flasks of RK-13 cells were infected at approximately 0.1 PFU/cell and incubated until 
complete CPE was observed (usually 2 days).  Cells were scraped off the surface of 
the infected flask, and the medium containing the cells was transferred to a 250 ml 
centrifuge tube.  Cells were collected by centrifugation at 2,000 × g for 5 min at 4 °C 
(Beckman Allegra 6R centrifuge) and resuspended in a small volume of DMEM 
containing 2.5 % FBS.  Infected cells were subjected to three cycles of freeze-
thawing, and were then aliquoted and stored at -80 °C. 
Chapter 2 – Materials and Methods 
75 
2.6.4 Determination of virus infectivity by plaque assay 
The amount of infectious virus in a stock was determined by plaque assay.  Viruses 
were sonicated, then serially diluted down in duplicate to the required level in DMEM 
containing 2.5 % FBS.  Diluted virus was used to infect, in duplicate, wells containing 
confluent monolayers of BS-C-1 cells in a six well plate.  The plates were incubated 
for 90 minutes, with rocking, and then the medium was replaced with DMEM 
supplemented with 2.5 % FBS containing 1.5 % carboxymethylcellulose (CMC).  After 
48 h, the medium was removed, the cells were washed once with PBS and stained 
with 0.01 % (w/v) crystal violet in 15 % ethanol.  This was left for 2 hours, and then 
washed by submersion in water.  The plates were left to dry, and the titre of the virus 
(expressed in PFU/ml) was determined based on the number of plaques and the 
dilution factor. 
2.6.5 Sucrose purification of VACV 
Flasks of RK-13 cells were infected at 0.1 PFU/cell and incubated until complete CPE 
was observed (usually 2 days).  Cells were scraped off the surface of the infected 
flask, and the medium containing the cells was transferred to a 250 ml centrifuge 
tube.  Cells were collected by centrifugation at 2,000 × g for 5 min at 4 °C (Beckman 
Allegra 6R centrifuge) and resuspended in ice cold 10 mM Tris HCl (pH 9) and 
allowed to swell on ice for 15 min.  The cells were then broken open in a dounce 
homogeniser and the nuclei were collected by centrifugation at 500 × g (Beckman 
GPR centrifuge, GH-3.7 rotor).  The supernatant was sonicated for 30 sec, and 
carefully added to an equal volume of 36 % (w/v) sucrose in 10 mM Tris HCl (pH 9).  
This was centrifuged at 15,000 × g for 80 min at 4 °C (Beckman L8-M ultracentrifuge, 
SW28 rotor).  The pellet (containing the virus) was resuspended in 1 mM Tris HCl pH 
9. 
2.6.6 Construction of recombinant VACV 
2.6.6.1 Construction of plasmids for generation of viruses by 
transient dominant selection 
Plasmids were made for deletion of B2R, B3R, B2R & B3R, for re-inserting the 
deleted DNA (revertant viruses) and for insertion of exogenous genes.  These were 
constructed using splice overlap PCR (Horton et al., 1989) and inserted into a 
shortened version of the pCI vector containing EcoGPT-eGFP under the control of 
the synthetic early/late VACV promoter (Davison & Moss, 1990) at a site proximal to 
the multiple cloning site. See Table 2-1 for the sequences of primers used.  The 
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plasmid for double deletion of B2R and B3R was generated by amplifying the left 
flanking region of B2R using primers KOF1plus and KOF1/F2minus and the right 
flanking region of B3R using primers KOF1/F2plus and KOF2minus.  The PCR 
products were purified (section 2.3.5) and splice-overlapped in a single reaction using 
primers KOF1plus and KOF2minus.  The PCR product and vector were digested with 
XmaI and NotI and ligated to create the p21N1 plasmid.  The plasmid for single 
deletion of B2R was generated by amplifying the left flanking region of B2R using 
primers KOF1plus and KNF1/FB2minus and the right flanking region of B2R using 
primers KNF1/FB2plus and FB2minus.  The PCR products were purified and splice 
overlapped in a single reaction using primers KOF1plus and FB2minus.  The PCR 
product and vector were digested with XmaI and NotI and ligated to create the p25N1 
plasmid.  The plasmid for single deletion of B3R was generated by amplifying the left 
flanking region of B3R using primers FB3plus and KNFB3/F2minus and the right 
flanking region of B3R using primers KNFB3/F2plus and KOF2minus.  The PCR 
products were purified and splice overlapped in a single reaction using primers 
FB3plus and KOF2minus.  The PCR product and vector were digested with XmaI and 
NotI and ligated to create the p26N2 plasmid.  The plasmid for generation of revertant 
viruses was generated by amplifying the entire section of the VACV genome from the 
left flank of B2R to the right flank of B3R using primers KOF1plus and KOF2minus.  
The PCR product and vector were digested with XmaI and NotI and ligated to create 
the p7N3 plasmid. 
2.6.6.2 Construction of plasmid for knocking in genes into the v-
slfn locus 
A plasmid for insertion of exogenous genes into the v-slfn locus was generated by 
inserting BsiWI and ApaI restriction sites between the left and right flanks in the 
p21N1 plasmid (section 2.6.6.1).  The left flank was amplified from the plasmid using 
primers KOF1plus and 21N1mutA and the right flank was amplified using primers 
21N1mutS and KOF2minus.  The PCR products were purified (section 2.3.5) and 
splice overlapped in a single reaction using primers KOF1plus and KOF2minus.  The 
PCR product and vector were digested with XmaI and NotI and ligated to create the 
pKIVEC plasmid. 
2.6.6.3 Construction of a plasmid to knock CMLV v-slfn into the 
VACV v-slfn locus 
CMLV 176R with the sequence coding for a C-terminal HA tag was amplified from 
pCI-v-slfn-CHA with primers 176KIF and 176KIR (Table 2-1).  The PCR product and 
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the pKIVEC plasmid were digested with BsiWI and ApaI restriction enzymes and 
ligated to create the pKICHA plasmid. 
2.6.6.4 Construction of plasmid for generation of VACV stably 
expressing EcoGPT/eGFP in the B2/B3 locus 
To create a plasmid for stable integration of EcoGPT-eGFP into the v-slfn locus of 
VACV, a plasmid was generated with EcoGPT-eGFP between the left and right flanks 
in the pKIVEC vector.  pKIVEC was digested with BsiWI and ApaI, and the sticky 
ends were blunted with the klenow enzyme (section 2.3.5).  EcoGPT-eGFP under the 
control of the synthetic early/late VACV promoter (Davison & Moss, 1990) was cut 
out of the pAFB plasmid (Fahy et al., 2008) with SmaI and ligated into the blunt-
ended digested pKIVEC vector to create plasmid pKIE/E. 
2.6.6.5 Construction of plasmid for removal of EcoGPT/eGFP from 
the B2/B3 locus 
The p21N1 and pKICHA plasmids were digested using NheI, and the sticky ends 
were filled in using klenow (section 2.3.5).  They were then digested using HindIII and 
gel purified (section 2.3.8).  The gene coding for the cherry protein was cut out of a 
vector designed to delete the A41L orthologue from MVA by transient dominant 
selection (Dr Mike Putz, Imperial College London).  This plasmid was cut with NotI 
and the sticky ends were filled in using klenow.  The gene of interest was then 
excised using HindIII.  The cherry gene was ligated into the linearised p21N1 and 
pKICHA vectors to create p21N1-Ch and pKICHA-Ch, respectively. 
2.6.6.6 Plaque purification of virus 
To isolate individual clones of viruses, confluent monolayers of BS-C-1 cells in a 6 
well plate were infected at a low enough level to allow adequate spacing between 
single foci of infection for isolation of individual plaques.  The wells were overlaid with 
2 ml DMEM containing 2.5 % FBS and 1 % type VII low melting point agarose 
(Sigma).  Plaques were identified 48 hpi and picked using a wide-bottomed p200 
pipette tip.  The entire plug of agarose containing the virus was added to 500 µl of 
DMEM containing 2.5 % FBS and freeze-thawed three times. 
2.6.6.7 Production of recombinant VACV by transient dominant 
selection 
Deletion viruses were constructed by transient dominant selection based on the 
∆B8R parental virus (Symons et al., 2002b) that lack the B2R ORF (v∆B2R) or the 
Chapter 2 – Materials and Methods 
78 
B3R ORF (v∆B3R), and revertant viruses were constructed in which the ORFs have 
been reinserted (vB2Rrev and vB3Rrev).  v∆B2R and v∆B3R were generated by 
transfecting BS-C-1 cells that had been infected with parental ∆B8R virus at an MOI 
of 0.05 with p25N1 and p26N2, respectively.  Recombinant viruses were selected in 
the presence of 25 µg/ml mycophenolic acid (MPA), 15 µg/ml hypoxanthine, 250 
µg/ml xanthine (Boyle & Coupar, 1988).  Control infections were included using 
v∆B8R and vSAD3 which stably expresses EcoGPT (Wilcock et al., 1999) with and 
without selection drugs.  In addition to the drug selection, recombinant viruses were 
also confirmed by the expression of eGFP as visualised by fluorescent microscopy.  
Each virus was put through three rounds of plaque purification with drug selection, 
and was then amplified in the absence of drug selection in a 25 cm2 flask of BS-C-1 
cells.  Viruses in which a second recombination event had occurred were selected for 
in a 25 cm2 flask of D98OR cells using DMEM containing 1 µg/ml 6-thioguanine (6-
TG) as growth medium.  Virus was harvested 48 hpi and plaque purified on BS-C-1 
cells.  After one round of plaque purification recombination was determined by PCR 
(section 2.6.6.10), and selected recombinant viruses were plaque purified three more 
times to ensure purity. 
2.6.6.8 Production of recombinant VACV by transfection of linear 
DNA for double homologous recombination 
A deletion virus in which the v-slfn locus was replaced with EcoGPT-eGFP (vRGKI) 
was constructed by transfecting linearised DNA from pKIE/E (section 2.6.6.4) vector 
that had been linearised with BamHI into cells infected with v∆B8R at an MOI of 
0.005.  Sixteen hpi recombinant viruses were selected as before (section 2.6.6.6) and 
harvested after 48 h.  Recombinant viruses were put through three rounds of plaque 
purification in the presence of selection drugs, and recombination was confirmed by 
PCR (section 2.6.6.10). 
2.6.6.9 Removal of EcoGPT/eGFP from the v-slfn locus by 
replacement with knockout or v-slfn sequences 
To remove the EcoGPT/eGFP insertion from vRGKI to generate a double knockout 
virus (v∆B2R∆B3R), p21N1-Ch was transfected into a 25 cm2 flask of BS-C-1 cells 
that had been infected with vRGKI at an MOI of 0.05.  When complete CPE was 
observed, virus was harvested from the cells and plaque purified four times.  On each 
round of plaque purification, only plaques that expressed a red fluorescent protein 
were picked.  When the red virus was purified, a stock was grown up in a 25 cm2 
flask.  Viruses in which a second recombination event had occurred were selected for 
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in a 25 cm2 flask of D98OR cells using DMEM containing 1 µg/ml 6-thioguanine (6-
TG) as growth medium.  Virus was harvested 48 hpi and plaque purified on BS-C-1 
cells.  After one round of plaque purification recombination was determined by PCR 
(section 2.6.6.10), and selected recombinant viruses were plaque purified three more 
times to ensure purity.  A similar method was used to replace the EcoGPT-eGFP 
cassette with v-slfn to make a knock-in virus (vKI176-CHA), using pKICHA-CHA in 
place of p21N1-Ch. 
2.6.6.10 Proteinase K extraction of DNA from infected cells 
Confluent monolayers of BS-C-1 cells in a flat-bottomed 96 well plate were infected 
with 50 µl of a plaque suspension (section 2.6.6.6) made up to 200 µl with DMEM 
containing 2.5 % FBS.  When full CPE was observed, the cells were washed twice 
with PBS, and 50 µl of proteinase K reaction solution was added (6 µg proteinase K 
[Invitrogen], 5 µl 10 x magnesium (Mg2+)-free buffer [Promega], 45 µl ddH2O) and the 
cells were freeze-thawed twice at -20 °C.  The entire contents of each well was 
transferred to a 0.2 ml PCR tube (Axygen) and incubated at 56 °C for 20 min followed 
by 85 °C for 10 min in a thermocycler. 
2.6.6.11 Identification of recombinant VACV 
To prepare a working stock of VACV DNA for PCR analysis, 50 µl of each plaque 
suspension was used to infect a confluent monolayer of BS-C-1 cells in a flat-
bottomed 96 well plate.  When full CPE was observed, DNA was extracted with 
proteinase K (section 2.6.6.10).  A series of PCR analyses were performed to 
determine whether the correct recombinant viruses had been isolated (Table 2-3) 
using sequence specific primers (Table 2-4). 
 
5 × GoTaq Mg‐free buffer 4 μl
MgCl2 (25 mM) 1.6 μl 95 °C 2 min
dNTP (10 mM) 0.4 μl 95 °C 30 s
Primer 1 (10 μM) 0.4 μl 50 °C 30 s × 30 cycles
Primer 2 (10 μM) 0.4 μl 72 °C 2.5 min
Proteinase K extracted DNA 2 μl 72 °C 5 min
GoTaq 0.2 μl
dd H2O 10.6 μl  
Table 2-3.  Conditions used for amplification of viral DNA by PCR. 
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Primer 1 Primer 2 Regions amplified Viruses Size of band (bp)
KOF1plus KOF2minus B2R  left flank to B3R right flank Parental and revertants 2101
vΔB2R 1440
vΔB3R 1294
vΔB2RΔB3R 606
vKI176‐CHA 2154
vRGKI 1910
WRB2F WRB3RWT B2R  and B3R Parental and revertants 1199
vΔB2R ‐
vΔB3R ‐
vΔB2RΔB3R ‐
vKI176‐CHA 1225
vRGKI ‐
KOF1plus WRB2RWT B2R  left flank and B2R Parental and revertants 961
vΔB2R ‐
vΔB3R 961
vΔB2RΔB3R ‐
vKI176‐CHA 986
vRGKI ‐
WRB3F KOF2minus B3R  and B3R  right flank Parental and revertants 1098
vΔB2R 1098
vΔB3R ‐
vΔB2RΔB3R ‐
vKI176‐CHA 1126
vRGKI ‐  
Table 2-4.  PCR analyses used to confirm recombination events in VACV. 
2.6.6.12 Amplification of virus stocks 
200 µl of the final purified plaque suspension was used to infect a 25 cm2 of confluent 
BS-C-1 cells.  The cells were incubated at 37 °C until complete CPE was observed 
(usually 2-3 days), and the cells were then scraped down into the medium and the 
cells were collected by centrifugation at 2,000 × g for 5 min at 4 °C (Beckman Allegra 
6R centrifuge).  The cell pellet was resuspended in 500 µl DMEM containing 2.5 % 
FBS (master stock).  Following 3 freeze-thaw cycles, 250 µl of this master stock was 
used to infect a confluent 175 cm2 flask of confluent BS-C-1 cells and incubated at 37 
°C until complete CPE was observed.  The cells were harvested as before and 
resuspended in 1 ml DMEM containing 2.5 % FBS (sub-master stock).  The titre of 
this sub-master stock was determined, and it was used to grow up a working stock of 
the virus (section 2.6.3). 
2.6.7 Analysis of recombinant VACV 
2.6.7.1 Plaque phenotype 
Monolayers of confluent BS-C-1 cells were infected with virus at an appropriate 
dilution to give good separation of individual plaques.  Infected cells were overlaid 
with 1.5 % CMC and incubated at 37 °C.  Cells were stained with 0.01 % (w/v) crystal 
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violet in 15 % ethanol 72 hpi and photographed using a Zeiss microscope.  Plaque 
areas were determined using ImageJ v1.41 software by drawing a best-fit oval 
around the plaque, from which the average diameter was extrapolated. 
2.6.7.2 Growth kinetics 
Confluent monolayers of BS-C-1 or RAW264.7 cells in a 25 cm2 flask were infected 
with virus at an MOI of 5 or 0.01 for single- or multi-step growth kinetic analysis, 
respectively.  Cells were incubated for the appropriate length of time, following which 
cells were scraped into the cell growth medium and collected by centrifugation at 
1500 x g at 4 ˚C for 10 min.  Cell pellets were resuspended in 500 µl DMEM 
containing 2.5 % FBS and freeze-thawed three times.  The titre of each sample was 
determined by plaque assay (section 2.6.4). 
2.7 Functional analysis of proteins 
2.7.1 Quantification of mRNA levels in the lungs of infected mice 
Mice were either mock infected or infected intranasally with 5 x 105 (VACV-WT) or 4 x 
106 (vH1 and v176-WT) PFU and euthanised at 3, 6 or 9 days pi.  Lungs were 
extracted and stored at -20 °C in RNAlater solution (Qiagen).  RNA was extracted 
with Trizol reagent (Invitrogen) following the standard RNA extraction protocol 
supplied by the manufacturer.  The RNA concentration was determined by measuring 
the UV absorbance at 260 nm (1 OD260 = 44 µg/ml ssRNA) and the purity of the RNA 
was determined by measuring the ratio of the A260 to A280; pure RNA having an 
A260:A280 ratio of 2:1.  Four µg RNA was trated with DNase (Invitrogen) and reverse 
transcribed using Superscript III reverse transcriptase (RT, Invitrogen) and oligo(dT) 
primers (Invitrogen).  GoTaq polymerase (Promega) was used for the amplification 
according to the manufacturer’s protocol using the primers detailed in Table 2-5.  
Optimal cycle numbers were determined for the different primer sets; m-slfn1, 29 
cycles; m-slfn3, 31 cycles; m-slfn8, 27 cycle; β-actin, 23 cycles.  Following the PCR, 
DNA samples were resolved on a 1% agarose gel. 
Gene  Primer name Sequence 
m-slfn1 Forward mSlfn1seqFwd AAGGTTGCAGGAGGAAGG 
 Reverse Mu-slfn1exp2 CGCCGCCCGGGCTAGCTAAGACATGAGGAGC
m-slfn3 Forward Mu-slfn3seqF1 GGCTATGAGCACTTAGTCCGG 
 Reverse Mu-slfn3exp2 CGCCGCCCGGGTCATACATTTC 
m-slfn8 Forward mSLFN8short8F ATGGAGACACATCCCTCC 
 Reverse mSlfn8intExRev CAAGGCTGTTCTGACACATGG 
β-actin Forward MURBACTINF CCAGATCATGTTTGAGACCT 
 Reverse MURBACTINR GTTGCCAATAGTGATGACCT 
Table 2-5.  Primers for amplification & quantification of m-slfns 1, 3, 8 and β-actin. 
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2.7.2 Measurement of cell division by cell counting and flow cytometry 
Cells were harvested by trypsinisation, washed twice in PBS and resuspended in 200 
µl PBS for cell counting using a haemocytometer (Fast-Read 102, Immune Systems 
Limited).  The volume was increased to 500 µl with PBS and the cells were analysed 
using a FACSCalibur flow cytometer (BD Biosciences).  Enhanced green fluorescent 
protein (eGFP) was used as a transfection marker and live cells were analysed for 
green fluorescent signal.  The cut-off was determined using un-transfected cells. 
2.7.3 Luciferase assays 
RAW264.7 or 18-9 cells were seeded at a density of 2.5 or 1.25 cells per well of a 24 
well plate, respectively.  Cells were transfected with a total of 400 ng of expression 
plasmids, 30 ng TK-Renilla internal control plasmid and 120 ng cyclin D1, E2F, NF-
κB, TCF or CRE luciferase plasmids (section 2.3.1).  At the appropriate time post-
transfection, cell lysates were harvested using 100 µl Passive Lysis Buffer (Promega) 
per well and freeze-thawed once.  Twenty µl of lysate was added to a luciferase 
measurement tube and luminescence in relative light units (RLU) was measured 
using a Luminoskan Luminometer (Labsystems) by adding luciferase assay mix (20 
mM tricine, 1.07 mM (MgCO3)4Mg(OH)2.5H2O, 2.67 mM MgSO4, 0.1 M EDTA, 33.3 
mM DTT, 270 mM coenzyme A, 470 mM luciferin (Lux Biotechnology), 530 mM ATP) 
to measure firefly luciferase or 2 µg/ml Coelenterazine (Lux Biotechnology) in PBS to 
measure Renilla luciferase.  Activation of firefly luciferase was normalised using the 
Renilla luciferase values and expressed as fold stimulation over samples transfected 
with empty expression vector and/or unstimulated. 
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3  Chapter 3
Analysis of CMLV 176R and VACV B2R & B3R ORFs 
3.1 Introduction 
In this chapter a characterisation of CMLV v-slfn and related proteins is presented. 
First, a bioinformatic analysis of v-slfn with mammalian slfns and v-slfns from other 
OPVs is shown.  Second, the v-slfn DNA sequence is analysed for signals that may 
control transcription of the gene.  Third, the v-slfn protein size, time of expression, 
sub-cellular location is characterised and compared to murine slfn-1.  Lastly, the 
expression of v-slfn by different OPVs is investigated.  
3.2 Bioinformatic analysis of CMLV v-slfn 
3.2.1 Sequence comparison of v-slfn and m-slfn proteins 
CMLV v-slfn shows similarity to m-slfns and the baculovirus p26 family of proteins 
(Fig. 3-1a).  A ClustalW alignment shows that the N-terminal part of v-slfn (aa 1-199) 
contains a region similar to the bacluovirus p26 proteins (section 1.2.6), whereas the 
C-terminal region (aa 215-502) shows similarity to the region conserved in m-slfns 
(Fig. 3-1b). However, v-slfn lacks similarity with the first 27 aa of m-slfn1, which are 
critical for the ability of m-slfn1 to cause growth arrest (Geserick et al., 2004) (Fig. 
3-1b).  An unrooted tree (Fig. 3-2) shows that the conserved core region (v-slfn aa 
215-502, Fig. 3-1a) of v-slfn proteins from several OPVs are most closely related to 
short m-slfns (m-slfns 1 and 2) and the divergent long form m-slfns (5 and 14).  v-slfn 
is least related to long m-slfns 8, 9 and 10 due to their lack of a C-terminal extension 
(Fig. 3-1a) and because of a lower degree of similarity within the m-slfn N-terminal 
conserved region (Fig. 3-1b).  This is also demonstrated by the level of identity within 
the conserved core region: v-slfn is most similar to short m-slfns (30 % identity, 50 % 
similarity to m-slfn1) and least similar to long m-slfns (24 % identity, 42 % similarity to 
m-slfn8) (Table 3-1).  Fig. 3-2 also highlights the previously reported divergence of m-
slfn5 protein sequence (Geserick et al., 2004) and that of the newly identified m-
slfn14 to other long m-slfns. 
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v‐slfn m‐slfn1 m‐slfn3 m‐slfn8
v‐slfn 30 (50) 27 (47) 24 (42)
m‐slfn1 30 (50) 45 (60) 32 (52)
m‐slfn3 27 (47) 45 (60) 28 (47)
m‐slfn8 24 (42) 32 (52) 28 (47)  
Table 3-1.  Amino acid conservation in v-slfns and m-slfns. 
Data from ClustalW aa alignment of the schlafen-like domains of v-slfn and a representative 
member of each of the short, intermediate and long murine schlafen proteins.  Data are 
expressed as the % identity (normal text) and the % similarity (in brackets). 
 
 
Fig. 3-1.  Sequence alignment of the schlafen conserved region of v-slfn and a 
representative member of each of the m-slfn sub families. 
(a) Schematic representation of CMLV strain CMS v-slfn (AAG37679), VACV-WR B2 
(YP_233066) and B3 (YP_233067), m-slfn1 (AAH52869), m-slfn3 (NP_035539) and m-slfn8 
(NP_853523). (b) aa alignment of the murine schlafen 1, 3 and 8 N-terminal conserved region 
with the C-terminal region of v-slfn.  Identical residues are shown in black and residues 
conserved in 2 or 3 out of 4 sequences are shown in light or dark grey, respectively. 
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Fig. 3-2.  The phylogenetic relationship of v-slfn to other schlafen-like proteins. 
Unrooted phylogenetic tree showing the relationship of v-slfn from CMLV, CPXV, MPXV, 
ECTV, GBLV and murine orthologues.  The protein sequences were aligned using 
CLUSTALW and this was used to generate an unrooted tree using PHYLIP on the European 
Bioinformatic Institute website (http://www.ebi.ac.uk/clustalw/).  Bootstrap values from 1000 
replica samplings and the divergence scale (substitutions per site) are indicated. 
3.2.2 Sequence comparison of poxvirus p26-like and baculovirus p26 
proteins 
The N terminal domain (aa 1-199) of v-slfn shares 20-21 % identity (34-38 % 
similarity) with the p26 proteins of baculoviruses (Bicknell et al., 1987) (Fig. 3-3).  The 
B2 protein from VACV WR comprises just a p26-like domain (Fig. 3-3).  The function 
of p26 in baculoviruses is currently not understood (section 1.2.6), and it is not 
necessary for replication or spread of baculoviruses. 
 
Chapter 3 – Analysis of CMLV 176R and VACV B2R and B3R ORFs 
86 
 
Fig. 3-3.  Sequence alignment of poxvirus p26-like proteins with baculovirus p26 
proteins. 
The p26 proteins from Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV), 
Rachiplusia ou multiple nucleopolyhedrovirus (RoMNPV), Choristoneura fumiferana 
multinucleopolyhedrovirus (CfMNPV), Adoxophyes honmai nucleopolyhedrovirus (AdhoNPV), 
aa 1-200 CMLV CMS v-slfn, Melanoplus sanguinipes entomopoxvirus strain Tucson (MSEV-
Tuc) protein 237 and VACV WR B2 were aligned using ClustalW.  Black shading indicates 
similar or identical aa residues present in all sequences, dark grey shading indicates similarity 
or identity in 6 sequences, light grey shading indicates similarity or identity in 4 or 5 
sequences. 
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Protein 237 of Melanoplus sanguinipes entomopoxvirus (MSEV) also has similarity to 
p26 proteins (Afonso et al., 1999) and shares 42 % identity (60 % similarity) with the 
p26-like domain of v-slfn (Fig. 3-3).  However, not all entomopoxviruses have a 
related protein; Amsacta moorei entomopoxvirus (AMEV) lacks a p26-like protein 
(Bawden et al., 2000).  The p26 domain of OPV slfn-like proteins are more closely 
related to MSEV 237 than baculovirus proteins, suggesting that the p26-like protein in 
poxviruses originated from a common ancestor rather than from two separate 
acquisitions.  As with the p26 proteins from baculovirus, the function of p26-like 
proteins in entomopoxviruses is not known. 
3.2.3 v-slfn contains an AAA_4 domain found in DNA/RNA helicases 
A “InterPro” search (http://www.ebi.ac.uk/interpro/) to identify sequence similarity 
between v-slfn and specific protein domains or superfamilies revealed a divergent 
ATPase family associated with diverse cellular activities (AAA) domain from the 
AAA_4 PF04326 family near the C terminus of v-slfn (Fig. 3-1a).  The presence of 
this domain has been reported previously in murine long slfns, which also contain 
Walker A (also known as phosphate-binding loop or P-loop) and B motifs in their C-
terminal domain (Geserick et al., 2004).  The AAA domain is a part of the large family 
of P-loop NTPases (Leipe et al., 2002) characterised by the presence of Walker 
motifs, which bind the phosphate group of bound ATP or GTP and are necessary for 
ATPase activity (Beyer, 1997).  As the name suggests, proteins with this domain are 
involved in a great variety of cellular processes involving ATPase activity, but do not 
seem to have a common function.  For example, AAA domain-containing proteins are 
involved in proteolysis, vesicle fusion, meiotic spindle formation and DNA unwinding 
(Beyer, 1997).  The presence of the AAA domain in all slfns but the Walker motifs in 
only long form mammalian slfns suggests that the long slfns are the ancestral form of 
the protein, and the only ones to retain the ATPase function.  It also suggests that 
short and intermediate mammalian slfns and v-slfn lack ATPase activity. 
3.2.4 Conservation of OPV slfn-like proteins 
The degree of conservation of v-slfn proteins amongst chordopoxviruses is low, with 
v-slfn orthologues only encoded by OPVs.  Within OPVs, full length orthologues of 
the CMLV 176R gene are present in CPXV, ECTV, GBLV and MPXV.  The level of 
aa identity between OPV v-slfns is between 84 % (CMLV vs. MPXV) and 98 % 
(CMLV vs. GBLV) (Table 3-2). 
Consistent with the close relationship between CMLV and Taterapox virus (GBLV) v-
slfn proteins (Fig. 3-2), comparison of other proteins from these viruses has shown 
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their close relationship.  Phylogenetic analysis has shown that the E5R and J2R 
ORFs of CMLV and GBLV are more closely related to one another than to the 
equivalent ECTV, MPXV or CPXV ORFs (Binns et al., 1992; Douglas & Dumbell, 
1996).  Analysis of 12 ORFs from several OPVs showed that ECTV, MPXV and 
CPXV are more closely related to one another than to CMLV (Gubser et al., 2004). 
CMLV CPXV MPXV ECTV GBLV
CMLV 87 (94) 84 (94) 87 (95) 98 (99)
CPXV 87 (94) 92 (96) 90 (95) 87 (94)
MPXV 84 (94) 92 (96) 92 (97) 85 (94)
ECTV 87 (95) 90 (95) 92 (97) 88 (95)
GBLV 98 (99) 87 (94) 85 (94) 88 (95)  
Table 3-2.  Amino acid conservation in OPV v-slfn proteins. 
Data from ClustalW aa alignment of v-slfn proteins from CMLV, CPXV, MPXV, ECTV and 
GBLV.  Data are expressed as the % identity (normal text) and the % similarity (in brackets) 
3.2.5 Frameshift mutations in VACV and VARV 
In comparison to the high level of conservation within several OPVs, the v-slfn ORF is 
broken into fragments in sequenced strains of VACV and VARV (Fig. 3-1a).  Of the 
47 strains of VARV for which the sequence is available (www.poxvirus.org), all 
contain the same frame shift mutations.  Genome sequence analysis of these viruses 
nevertheless shows a high conservation at the nucleotide level (Fig. 3-4), with VACV 
and VARV DNA sequences sharing 91 % and 96 % identity with CMLV 176R, 
respectively.  The mutations that caused the frameshifts are highlighted in Fig. 3-4 
with green arrows for VACV and red arrows for VARV.  This also shows that the 
mutations in the VACV and VARV genome did not originate from a common 
ancestor, as the mutations are not shared and therefore originated independently. 
Within this region, VARV Garcia contains 4 ORFs named H2L, H3R, H4L, and H5R, 
that potentially might code for proteins of 65, 66, 68 and 65 aa, respectively.  In 
contrast, VACV WR contains 2 ORFs named B2R and B3R, coding for proteins of 
219 and 167 aa, respectively (Fig. 3-5). B2R is predicted to express a protein 94 % 
identity to aa 1-219 of CMLV v-slfn, but none of the conserved region is retained 
within this protein (Fig. 3-1a and Fig. 3-5).  Although the protein expressed from ORF 
B3R contains elements of the slfn conserved region, it is missing much of the highly 
conserved sequence near the C terminus (Fig. 3-1a and Fig. 3-5). 
The presence of these mutations shows that full length v-slfn is not required for viral 
replication or for survival of the viruses within their hosts. 
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Fig. 3-4 
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Fig. 3-4.  Nucleotide sequence alignment of the slfn locus of CMLV CMS, VACV WR and 
VARV Garcia showing mutations, including those leading to disruption of the v-slfn 
ORF. 
Gene 176R from CMLV strain CMS was aligned with the corresponding genome sequence 
from VACV WR and VARV Garcia using ClustalW.  The positions of predicted ORFs are 
shown with lines underneath the sequence in colours corresponding to the legend.  Positions  
frameshifts and introduction of in-frame stop codons are indicated with arrows.  Black shading 
indicates identity in all 3 sequences and grey shading indicates identity in 2. 
 
 
 
Fig. 3-5.  Amino acid sequence alignment of CMLV v-slfn and related proteins from 
VACV and VARV. 
The proteins coded for by CMLV CMS ORF 176R, VACV WR ORFs B2R and B3R, and 
VARV Garcia ORFs H3R and H5R were aligned using ClustalW.  Black shading in VACV and 
VARV sequences indicates identity with CMLV v-slfn sequence. 
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3.3 Expression of v-slfn and m-slfn proteins 
3.3.1 Cloning and expression of v-slfn and m-slfns 
To study v-slfn in vitro in the absence of virus infection, v-slfn and a representative 
member of each of the short, intermediate and long form murine slfns were amplified 
by PCR and cloned into the pCI vector (Promega) with a C-terminal HA tag.  Cloning 
strategies were designed to include a Kozak sequence around the initiating 
methionine codon, which increases efficiency of translation.  pCI promotes 
expression from the HCMV immediate-early gene enhancer/promoter region.  This 
allows for strong, constitutive expression, which was why this plasmid was chosen for 
transient expression.  Fig. 3-6 shows expression of each of these proteins in HeLa 
cells.  The m-slfns were always detected at a lower level than v-slfn after transient 
transfection.  There are several reasons why this may occur, including lower mRNA 
stability or transport, differing efficiency of translation initiation, protein stability, codon 
usage or lower stability of the HA tag.   
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Fig. 3-6.  Expression of v-slfn and m-slfns in transfected HeLa cells. 
HeLa cells were transfected with plasmids encoding v-slfn or m-slfns 1, 3 or 8.  Cell extracts 
were prepared 16 h post-transfection and analysed by immunoblotting using anti-HA mAb.  
Molecular size markers indicate mass in kDa. 
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3.3.2 Cloning of p26-like and slfn-like domains of v-slfn 
To study the role of the p26-like domain (p26 domain) and the slfn-like core domain, 
these domains were cloned separately into pCI.  Fig. 3-7a shows a schematic 
representation of the cloned domains in relation to v-slfn.  Amino acid 199 was 
chosen as the point to split the two domains based on the alignments of v-slfn with m-
slfn1 and AcMNPV p26 (Fig. 3-7).   
 
 
Fig. 3-7.  Cloning of v-slfn p26 and slfn core region. 
(a) Schematic representation of v-slfn and the cloned domains.  (b) Extract from an alignment 
of v-slfn with baculovirus p26 proteins and m-slfn proteins, showing aa 150 to 239 of v-slfn.  
Black shading in m-slfn1 and AcMNPV p26 proteins indicates residues identical to v-slfn.  
Green shading in v-slfn indicates the region chosen with similarity to the p26 domain and red 
shading indicates the region chosen with similarity to the slfn core domain. 
 
 
Fig. 3-8 shows that both the p26 domain and slfn domain of v-slfn were expressed 
and were detected by the anti-HA Ab.  They were also detected by the anti-v-slfn Ab 
(produced as described in chapter 4), although there are cross-reacting bands slightly 
larger than v-slfn and at a similar size to the slfn core domain. 
The B2R and B3R ORFs from VACV WR were also cloned into pCI using a similar 
cloning strategy.  However, B2 could only be detected using the anti-v-slfn Ab, and 
B3 could not be detected at all at 16 h post-transfection (Fig. 3-8). 
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Fig. 3-8.  Expression of v-slfn p26 and core domains and VACV B2 and B3 in 
transfected HeLa cells. 
HeLa cells were transfected with plasmids expressing full length v-slfn, v-slfn p26 domain, slfn 
core domain , VACV B2 or VACV B3.  Cell extracts were prepared 16 h post-transfection and 
analysed by immunoblotting using anti-HA or anti-v-slfn Abs.  Molecular size markers indicate 
mass in kDa. 
3.3.3 v-slfn is expressed as a 57-kDa protein both from transfection and 
infection 
Fig. 3-9 shows that the anti-v-slfn Ab detected untagged v-slfn and v-slfn with an HA 
tag at the N or C terminus expressed within (a) cells infected for 16 h with 
recombinant VACV expressing v-slfn from the TK locus (described in chapter 6), or 
(b) transfected cells.  The parental virus used in this experiment is VACV WR lacking 
the soluble IFNγ receptor coded for by B8R (v∆B8R).  v-slfn was expressed from the 
TK locus, either untagged or tagged at the N or C terminus (v176-WT, v176-NHA and 
v176-CHA, respectively) and HA from influenza virus was expressed from the same 
locus as a control (vH1). 
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A protein of approximately 60 kDa was detected in both infected and transfected 
cells, which is close to the predicted size (57 kDa) of v-slfn.  However, the anti-HA Ab 
detects higher levels of protein when the tag is at the C terminus.  This could indicate 
either instability of the tag at the N terminus or the fact that the tag is inaccessible at 
this end, even when the protein is denatured by SDS and DTT.  Mice infected with 
VACV expressing v-slfn with a tag at the N terminus has a different phenotype in the 
intranasal model of infection (Gubser et al., 2007), possibly as a result of incorrect 
folding caused by the tag.  The immunoblot for VACV protein F13 shows that 
expression of a late virus protein was similar in all infections, indicating that cells 
were infected at comparable levels. 
The Ab also detects a protein of approximately 37 kDa in transfected cells (Fig. 3-9b).  
This was not due to cross-reactivity between v-slfn and m-slfns, as the anti-v-slfn Ab 
did not detect m-slfn1 (Fig. 3-9b).  Therefore, this smaller proteins is more likely to be 
a degradation product of full length v-slfn. 
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Fig. 3-9.  v-slfn is expressed as a 57-kDa protein from  VACV infection and transfection. 
(a) HeLa cells were either mock-infected, or infected with the indicated viruses.  Cell extracts 
were prepared 16 hours post-infection (hpi) and analysed by immunoblotting using anti-v-slfn, 
anti-HA or anti-F13 Abs.  (b) HeLa cells were transfected with the indicated plasmids.  Cell 
extracts were prepared 16 h post-transfection and analysed by immunoblotting using anti-v-
slfn or anti-HA Abs.  Molecular size markers indicate mass in kDa. 
3.3.4 Subcellular localisation of v-slfn in transfection and infection 
models 
To characterise the sub-cellular localisation of v-slfn, HeLa cells were transfected 
with a plasmid expressing v-slfn with an HA tag at the C terminus.  Fig. 3-10 shows 
that v-slfn is present predominantly in the cytoplasm of transfected cells, as detected 
by both the anti-v-slfn and the anti-HA Abs.  There was no obvious localisation to any 
organelles, although with longer transfection times the expressed proteins 
aggregated into distinct clusters in the cytoplasm (data not shown). 
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Fig. 3-10.  Subcellular localisation of v-slfn in transfected HeLa cells. 
HeLa cells were transfected with pv-slfn_CHA, expressing v-slfn with an HA tag at the C 
terminus.  Cells were fixed 16 h post-transfection and stained with anti-v-slfn and anti-HA Abs, 
and fluorescent secondary Abs were viewed by confocal microscopy.  Scale bars, 20 µm. 
 
To determine whether v-slfn has the same localisation in the context of a virus 
infection, HeLa cells were infected with CMLV CMS, v∆B8R or v176-CHA.  v176-
CHA expresses v-slfn under the control of the synthetic early/late promoter in the TK 
locus, and v∆B8R is the parental virus (viruses described further in section 6.2.1).  
Fig. 3-11 shows that both anti-v-slfn and anti HA Abs detected v-slfn predominantly in 
the cytoplasm with some in the nucleus. 
Interestingly, cells infected with v∆B8R, the parental virus for v176-CHA, had a signal 
in the green channel, which was used to detect the anti-v-slfn Ab, with similar 
distribution to cells infected with CMLV or v176-CHA, albeit at a lower level.  Although 
highly infected cells autofluoresce, this was at a higher level than background.  This 
signal might be from the B2 protein, which is made by the virus (Fig. 3-5) and which 
would be recognised by the Ab was raised against the entire v-slfn protein.  Detection 
of B2 by the anti-v-slfn Ab is discussed in more detail in chapter 6. 
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Fig. 3-11.  Subcellular localisation of v-slfn in cells infected with CMLV or v176-CHA. 
HeLa cells were infected with CMLV or v176-CHA, expressing v-slfn with an HA tag at the C 
terminus, at an MOI of 5.  Cells were fixed 6 hpi, stained with anti-v-slfn and anti-HA Abs, and 
fluorescent secondary Abs were viewed by confocal microscopy.  Scale bars, 20 µm. 
 
Fig. 3-12.  Sub-cellular localisation of VACV B2 in transfected HeLa cells. 
HeLa cells were transfected with empty pCI vector (upper panels) alone or pB2_CHA, 
expressing B2 with an HA tag at the C terminus (lower panels).  Cells were fixed 16 h post-
transfection and stained with anti-v-slfn and anti-HA Abs, and fluorescent secondary Abs were 
viewed by confocal microscopy.  Scale bars, 20 µm. 
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3.3.5 Subcellular localisation of VACV B2 and B3 proteins 
To determine whether the VACV proteins with sequence similarity to v-slfn have 
similar localisation patterns, plasmids engineered to express the B2 or B3 proteins 
were transfected into HeLa cells.  Although both proteins have a HA tag at the C 
terminus, neither protein could be detected by fluorescence using the anti-HA Ab 
(data not shown).  B2 was detected in transfected cells by immunoblotting with the 
anti-HA Ab, but B3 was not (Fig. 3-8).  B2 was detected by fluorescence, however, 
using the anti-v-slfn Ab and it appeared to co-localise with actin-like structures (Fig. 
3-12). 
To confirm the co-localisation with actin, the transfection was repeated and the cells 
were treated with rhodamine labelled phalloidin, which binds to actin (Dancker et al., 
1975).  Fig. 3-13 shows that, while v-slfn retains the predominantly diffuse 
cytoplasmic localisation observed previously, B2 is seen to co-localise with the 
filamentous actin (F-actin). 
 
Fig. 3-13.  Subcellular localisation of CMLV v-slfn, VACV B2 and actin. 
HeLa cells were transfected with pv-slfn_CHA (left panels) or pB2_CHA (right panels), 
expressing v-slfn or B2 with an HA tag at the C termini, respectively.  Cells were fixed 16 h 
post-transfection, stained with anti-v-slfn, anti-rabbit fluorescent secondary Ab and 
rhodamine-labelled phalloidin and viewed by confocal microscopy.  Scale bars 20 µm. 
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3.3.6 Subcellular localisation of p26-like and schlafen-like domains of v-
slfn 
VACV B2 has high sequence similarity with the p26 domain of v-slfn.  To determine 
the subcellular localisation of the domains of v-slfn, plasmids expressing the p26 and 
slfn core domains were transfected into HeLa cells and stained with anti-v-slfn Ab 
and rhodamine-labelled phalloidin.  Fig. 3-14 shows that the p26 domain of v-slfn has 
similar subcellular localisation to VACV B2.  However, the schlafen core domain has 
diffuse cytoplasmic localisation with some localisation to the nucleus, similar to the 
localisation of full length v-slfn. 
 
 
Fig. 3-14.  Subcellular localisation of p26-like and schlafen-like domains of v-slfn. 
HeLa cells were transfected with pCI vector expressing the p26 (left panels) or slfn core 
domains (right panels) from v-slfn with an HA tag at the C termini.  Cells were fixed 16 h post-
transfection and stained with anti-v-slfn and phalloidin, and the anti-rabbit fluorescent 
secondary Ab and rhodamine labelled phalloidin were viewed by confocal microscopy.  Scale 
bars 20 µm. 
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3.3.7 Subcellular localisation of m-slfns 
In previous studies, short and intermediate m-slfns were reported to localise 
predominantly to the cytoplasm, whereas long m-slfns localise predominantly to the 
nucleus (Neumann et al., 2008).  However, the same research group were unable to 
reproduce the results generated by several labs with regard to the function of m-slfns 
as regulators of the cell cycle (Brady, 2004; Brady et al., 2005; Geserick et al., 2004; 
Schwarz et al., 1998; Zhang et al., 2008) possibly due to variability in NIH3T3 used 
for the assays (Zhao et al., 2008). 
Commercial Abs to several m-slfns are currently available, but none of them were 
sensitive enough to determine the subcellular localisation of the m-slfns, either 
expressed at endogenous levels or overexpressed.  Fig. 3-15 shows the subcellular 
localisation of overexpressed m-slfns using an anti-HA Ab.  m-slfn1 is predominantly 
nuclear, with a lower amount dispersed diffusely in the cytoplasm.  m-slfn3 has the 
opposite localisation, with the majority present in the cytoplasm and a lower amount 
in the nucleus.  This localisation is comparable to v-slfn.  m-slfn8 is equally dispersed 
in the nucleus and cytoplasm. 
 
 
Fig. 3-15.  Subcellular localisation of murine schlafens. 
HeLa cells were transfected with pCI vector expressing m-slfn1, m-slfn3 or m-slfn8 with an HA 
tag at the C termini.  Cells were fixed 16 h post-transfection and stained with anti-HA, and the 
fluorescent secondary Ab was viewed by confocal microscopy.  Scale bars 20 µm. 
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3.3.8 Expression of v-slfn does not change the sub-cellular localisation 
of m-slfns 
To determine whether localisation of the m-slfns is altered by expression of v-slfn, or 
vice versa, HeLa cells were co-transfected with untagged v-slfn and either m-slfn1, 
m-slfn3 or m-slfn8 with a C-terminal HA tag.  Fig. 3-16 shows that the localisation of 
the m-slfns when co-expressed with v-slfn is comparable to the localisation observed 
when expressed on their own.  This shows that expression of v-slfn does not alter the 
localisation of m-slfn1, and any differences seen in the effect of m-slfn1 with v-slfn co-
expression is not a result of altered localisation. 
 
 
Fig. 3-16.  Subcellular localisation of m-slfns with co-expression of v-slfn. 
HeLa cells were transfected with pCI vector expressing untagged v-slfn and either m-slfn1, m-
slfn3 or m-slfn8 with an HA tag at the C terminus.  Cells were fixed 16 h post-transfection and 
stained with anti-v-slfn and anti-HA Abs, and fluorescent secondary Abs were viewed by 
confocal microscopy.  Scale bars, 20 µm. 
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3.4 Kinetics of expression of v-slfn and B2 proteins 
3.4.1 Prediction of the kinetics of transcription 
The annotation of ORFs in poxviruses between viruses, and the number of predicted 
ORFs per virus varies based on the stringency of the prediction by the original 
authors (Upton et al., 2003).  In addition to in frame start and stop codons, an mRNA 
expression and subsequent protein production requires a specific promoter for 
transcription.  These promoters are specific to the stage of viral replication, and are 
tightly regulated during VACV infection (sections 1.1.8.1 and 1.1.8.3). 
As the ORF coding for v-slfn-like proteins is fragmented in VACV into two separate 
ORFs, the sequences of CMLV 176R and VACV B2R & B3R, and the surrounding 
sequences, were analysed for the presence of promoter elements and transcription 
termination sequences to determine the likelihood of expression and the likely 
kinetics of expression during viral infection.  Transcriptome analysis of VACV infected 
HeLa cells showed that mRNA transcribed from B2R and B3R can be detected from 
0.5 hpi and continues to be present up to 24 hpi and in the presence of the DNA 
replication inhibitor AraC, which inhibits DNA replication and thereby prevents 
expression of intermediate and late proteins (Assarsson et al., 2008).  This suggests 
an early and late expression profile for both ORFs. 
A sequence comparable to the early promoter consensus sequence (Davison & 
Moss, 1989a) was identified upstream of 176R and B2R in both CMLV and VACV, 
respectively (Fig. 3-17 a and b; highlighted in yellow).  Immediately downstream of 
this is a T-rich spacer, as required for efficient promoter activity (Davison & Moss, 
1989a).  However, nothing resembling an early promoter was found in close proximity 
to the B3R ORF.  Early transcripts are terminated 30 to 50 bp downstream of the 
sequence TTTTTNT, where N represents any nucleotide (Piacente et al., 2008; Yuen 
& Moss, 1986; 1987).  Both CMLV and VACV contain several of these sequences in 
this region of the genome (Fig. 3-17 a and b; highlighted in green). VACV only has 
this sequence after the B3R ORF, so B2R early transcripts would not terminate until 
this point. 
The sequence was then analysed to determine the possibility of intermediate 
promoter activity.  Intermediate promoters require the initiator sequence TAAA with a 
very specific “core element” 10 or 11 bp upstream (Baldick et al., 1992).  This core 
element has reduced activity if any of the residues are mutated, most drastically if 
mutated to C or G.  Of the three potential intermediate promoter elements upstream 
of CMLV 176R and VACV B2R (Fig. 3-17 a and b; underlined), the third has the 
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potential to be transcribed as an intermediate gene based on the high A/T content 
from -13 to -22.  However, closer analysis and comparison with the core element 
consensus shows that intermediate gene transcription from this potential promoter 
would be unlikely (Baldick et al., 1992; Hirschmann et al., 1990).  Of the two potential 
intermediate promoter elements directly upstream of VACV B3R (Fig. 3-17b; 
underlined), neither of them have anything resembling the core element required. 
Late transcription requires the presence of the conserved TAAAT initiator sequence, 
with an upstream A/T rich sequence of about 20 bp followed by a spacer of about 6 
bp (Davison & Moss, 1989b).  Neither VACV nor CMLV have a TAAAT sequence 
directly upstream of B2R or 176R (Fig. 3-17).  There is no TAAAT sequence 
directlyupstream of VACV B3R.  Mutation of this consensus sequence reduces 
transcriptional efficiency to greater or lesser degrees depending on the mutation 
introduced (Davison & Moss, 1989b).  In some late promoters, mutation of the final T 
to A results in a less drastic loss in efficiency than other mutations.  However, it 
drastically reduces efficiency in other late promoters so it’s difficult to make a 
prediction of promoter activity from this initiator.  There are several TAAAA 
sequences with potential upstream A/T rich sequences upstream (Fig. 3-17 a and b; 
lower case). 
It is most likely, based on the analysis of the potential promoters in VACV and CMLV 
and on the kinetics of expression of B2R and B3R mRNA from VACV infected cells 
(Assarsson et al., 2008), that both VACV B2 and CMLV v-slfn are expressed early in 
infection.  The detection of mRNA overlapping the VACV B3R ORF at early times pi 
was probably a result of the read-through caused by the lack of an early transcription 
termination sequence directly after B2R.  Such a transcript would be unlikely to be 
translated to give a B3 protein, because eukaryotic ribosomes do not bind internally 
to mRNA unless there is an internal ribosome entry sequence (IRES) present (Jang 
et al., 1990).  Analysis of the region upstream of B3R showed that an IRES was not 
present. 
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Fig. 3-17  
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Fig. 3-17.  Analysis of CMLV CMS 176R, VACV WR B2R & B3R and surrounding 
sequences. 
(a) CMLV 176R and flanking DNA sequence.  (b) VACV B2R and B3R and flanking DNA 
sequence.  Yellow shading, potential early transcription initiation site; underlined text, potential 
intermediate transcription initiation site; lower case text, potential late transcription initiation 
site; green shading, early transcription termination sequence; red shading, start and stop 
codons for CMLV 176R and VACV B2R & B3R. 
3.4.2 Kinetics of protein expression 
To determine the kinetics of v-slfn expression experimentally, BS-C-1 cells were 
mock-infected or infected with CMLV CMS or VACV WR at 10 PFU/cell.  At specified 
times pi, infected cells were lysed and the proteins were resolved by immunoblotting.  
Fig. 3-18 shows that both v-slfn and B2 are expressed early in infection and are 
expressed in the presence of AraC, which prevents DNA replication and thereby 
prevents late gene expression.  Both proteins are slightly reduced at a late time point 
in the presence of AraC, showing that inhibition of late gene expression reduces their 
expression.  In contrast, VACV F13 and its CMLV orthologue did not express in the 
presence of AraC.  Either both proteins are expressed early and late in infection or a 
protein is produced late in infection that affects v-slfn and B2 stability. 
3.5 Conservation of v-slfn and related proteins 
To determine whether any strains of VACV express a full length v-slfn and to confirm 
expression in CPXV, BS-C-1 cells were infected with 16 strains of VACV and 2 
strains of CPXV and cell extracts were analysed by immunoblotting (Fig. 3-19).  This 
showed that none of the VACV strains examined expressed a protein comparable in 
size to CMLV v-slfn that could be detected by the anti-v-slfn Ab. However, in 
accordance with available sequence data, v-slfn orthologues were detected in lysates 
from cells infected with CPXV strains Brighton Red (BR) and elephantpox-2 (EP2).  
For both CPXV strains, the proteins migrated slightly faster than CMLV v-slfn despite 
having a comparable predicted molecular mass (CPXV strain BR, www.poxvirus.org). 
Both CPXV v-slfns were detected at lower levels (Fig. 3-19), however, this might be 
due to anti-v-slfn Ab specificity.  B2 was detected in all strains tested that did not 
express full length v-slfn (Fig. 3-19, lower panels) except VACV-MVA.  The B2R ORF 
of VACV is not present in MVA as a result of a frame-shift mutation.  The recognition 
of the 37-kDa VACV F13 orthologue with a F13 Ab confirmed that all cells had been 
infected.  Note that the F13 orthologue in Buffalopox virus (BPXV)-infected cells 
could only be detected at later times pi. 
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Fig. 3-18.  Kinetics of expression of v-slfn from CMLV and B2 from VACV. 
BS-C-1 cells were infected with (a) CMLV CMS or (b) VACV WR at 10 PFU/cell in the 
presence (+) or absence (-) or 40 µg/ml cytosine arabinoside (AraC).  At the indicated time pi, 
cells lysates were resolved by SDS-PAGE and analysed by immunoblotting using the anti-v-
slfn (top panel), anti-F13 (middle panel) or anti-tubulin (bottom panel) Abs.  Molecular size 
markers indicate mass in kDa. 
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Fig. 3-19.  Expression of v-slfn and B2 from different OPV strains. 
Monolayers of BS-C-1 cells were mock infected or infected with 5 PFU/cell. of the indicated 
virus and harvested at 6 h pi.  Cell extracts were prepared and analysed by immunoblotting 
using either anti-v-slfn or anti-F13 Abs. WR, Western Reserve; King’s Ins, King’s Institute; 
EP2, elephantpox-2; BPXV, buffalopox virus; RPXV, rabbitpox virus.  Molecular size markers 
indicate mass in kDa. 
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3.6 Conclusions 
A basic characterisation of v-slfn and m-slfns was performed in both transfection and 
infection systems.  v-slfn is expressed as an intracellular protein with a molecular 
mass of approximately 57 kDa.  It is found predominantly in the cytoplasm of both 
transfected and infected cells, in contrast to the predominant nuclear localisation of 
m-slfn1.  It is therefore unlikely that the primary function of v-slfn is to directly bind m-
slfn1. 
The p26 domain of v-slfn, and of the related B2 protein expressed from VACV, 
appears to be partially co-localised with actin filaments after transfection.  However, 
this localisation is not observed after virus infection, suggesting that it might be an 
artefact of overexpression in a different cellular environment to normal expression. 
As predicted from analysis of the CMLV 176R and VACV B2R promoters, the 
proteins expressed from these ORFs are both expressed early in infection and 
appear to continue to be expressed in the late stage of infection.  B2 is was detected 
in cells infected with a wide range of VACV strains, with the exception of MVA, and v-
slfn was detected in cells infected with both CMLV and CPXV. 
 
 108 
4 Chapter 4
Recombinant Protein Production and Purification 
4.1 Introduction 
A source of pure v-slfn was required to raise a polyclonal Ab to (i) enable the 
identification and characterisation of v-slfn in cells and (ii) obtain material for 
crystallisation trials to determine protein structure by X-ray crystallography.  Milligram 
quantities of purified protein were required, so a high level of protein expresion was 
needed. 
4.2 Expression of v-slfn protein in E. coli 
4.2.1 Cloning of v-slfn and m-slfn1 for expression in E. coli 
The v-slfn and m-slfn1 ORFs were cloned into the pET28a vector (Novagen), which 
includes the sequence encoding a 6 × histidine (His) tag at both the 5’ and 3’ ends of 
the multiple cloning site.  This vector was chosen because the His tag can be used to 
purify the protein using a nickel affinity chromatography column.  Each ORF was 
cloned with either an N- or a C-terminal His tag and tested for expression.  Both the 
N- and C-terminally tagged v-slfn proteins expressed to a similar level (Fig. 4-1a) and 
the C-terminally tagged protein was therefore chosen for further studies because of 
differences in function between untagged and N-terminally tagged v-slfn when 
expressed by VACV, as reported previously (Gubser et al., 2007).  m-slfn1 with an N-
terminal His tag expressed at a higher level and was more readily detected with anti-
His Ab, and was therefore chosen for further studies (data not shown).  Genes cloned 
into these plasmids are under the control of the bacteriophage T7 promoter, and 
require a source of T7 RNA polymerase for expression.  The strains of E. coli used 
for expression of the proteins (B834(DE3) and Rosetta-gami 2) carry a chromosomal 
copy of T7 RNA polymerase under the control of the lacUV5 promoter, which can be 
induced by addition of IPTG. 
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Fig. 4-1.  Determination of v-slfn and m-slfn1 solubility. 
Plasmids expressing the indicated proteins were transformed into E. coli strain B834 and 
protein expression was induced by addition of 1 mM IPTG where indicated.  (a and b) Cells 
lysates were prepared, resolved by SDS-PAGE and stained with coomassie blue.  (c) 
Duplicate samples from (b) were resolved by SDS-PAGE, transferred to a nitrocellulose 
membrane and probed with anti-His Ab.  (d and e) E. coli strain B834 was transformed with 
empty vector (pET28a) or plasmids expressing v-slfn C-His or v-slfn C-GST.  Cells lysates 
were prepared, separated into (d) insoluble and (e) soluble fractions, resolved by SDS-PAGE 
and stained with coomassie blue.  0.6, untransformed bacteria harvested at time of induction 
when bacteria were at an optical density of 0.6 at 595 nm; U, uninduced; Ind, induced.  
Molecular mass markers indicate mass in kDa. 
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4.2.2 v-slfn and m-slfn1 are found in the insoluble fraction of E. coli 
lysates 
Several conditions were tested in an attempt to increase slfn solubility, including 
variation of the temperature of the bacterial culture after addition of IPTG (30 °C to 37 
°C), modification of the amount of IPTG added (0.25 to 2 mM), and expression in 
different strains of E. coli (B834, BL21, Rosetta-Gami).  It was determined that the 
optimal conditions for expression of both v-slfn and m-slfn1 were in E. coli strain 
B834  for 3 h at 37 °C after induction with 1 mM IPTG.  Both v-slfn and m-slfn1 were 
expressed in the presence, but not the absence, of IPTG in the growth medium and 
ran at the size predicted by their sequence (57 kDa and 37 kDa, respectively, Fig. 
4-1b).  None of the conditions tested resulted in expression of soluble protein (Fig. 
4-1 b,c).  Recombinant v-slfn with a C-terminal GST tag, which was constructed by Dr 
Gareth Brady (Trinity College Dublin), was also tested for solubility.  As with the His-
tagged protein, GST-tagged v-slfn is expressed in the insoluble fraction (Fig. 4-1d) 
but not in the soluble fraction (Fig. 4-1e). 
4.2.3 Production of a rabbit polyclonal antiserum to v-slfn and Ab 
purification 
To purify v-slfn further for generation of anti-v-slfn polyclonal antiserum in rabbits, the 
insoluble protein, which was contained within inclusion bodies, was extracted and 
washed extensively (methods).  Fig. 4-2 shows a serial dilution of the protein purified 
from the inclusion bodies.  This shows that the protein is purified (> 95 % purity) and 
remains stable during the process of purification from the inclusion bodies.  Purified 
protein (200 µg) was emulsified in Freund’s complete adjuvant and used to immunise 
New Zealand white rabbits at Harlan Seralabs.  The same quantity of protein was 
then used for 5 subsequent immunisations at approximately fortnightly intervals in 
incomplete Freund’s adjuvant.  Test bleeds were taken after the second, third and 
fourth boosts and tested for detection of proteins in lysates from cells transfected with 
plasmids expressing v-slfn.  Two weeks after the final booster, a terminal bleed was 
taken and the IgG fraction from 10 ml of this serum was purified by Harlan Seralabs 
using protein A agarose, which binds to the Fc portion of IgG.   
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Fig. 4-2.  Purified v-slfn from E. coli inclusion bodies. 
E. coli strain B834 was induced to express recombinant v-slfn for 3 h at 37 °C with 1 mM 
IPTG.  Following a clean up procedure (methods), serial dilutions of the remaining inclusion 
body suspension was performed, resolved by SDS-PAGE and stained with coomassie blue. 
Molecular size markers indicate mass in kDa. 
 
The IgG fraction from the final bleed detected a protein with a molecular mass of 
approximately 60 kDa in lysates from cells infected with CMLV or recombinant VACV 
expressing v-slfn (Fig. 4-3).  This is close to the predicted 57 kDa of v-slfn.  A non-
specific band of approximately the same size was detected in lysates from uninfected 
cells and cells infected with VACV WT, making visualisation of differences in protein 
expression level difficult (Fig. 4-3, left panels).  A cleanup procedure was required to 
purify the IgG fraction further so that it was sensitive enough for use.  Total cellular 
protein was precipitated from uninfected HeLa cells with acetone and the antiserum 
was incubated with the precipitate to remove cross reacting Abs (methods).  On 
removal of the precipitated protein by centrifugation, the remaining Ab was found to 
be specific for v-slfn, which was detected in lysates from cells infected with CMLV or 
VACV expressing v-slfn but not in lysates from mock- or VACV WR-infected cells 
(Fig. 4-3, right panel).  The IgG fraction also detected the VACV B2 protein.  A higher 
level of B2 (or a protein of similar molecular mass) was detected in cell lysates from 
cells infected with recombinant VACV expressing v-slfn (Fig. 4-3).  This protein is not 
seen in lysates of cells infected with virus expressing v-slfn but not B2 (Fig. 6-13).  
This will be discussed in more detail in section 6.5.2, when the expression of proteins 
by viruses lacking B2R or B3R or expressing CMLV 176R is discussed.  The level of 
expression of F13 and its CMLV orthologue was comparable in all infections, showing 
equal infection with all viruses. 
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Fig. 4-3.  Purification of anti-v-slfn polyclonal antiserum. 
HeLa cells were either mock-infected or infected with VACV WR, CMLV CMS or recombinant 
VACV expressing v-slfn (v176-WT).  Cell extracts were analysed by immunoblotting using 
unpurified (left panels) or purified (right panels) anti-v-slfn polyclonal Ab, anti-tubulin or anti-
F13 mAbs.  The v-slfn and B2 proteins are indicated with arrows.  Molecular size markers 
indicate mass in kDa. 
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4.2.4 Attempt to purify soluble m-slfn1 and v-slfn from E. coli 
v-slfn was expressed in E. coli strain Rosetta-gami 2 (Novagen) in an attempt to 
increase solubility.  Rosetta-gami 2 cells were chosen because they express a 
plasmid (pRARE2) that supplies tRNAs for rare codons (AUA, AGG, AGA, CUA, 
CCC, CGG and GGA), which are normally expressed at low levels in E. coli.  They 
also have mutations in the thioredoxin reductase (trxB) and glutathione reductase 
(gor) genes, which allows more efficient formation of disulphide bonds in the 
periplasm (Bessette et al., 1999; Derman et al., 1993; Prinz et al., 1997). 
Although the majority v-slfn and m-slfn1 produced in Rosetta-gami cells was still 
insoluble, there was a small increase in the amount of soluble protein (data not 
shown).  Large scale protein production was undertaken (2 litre cultures) and induced 
to express the proteins using the same conditions as described previously (section 
4.2.2).  Total protein was run through a His-trap nickel affinity chromatography 
column, and an imidazole gradient was used to elute the bound m-slfn1 (Fig. 4-4a) or 
v-slfn (Fig. 4-5a), both of which eluted as a double peak.  Large amounts of the 
protein eluted from the columns in these peaks are non-specific bacterial proteins of 
approximately 37 kDa and 50 kDa, which obscure m-slfn1 in coomassie-stained gels 
(37 kDa, Fig. 4-4b) and also co-purify with v-slfn (57 kDa, Fig. 4-5b).  Binding of 
bacterial proteins during purification has been reported previously for proteins such 
as the 25 kDa YodA protein (David et al., 2002), although it is unclear what these 
proteins are in this instance.  These proteins constitute the majority of the protein in 
the first peak, but the protein in the second peak contains some m-slfn1 and v-slfn, as 
can be seen in Fig. 4-4b and Fig. 4-5b, respectively. 
The fractions containing m-slfn1 and v-slfn were concentrated and separated by size 
exclusion on a Superdex 200 10/30 GL column.  The protein from the m-slfn1 
expression eluted as a broad peak with shoulders indicating heterogeneity of the 
preparation (Fig. 4-4c), and the majority of the protein was not m-slfn1 (Fig. 4-4d).  A 
similar peak was observed during the purification of v-slfn (Fig. 4-5c), but in this 
instance there was a higher ratio of v-slfn to non-specific contaminant (Fig. 4-5d).  
However, it was not possible to remove the contaminating bands from these samples 
by either affinity chromatography or size exclusion chromatography.  In addition, the 
yields of protein obtained from this purification were very low. 
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Fig. 4-4.  Purification of soluble m-slfn1 from E. coli. 
(a) Chromatograph showing the elution of soluble m-slfn1 from a His-trap column.  (b) The 
proteins from the indicated fractions were resolved by SDS-PAGE and either analysed by 
immunoblotting using an anti-His mAb (upper panel) or stained with coomassie blue (lower 
panel).  (c) Chromatograph showing the elution of protein from a Superdex 200 10/30 GL 
column.  (d) The proteins from the indicated fractions were resolved by SDS-PAGE and 
stained with coomassie blue.  Molecular size markers indicate mass in kDa. 
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Fig. 4-5.  Purification of soluble v-slfn from E. coli. 
(a) Chromatograph showing the elution of soluble v-slfn from a His-trap column.  (b) The 
proteins from the indicated fractions were resolved by SDS-PAGE and either analysed by 
immunoblotting using an anti-His mAb (upper panel) or stained with coomassie blue (lower 
panel).  (c) Chromatograph showing the elution of protein from a Superdex 200 10/30 GL 
column.  (d) The proteins from the indicated fractions were resolved by SDS-PAGE and 
stained with coomassie blue.  Red boxes indicate v-slfn protein.  Molecular size markers 
indicate mass in kDa. 
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4.2.5 Denaturation and refolding of v-slfn expressed in E. coli 
A large (1 litre) culture of E. coli strain B834 was grown and induced to express v-slfn 
for 3 h at 37 °C with 1 mM IPTG.  The bacteria were lysed and the inclusion bodies 
were washed as before (section 4.2.3).  Lysates were dissolved in denaturation buffer 
(methods) and left at 4 °C overnight, which allows full denaturation of the proteins.  
The insoluble precipitates were removed by centrifugation and the proteins were 
partially refolded by rapid dilution into 100 ml arginine refolding buffer, which assists 
in the refolding process (Arakawa & Tsumoto, 2003; Arora & Khanna, 1996).  There 
is no standard protocol for oxidative refolding of proteins, and an optimal system must 
be found for each protein (Fischer et al., 1993).  The buffer also contained 
cysteamine and cystimine to aid in the correct formation of disulphide bridges by 
initially preventing the cysteine thiols from forming S-S bonds (Huth et al., 1994).  
This was then dialised against gel filtration buffer (50 mM Tris-HCl pH 7.5, 200 mM 
NaCl) overnight at 4 °C, slowly removing the cysteamine and cystamine, and finally it 
was concentrated and separated by size exclusion on a Superdex 200 10/30 GL 
column.  The dialisation and the subsequent concentration of the protein resulted in a 
large amount of aggregated protein deposits.  It is likely that these were incorrectly 
folded protein that crashed out of solution. 
Separation of the remaining soluble protein by size exclusion chromatography and 
analysis by SDS-PAGE revealed that the large peaks of eluted protein were 
heterogeneous (data not shown).  Affinity chromatography using a nickel column did 
not result in further purification of v-slfn.  At every step in the purification, large 
amounts of protein precipitated out of solution.  It was decided based on these 
observations that a different strategy would be used. 
4.2.6 Conservation of cysteine residues in viral and mammalian 
schlafens 
v-slfn contains 15 cysteine residues (Fig. 3-5), and the formation of numerous 
disulphide bridges may be important for protein folding, stability or multimerisation.  
Of these 15 cysteine residues, 4 are within the p26-like domain and none of these are 
shared with baculovirus p26 proteins.  Of the 11 within the schlafen-like domain, 4 
are conserved across short, intermediate and long m-slfns and 1 is conserved in 
short and intermediate m-slfns (Fig. 4-6).  It was decided to express v-slfn in cells in 
which disulphide bridge formation occurs naturally, and recombinant baculoviruses 
were therefore constructed for v-slfn and m-slfn expression in infected insect cells.   
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Fig. 4-6.  Conservation of cysteines in the schlafen-like domain of v-slfn. 
Alignment of the murine schlafen 1, 3 and 8 N-terminal conserved region with the C-terminal 
domain of v-slfn (aa 167-502).  Identical residues are shown in black and residues conserved 
in 2 or 3 out of 4 sequences are shown in light or dark grey, respectively.  Cysteine residues 
are highlighted in red. 
4.3 Expression of v-slfn and m-slfn proteins from baculoviruses 
A set of recombinant baculoviruses based on Autographa californica 
multinucleocapsid nucleopolyhedrovirus (AcMNPV) was constructed using the 
BacVector system (Novagen).  The system is based on a parental virus in which 
polyhedrin has been replaced with LacZ (Fig. 4-7a).  Polyhedrin is the major protein 
in the occlusion bodies made by baculoviruses, but it is non-essential for the 
production of extracellular infectious virus (Smith et al., 1983a).  In cells infected with 
WT virus, polyhedrin can constitute 25 % or more of the total cellular protein (Smith et 
al., 1983b).  In addition to the replacement of polyhedrin, Bsu36 I restriction sites 
have been entered into the ORFs flanking polyhedrin (Fig. 4-7a), ORF 603 and ORF 
1629, both of which are essential for virus replication (Kitts & Possee, 1993).  The 
parental virus is viable, but genomic DNA linearised with Bsu36 I is incapable of 
reforming into viable virus.  The plasmid into which the genes to be expressed are 
cloned (pBAC-1) contains a multiple cloning site flanked by ORF 603 and ORF 1629, 
and can therefore be used to rescue the linearised virus DNA and create viable virus 
through double homologous recombination (Fig. 4-7 b,c).  
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Fig. 4-7.  Construction of recombinant baculoviruses. 
Schematic representation of the generation of a recombinant baculovirus expressing v-slfn 
(vBacV22).  (a) Parental virus expressing LacZ from the polyhedrin locus.  Red arrows 
indicate Bsu36 I restriction sites.  (b) Double homologous recombination between triple-cut 
virus DNA and transfer plasmid.  (c) Resultant virus from recombination.  A similar approach 
was used to generate viruses expressing m-slfns 1, 3 and 8. 
4.3.1 Production of recombinant baculoviruses expressing v-slfn, m-
slfn1, m-slfn3 and m-slfn8 
CMLV 176R and m-slfns 1, 3 and 8 were cloned into the HindIII and XhoI sites of 
pBAC-1 to create plasmids pBACvS, pBACS1, pBACS3 and pBACS8, respectively.  
Stop codons were removed for expression of a 6 × histidine tag at the C terminus. 
Following transfection, the viruses resulting from the recombination between the 
triple-cut vector and the transfer plasmids were plaque purified twice and then tested 
for expression of exogenous protein.  An anti-His immunoblot of protein extracts from 
Sf9 cells infected with different clones of the viruses shows that v-slfn and m-slfn1 
express well from all tested clones but m-slfn3 and m-slfn8 express at a lower level 
(Fig. 4-8).  No protein was detected in lysates from mock-infected cells.  Clones V22, 
111, 332 and 831 were chosen (Fig. 4-8) and plaque purified twice more to ensure 
purity of the viral stock.  The viruses were named based on the plaque picks from the 
initial purification, and are referred to as vBacV22, vBac111, vBac332 and vBac831. 
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Fig. 4-8.  Expression of v-slfn and m-slfns from baculovirus-infected Sf9 cells. 
Sf9 cells were mock-infected or infected with the indicated viruses expressing v-slfn, m-slfn1, 
m-slfn3 or m-slfn8 at 5 PFU/cell.  Cell extracts were prepared when complete CPE was 
observed, 96 – 120 hpi, and analysed by immunoblotting using anti-His mAb.  Molecular size 
markers indicate mass in kDa.  The predicted molecular mass of the exogenously-expressed 
proteins are shown below each panel. 
 
 
4.3.2 v-slfn and m-slfn1 are in the soluble fraction of lysates from 
baculovirus-infected Sf9 cells 
Overexpression of protein from baculovirus-infected insect cells can result in 
expression of insoluble protein (Berndt & Cohen, 1990).  To determine whether 
soluble protein was being produced, the soluble and insoluble protein fractions from 
infected cell lysates were separated by centrifugation.  The majority of v-slfn and m-
slfn1 were found in the soluble fraction (Fig. 4-9).  It is also evident from this figure 
that v-slfn is expressed at a high enough level to be distinguished from other proteins 
by coomassie staining alone (Fig. 4-9, left panel). 
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Fig. 4-9.  v-slfn and m-slfn1 are found in the soluble fraction of baculovirus-infected Sf9 
cells. 
Sf9 cells were infected with the indicated viruses expressing v-slfn or m-slfn1 at 5 PFU/cell.  
Cell extracts were prepared 72 hpi, separated into soluble and insoluble fractions by 
centrifugation and stained with coomassie blue (left panel) or analysed by immunoblotting 
using anti-His mAb (right panel).  Molecular size markers indicate mass in kDa. 
4.3.3 Purification of v-slfn from baculovirus-infected Sf9 
Cultures of Sf9 cells (1.5 litres) at a density of 2 × 106 per ml were infected with 
vBacV22, vBac111, vBac332 or vBac831 at 5 PFU/cell and harvested 72 hpi.  
Infected cell lysates were treated with benzonase to disrupt genomic DNA, the 
insoluble fraction was removed by centrifugation at 10,000 × g for 30 min at 4 °C, and 
the supernatant was filtered to purify the soluble fraction of protein.  This was then 
applied to a 5 ml His-trap column (GE Healthcare).  After washing to remove any 
unbound protein, the bound protein was eluted using a gradient of imidazole ranging 
from 20 to 500 mM. 
Only very small amounts of m-slfn1 could be purified from vBac111-, vBac332- or 
vBac 831-infected cells (data not shown) and the yields did not justify further 
purification, so efforts were focused on purification of v-slfn.   
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Fig. 4-10.  Purification of v-slfn from baculovirus-infected Sf9 cells. 
(a) Chromatograph showing the elution of protein from a His-trap column.  (b) Chromatograph 
showing the elution of protein from a Superdex 200 10/30 GL column.  (c) Unpurified protein 
(I), protein purified from the His-trap (HT) or the proteins from the indicated fractions from gel 
filtration (A10, B1, B4, B8, marked with asterisks) were resolved by SDS-PAGE and either 
stained with coomassie blue (upper panel) or transferred to a nitrocellulose membrane and 
probed with an anti-His mAb (lower panel).  Molecular size markers indicate mass in kDa. 
Following addition of cell lysates from vBacV22-infected cells to a HisTrap column 
and extensive washing, a single peak was eluted (Fig. 4-10a) at a concentration of 
approximately 225 mM imidazole.  This protein was concentrated using a Centricon 
YM-10 filter and applied to a Superdex 200 10/300 GL column (GE Healthcare) to 
further purify the protein by size exclusion chromatography.  The protein eluted in two 
peaks with a small shoulder in between (Fig. 4-10b).  Further analysis of the elute 
(Fig. 4-10c) showed that the upper and lower contaminating bands observed in the 
His-trap purified protein were largely removed by size exclusion chromatography.  
The lower bands eluted in the first peak as part of the void fraction (up to 7.6 ml on 
this column), and are most likely an oligomeric complex > 200 kDa.  The upper band 
eluted from the column in the small shoulder, which is just within the limit for proteins 
eluted from the matrix rather than the void fraction.  v-slfn eluted from the column 
(10.5 – 13 ml) and based on a comparison to size markers is most likely a dimer. 
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4.4 Further analysis of v-slfn expressed in Sf9 cells from recombinant 
baculoviruses 
Purified v-slfn protein was sent to Professor Dave Stuart’s group at the Division of 
Structural Biology (STRUBI) at Oxford University for further analysis and 
crystallisation trials.  All data presented in this sub-section was carried out by Dr 
Mohammad W. Bahar. 
4.4.1 Multiple-angle light scattering analysis of purified v-slfn 
Purified v-slfn was analysed by multiple-angle light scattering (MALS) to determine 
the size accurately and to investigate heterogeneity of the protein sample (Chuan et 
al., 2008).  The method is based on asymmetric flow field-flow fractionation (AFFFF), 
which allows accurate resolution of a large range of particles sizes, from a few 
nanometres to several micrometres (Fraunhofer et al., 2004; Zillies et al., 2007).  This 
is achieved by determining the time taken by the sample (analyte) to travel through a 
thin channel containing an eluant before landing on an ultrafiltration membrane 
(Chuan et al., 2008).  v-slfn elutes as a single peak (Fig. 4-11), showing that it is 
homogeneic, and the mass is approximately 126 kDa.  The predicted molecular mass 
of v-slfn (with the additional 6 × histidine tag at the C terminus) is 58.1 kDa.  A dimer 
would be approximately 116 kDa, and so it is possible that the protein has been post-
translationally modified. 
 
 
Fig. 4-11.  Characterisation of the multimeric state of purified v-slfn. 
Purified v-slfn was analysed by MALS.  Shown above is the elution profile of v-slfn, including 
molar mass, UV absorbance and the refractive index of v-slfn. 
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4.4.2 Optimisation of optimum crystallisation conditions 
Crystallisation conditions were optimised using the INDEX screen (Hampton 
Research), which allows for a large range of different conditions to be tested using a 
96 well format.  The variables include different salts, buffers and precipitants.  
Purified v-slfn was incubated in drops of different solutions from this kit at a final 
concentration of 5 mg/ml and left to crystallise (Walter et al., 2005).  Fig. 4-12a shows 
the first small crystals formed, which were further optimised to form needle-like 
crystals (Fig. 4-12b) and larger crystals (Fig. 4-12c).  The first crystals (Fig. 4-12a) 
were formed in the original buffer used for purification (500 mM NaCl, 50 mM Tris-
HCl, pH 7.5) supplemented with the 2.8 M sodium acetate trihydrate pH 7 as a 
precipitant, (condition #24 in the optimisation process) (Walter et al., 2005).  This was 
modified by variation of the crystallisation drop pH, and the protein:precipitant ratio. 
Further optimisation of the crystallisation conditions will be required before the protein 
is ready for X-ray diffraction.  Selenomethionine-labelled protein will also be required 
to overcome the ‘phase problem’ inherent in X-ray crystallography, which will allow 
the collected data to be interpreted into a 3D structure. 
 
Fig. 4-12.  Crystals formed by solutions of v-slfn. 
v-slfn was crystallised using the INDEX screening method.  (a) Small crystals were formed in 
the buffer used for purification supplemented with a precipitant (500 mM NaCl, 50 mM Tris-
HCl, pH 7.5, 2.8 M sodium acetate trihydrate, pH 7), (b) Needle-like crystals and (c) larger 
crystals were obtained through modification of the protein:precipitant ratio. 
4.5 Conclusions 
Recombinant v-slfn and m-slfn1 were expressed in both E. coli from transfected 
plasmids and in Sf9 cells from recombinant baculoviruses.  Expression in E. coli 
resulted in insoluble protein in inclusion bodies.  These were used to generate an 
anti-v-slfn polyclonal Ab in rabbits but could not be purified in soluble form.  On the 
other hand, expression in Sf9 cells resulted in expression of soluble protein that could 
be highly purified.  This was used to set up crystallisation trials, which are ongoing. 
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5 Chapter 5
Functional Analysis of v-slfn and m-slfn Proteins 
5.1 Introduction 
Functional analyses were performed to investigate cellular responses induced by 
either m-slfn1 or v-slfn, or both together.  These analyses were based on previous 
work showing that m-slfn1 caused cell growth arrest in mid-G1 phase of the cell cycle 
through inhibition of cyclin D1 transcription (Brady et al., 2005) and included 
expression in cells following transfection or after VACV infection.  The role(s) of the 
truncated forms of v-slfn that are predicted to be expressed from VACV strain WR 
were also investigated, as were the effects of the two domains predicted in v-slfn. 
In addition to the reported functions of m-slfn1, potential binding partners have been 
reported for m-slfn1 (Brady, 2004; Zhang et al., 2008) and v-slfn (Brady, 2004).  The 
ability of m-slfn1 and v-slfn to bind these proteins and influence their activity was 
therefore investigated. 
5.2 Up-regulation of murine schlafen proteins 
The majority of the work on m-slfns has focused on m-slfn1.  This protein is 
expressed by mice but not by humans or primates (section 1.2.2).  Therefore all 
functional assays were done in mouse cells. 
Recently, transcriptional upregulation of murine slfn genes was reported in response 
to various stimuli, including infections, was reported, and suggested an upregulation 
of m-slfn gene expression in response to NF-κB activation (Eskra et al., 2003; Froese 
et al., 2006; Geserick et al., 2004; Schurr et al., 2005).  Notably, the promoter for 
murine slfn2 has NF-κB and AP-1 binding sites (Sohn et al., 2007).  Therefore it was 
decided to investigate the role of slfns in a cell line that expressed TLRs and could 
activate NF-κB in response to PAMPs.  A murine macrophage cell (RAW264.7 cells, 
ATCC no. TIB-71) line that expresses TLRs was chosen for in vitro assays, in 
addition to the 18-9 murine fibroblast cell lines used for previous studies on the 
function of m-slfn1. 
5.2.1 Up-regulation in RAW264.7 cells following stimulation of TLRs 
To confirm that m-slfns can be up-regulated by stimulation of TLRs in cell culture, 
RAW264.7 cells were stimulated with ligands for TLR 2, 3 and 4, and the cells were 
then lysed and analysed by immunoblotting (Fig. 5-1) using an anti-m-slfn1 polyclonal 
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Ab (Santa Cruz).  Stimulation of all three TLRs resulted in an increase of m-slfn1 
expression from undetectable levels in mock-treated cells, consistent with previous 
reports of m-slfn upregulation in response to infection with B. abortus, K. pneumoniae 
or L. monocytogenes (Eskra et al., 2003; Froese et al., 2006; Geserick et al., 2004; 
Schurr et al., 2005).  Levels of tubulin, which was used as a loading control, remained 
constant.  Commercial Abs against m-slfn3/4 (Santa Cruz) and m-slfn8 (AbCam) 
were also used, but were unable to detect endogenous protein either with or without 
stimulation (data not shown).  However, these Abs were also unable to detect 
transfected m-slfn 3 or 8 under the conditions tested. 
 
Fig. 5-1.  Up-regulation of m-slfn1 in RAW cells following stimulation of TLRs. 
Monolayers of RAW264.7 cells were mock treated or treated with 100 ng/ml Pam3Cys (P3C), 
25 µg/ml poly(I:C) (p(I:C)) or 50 ng/ml LPS.  Cell extracts were prepared 6 h post-stimulation 
and analysed by immunoblotting using either anti-m-slfn1 or anti-tubulin Abs.  Molecular size 
markers indicate mass in kDa. 
5.2.2 Up-regulation in cells extracted from the lungs of mice infected 
with recombinant VACVs 
To determine whether levels of m-slfns are increased in the lungs of mice infected 
with VACV and whether expression of v-slfn has any influence on this, mice were 
infected intranasally with wild type VACV strain WR (VACV WT), a control virus 
expressing HA from influenza A/PR/8/34 (vH1) (Bennink et al., 1986) or VACV 
expressing v-slfn (v176-WT) (Gubser et al., 2007). These viruses are described 
further in section 6.2.1.   
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Fig. 5-2.  Upregulation of m-slfn mRNA in mice infected with VACV. 
Groups of BALB/C mice were mock infected or infected intranasally with 5 x 105 (VACV-WT) 
or 4 x 106 (vH1 and v176-WT) PFU.  (a) Mice were weighed daily, and results are the mean 
percentage weight change of each group compared with the weight on the day of infection.  
(b) Animals were monitored daily for signs of illness, scored 1 to 4.  P values were determined 
using the Student’s t test and indicate the mean % weight changes or signs of illness that 
were significantly different between v176 WT and VACV WT.  *, p<0.05; **, p<0.002  (c) RNA 
extracted from the lungs of mock-infected mice (M) or mice infected intranasally with the 
indicated viruses for 3, 6 or 9 days was analysed by RT-PCR for each of the genes shown.  
PCR products were resolved on a 1 % agarose gel and stained with ethidium bromide. 
 
Mice infected with v176-WT lost less weight than mice infected with vH1 or VACV WT 
(Fig. 5-2a) and they displayed lower signs of illness (Fig. 5-2b), consistent with data 
published previously (Gubser et al., 2007).  Mice were euthanised at 3, 6 or 9 days pi 
and total RNA was extracted from the lungs.  mRNA was reverse transcribed using 
oligo(dT) primers and the relative level of m-slfn1, m-slfn3 and m-slfn8 mRNA was 
determined by semi-quantitative PCR using gene-specific primers (methods).  The 
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level of both m-slfn1 and m-slfn8 mRNA increased in the lungs after infection with all 
three viruses (Fig. 5-2c) and expression of v-slfn did not influence this.  However, it 
remains possible that v-slfn affects m-slfn levels in specific cell types in the lung or in 
circulating leukocytes.  Levels of β-actin, which was used as an internal control, 
remained constant.  The up-regulation of m-slfns 1 and 8 following VACV infection is 
consistent with the hypothesis that m-slfns are up-regulated through stimulation of 
PRRs by PAMPs. 
5.3 Effect of v-slfn on m-slfn1-induced cell proliferation arrest 
To investigate any effect of v-slfn on m-slfn-induced reduction in cellular proliferation, 
an attempt was made to generate an m-slfn1 and v-slfn double-inducible cell line.  
The strategy used was to use B7 cells, a stable NIH3T3 cell line with v-slfn 
expression dependent on tetracycline in the cell growth medium (Gubser et al., 
2007), and establish an m-slfn1-inducible stable cell line from this background.  C-
terminally HA-tagged m-slfn1 was cloned into pMEP4, which has a metallothionein 
promoter and can be induced by inclusion of heavy metals such as cadmium in the 
growth medium (Andrews, 2000; Saydam et al., 2003).  pMEP4 can be used to 
generate episomally-maintained stable cell lines through treatment with hygromycin.  
Although the empty vector-transfected cells divided in the presence of hygromycin, 
the pMEP4-m-slfn1 transfected cells that survived the hygromycin treatment did not 
divide in the presence or absence of v-slfn expression.  It is possible that there was 
low level expression of m-slfn1 from the plasmid, even in the absence of CdCl2, and 
this prevented the cells from dividing. 
slfn function was therefore investigated using transfection models.  Previous 
characterisation in the 18-9 stable cell line showed m-slfn1 expression inhibited cell 
growth and division (Brady et al., 2005; Schwarz et al., 1998).  It was hypothesised 
that v-slfn may counteract this effect of m-slfn1and this hypothesis was tested using 
stable cell lines as described previously (Brady et al., 2005) with additional proteins 
expressed from transfected plasmids. 
5.3.1 v-slfn reverses the growth arrest of NIH3T3 cells caused by 
induction of m-slfn1 
m-slfn1-expressing 18-9 cells were transfected with empty vector (pCI) or pCI 
expressing v-slfn or cyclin D1, and 6 h later induced to express m-slfn1.  A plasmid 
expressing enhanced green fluorescent protein (eGFP) was co-transfected to enable 
transfected and untransfected cells to be distinguished.   
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Transient expression of v-slfn reversed the growth arrest induced by m-slfn1 (Fig. 
5-3).  This was evident from both the total number of cells (Fig. 5-3a) and the 
percentage of eGFP-positive cells as compared to the total cell number (Fig. 5-3b).  
Since m-slfn1 has been shown to prevent transcription of the cyclin D1 gene 
(CCND1) (Brady et al., 2005), the plasmid expressing cyclin D1 from the HCMV 
major intermediate/early promoter acts as a positive control for the reversal of the 
effect of m-slfn1. 
 
Fig. 5-3.  Effect of v-slfn on the growth inhibition caused by m-slfn1. 
18-9 cells were seeded at a density of 2.5 × 105 per 10 cm dish and transfected 16 h later with 
empty vector (pCI) or plasmids expressing the indicated proteins.  All samples were co-
transfected with a plasmid expressing eGFP as a transfection marker.  Six h post-transfection, 
the medium was changed and m-slfn1 was induced where indicated by removal of 
tetracycline.  One day later (a) cells were counted using a haemocytometer and the total 
number of cells per 10 cm dish was calculated ± SD (b) The number of eGFP positive cells 
was determined by flow cytometry and expressed as a percentage of total cell number ± SD.  
P values were determined using the Student’s t test and indicate the mean differences in cell 
numbers with statistical significance.  P values and SD were calculated from combined results 
from three separate experiments. 
Extracts were prepared from the cells analysed by flow cytometery and analysed by 
immunoblotting to determine whether v-slfn can reverse the reduction in cyclin D1 
protein levels caused by expression of m-slfn1.  Fig. 5-4 shows that the level of cyclin 
D1 in the presence of m-slfn1 was increased slightly by the expression of v-slfn, and 
this is consistent with the re-establishment of cellular proliferation resulting from v-slfn 
expression.  The level of cyclin D1 was not as high as in cells transfected with a 
plasmid expressing cyclin D1 under the control of an HCMV promoter. 
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Fig. 5-4.  Effect of v-slfn on m-slfn1-induced repression of cyclin D1 expression. 
m-slfn1-expressing 18-9 cells were transfected empty vector (pCI) or plasmids expressing the 
indicated proteins and induced to express m-slfn1 by removal of tetracycline 6 h post-
transfection.  Cell extracts were prepared 24 h post-transfection and analysed by 
immunoblotting using anti-cyclin D1, anti-FLAG or anti-HA Abs.  Loading was normalised to 
cell number as determined by cell counting to remove any variation caused by fluctuation in 
cell proliferation as a result of slfn expression.  Molecular size markers indicate mass in kDa. 
5.3.2 Effect of different domains from v-slfn and VACV B2 and B3 
proteins on cell proliferation 
To determine which domain of v-slfn or the v-slfn-like proteins expressed from VACV 
mediate this effect, plasmids expressing the p26 domain, the slfn core domain, B2 or 
B3 were transfected into 18-9 cells with or without m-slfn1 induction.  Fig. 5-5a shows 
that the slfn core domain inhibited m-slfn1-induced cell growth arrest in a similar 
manner to full length v-slfn, but the other proteins were unable to do so.  The slfn 
core domain was the only protein tested with sequence similarity to the entire slfn 
domain of v-slfn (section 3.2.5 and 3.3.2). 
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Fig. 5-5.  Effect of p26-like domain and schlafen-like domain from v-slfn and VACV B2 
and B3 proteins on m-slfn1-induced inhibition of cell proliferation. 
m-slfn1-expressing 18-9 cells were seeded at a density of 2.5 × 105 per 10 cm dish and 
transfected 16 h later with empty vector (pCI) or plasmids expressing the indicated proteins.  
Six h post-transfection m-slfn1 was induced where indicated by removal of tetracycline.  One 
day later, cells were (a) counted using a haemocytometer and the total number of cells per 10 
cm dish was calculated ± SD (calculated from triplicate samples).  Results are representative 
of three separate experiments.  P values were determined using the Student’s t test and 
indicate the mean differences in cell numbers with statistical significance. (b) Cell extracts 
were prepared, resolved by SDS-PAGE and analysed by immunoblotting using anti-HA, anti-
v-slfn, anti-m-slfn1 or anti-tubulin Abs.  Molecular size markers indicate mass in kDa. 
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The v-slfn p26 domain and the VACV B2 and B3 proteins were unable to reverse the 
effect of m-slfn1.  Immunoblotting showed that v-slfn, the p26 domain and slfn core 
domains and VACV B2 can be detected but VACV B3 could not be detected using 
the anti-HA or anti-v-slfn Abs (Fig. 5-5b).  Expression of m-slfn1 was confirmed and 
tubulin was used as a loading control (Fig. 5-5b).  Cyclin D1 was used as a positive 
control, and its expression results in reversal of the effect of m-slfn1.   
5.4 Effect of v-slfn on cyclin D1 induction and E2F-dependent gene 
transcription 
Reporter assays were performed to further elucidate the function of v-slfn and its 
effect on m-slfn1-induced cell growth arrest.  Initially, these focused on the system 
used previously in 18-9 cells in which m-slfn1 is induced by removal of tetracycline, 
and thereafter on the effect of m-slfn and v-slfn expression from transient transfection 
of RAW cells. 
5.4.1 v-slfn reverses the inhibition of cyclin D1 expression caused by m-
slfn1 and subsequent activation of E2F in 18-9 cells 
m-slfn1 induced a 95 % decrease in cyclin D1 promoter activity as measured by 
luciferase expression from -1745CD1LUC (Brady et al., 2005).  The approach used 
was appropriate for the experiments being performed, as there was no further 
expression of exogenous proteins from transiently transfected plasmids planned.  It 
ensured an overwhelming expression of m-slfn1 by inducing for 24 h before reporter 
plasmid transfection, and therefore resulted in an almost complete inhibition of 
promoter activity. 
A different approach was used for the experiments discussed in this section.  v-slfn 
and m-slfns were expressed simultaneously in 18-9 cells from transfected plasmids 
or induction by removal of tetracycline, respectively, at the same time as transfection 
of reporter plasmids.  Firstly, this would allow comparable levels of protein expression 
rather than overwhelming expression of one protein before the other.  Secondly, it 
would establish a system that could be compared to previous studies but could also 
be extended to different cell types in the future without relying on a stable cell line.  
The reporter plasmids express luciferase under the control of the cyclin D1 (-
1745CD1LUC) or E2F-dependent (pE2F-luc) promoters.  Activation of E2F is 
downstream of cyclin D1 upregulation, and analysis of the E2F-dependent promoter 
was included because of the reported cyclin D1-independent activation of E2F 
following VACV infection (Yoo et al., 2008). 
Chapter 5 – Functional Analysis of v-slfn and m-slfn Proteins 
132 
The -1745CD1LUC and pE2F-luc plasmids were generated by insertion of the 1,882 
bp PvuII fragment of the human cyclin D1 genomic clone (Motokura & Arnold, 1993) 
into the pA3LUC plasmid (Wood et al., 1989) or by insertion of a TATA box and 3 E2F 
binding sites into the pGL2BASIC plasmid (Krek et al., 1993), respectively.  Both the 
pA3LUC and pGL2BASIC empty vectors code for luciferase but lack a promoter. 
Transfection of a plasmid expressing v-slfn reversed the m-slfn1-mediated inhibition 
luciferase controlled by the cyclin D1 promoter or an E2F-dependent promoter (Fig. 
5-6a).  This is consistent with the hypothesis that v-slfn reverses the effect of m-slfn1 
on cyclin D1 expression and with the reversal of the effect of m-slfn1 on cell division 
(Fig. 5-3).  The level of reduction of cyclin D1 promoter activity resulting from 
expression of m-slfn1 is comparable to that shown with co-transfection of -
1745CD1LUC and a plasmid expressing m-slfn1 in CHO cells (Brady et al., 2005); m-
slfn1 reduces the transcription of luciferase under the control of the cyclin D1 and 
E2F-dependent promoters by approximately 40 %.  When expressed on its own, v-
slfn increases transcription from both promoters slightly.  Expression of v-slfn and m-
slfn1 was confirmed by immunoblotting, and the level of tubulin in each sample was 
compared as a loading control (Fig. 5-6b). 
To determine whether the p26 and core domains of v-slfn were able to reverse the 
effect of m-slfn1 in a similar manner to full length v-slfn, a similar approach was taken 
with the same induction and transfection conditions (Fig. 5-7).  Consistent with the 
effect on cell proliferation (Fig. 5-5a), the p26 domain did not reverse the effect of m-
slfn1 on cyclin D1 or E2F-dependent luciferase, while the core domain reversed the 
effect a small (but significant) amount (Fig. 5-7a).  However, the effect of the core 
domain was small compared to the effect of v-slfn expression.  Expression of the p26 
and the core domains and m-slfn1 were confirmed by immunoblotting (Fig. 5-7b). 
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Fig. 5-6.  Effect of v-slfn on the reduction in cyclin D1 transcription and E2F-dependent 
transcription caused by m-slfn1 in 18-9 cells. 
18-9 cells were seeded at a density of 1.25 × 104 cells/well in 24-well plates. Cells were 
induced 16 h later for m-slfn1 expression or left uninduced.  Cells were transfected with 
expression plasmids (350 ng pCI or pCI-v-slfn-CHA) and reporter plasmids (120 ng -
1745CD1LUC or pE2F-luc and 30 ng pTK-Renilla-luc).  (a) Cells were harvested 16 h later 
and assayed for luciferase activity. Data are presented in relative light units (RLU) ± SD 
(calculated from triplicate samples) relative to uninduced pCI-transfected cells, which have 
been normalised to 1.  Results are representative of four separate experiments.  P values 
were determined using the Student’s t test and indicate the mean differences in RLU with 
statistical significance.  (b) Cell extracts were prepared and analysed by immunoblotting using 
anti-HA, anti-m-slfn1 or anti-tubulin Abs.  Molecular size markers indicate mass in kDa. 
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Fig. 5-7.  Effect of p26-  and schlafen-like domains of v-slfn on the reduction in cyclin 
D1 transcription and E2F-dependent transcription caused by m-slfn1. 
18-9 cells were seeded at a density of 1.25 × 104 cells/well in 24-well plates. Cells were 
induced for m-slfn1 expression or left uninduced.  Cells were transfected with expression 
plasmids (350 ng pCI, pCI-v-slfn-CHA, pCI-p26 or pCI-Core) and reporter plasmids (120 ng -
1745CD1LUC or E2F-luc and 30 ng pTK-Renilla-luc).  (a) Cells were harvested 16 h later and 
assayed for luciferase activity.  Data are presented in RLU ± SD (calculated from triplicate 
samples) relative to uninduced pCI-transfected cells, which have been normalised to 1. 
Results are representative of three separate experiments.  (b) Cells extracts were prepared 
and analysed by immunoblotting using anti-HA, anti-v-slfn, anti-m-slfn1 or anti-tubulin Abs.  
Molecular size markers indicate mass in kDa. 
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5.4.2 The effect of v-slfn and m-slfn expression in RAW264.7 cells 
Similar experiments were used to study the effects of m-slfn1 and v-slfn in RAW264.7 
cells.  Expression of slfns in this system resulted in a comparable effect to that seen 
in 18-9 cells, both with cyclin D1 and E2F-dependent luciferase plasmids (Fig. 5-8a).  
m-slfn1 repressed the cyclin D1 promoter and the E2F-dependent promoter, but only 
after stimulation of cells with a TLR ligand (Fig. 5-8a).  v-slfn increases the activity of 
the cyclin D1 promoter over that of cells transfected with pCI to a greater extent than 
that seen in 18-9 cells (Fig. 5-6a).  In the presence of m-slfn1, the effect of v-slfn is 
increased over that of v-slfn on its own.  These data are consistent with the observed 
effect of v-slfn in 18-9 cells (Fig. 5-6a) and further support the hypothesis that v-slfn 
reverses the effect of m-slfn1.  Expression of v-slfn and m-slfn1 was confirmed by 
immunoblotting (Fig. 5-8b). 
As m-slfns are not expressed at detectable levels in RAW cells without TLR 
stimulation (section 5.2.1), it is possible that other factors contributing to the effect of 
m-slfns on cyclin D1 expression are also upregulated treatment with a TLR ligand.  It 
is also possible that this stimulation leads to an increase in cyclin D1 transcription 
through binding of activated NF-κB to the NF-κB binding sites in the cyclin D1 
promoter (section 5.4.3), and this allows differences to be distinguished more easily. 
To determine whether intermediate and long form m-slfns have a similar effect in this 
assay and whether v-slfn can alter any observed effect of these slfns, cells were co-
transfected as before but this time including plasmids expressing m-slfns 3 and 8 in 
place of m-slfn1.  In contrast to the effect of m-slfn1, expression of m-slfns 3 and 8 
have increased the activity of both the cyclin D1 promoter and the E2F-dependent 
promoter (Fig. 5-9a).  The activity of these promoters was further increased by the 
expression of v-slfn.  It is possible that these proteins act as antagonists for m-slfn1, 
regulating its activity by reversing its effect on transcription.  Expression of v-slfn and 
m-slfns was confirmed by immunoblotting (Fig. 5-9b). 
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Fig. 5-8.  Effect of v-slfn on the reduction in cyclin D1 transcription and E2F-dependent 
transcription caused by m-slfn1 in RAW cells. 
RAW264.7 cells were seeded at a density of 2.5 × 104 cells/well in 24-well plates. Cells were 
transfected with a total of 400 ng of expression plasmids (200 ng pCI, pCI-m-slfn1-CHA or 
pCI-v-slfn-CHA) and reporter plasmids (120 ng -1745CD1LUC or pE2F-luc and 30 ng pTK-
Renilla-luc) and stimulated with 100 ng/ml Pam3Cys where indicated.  (a) Cells were 
harvested 16 h later and assayed for luciferase activity.  Data are presented in RLU ± SD 
(calculated from triplicate samples) relative to pCI-transfected cells, which have been 
normalised to 1. Results are representative of three separate experiments.  P values were 
determined using the Student’s t test and indicate the mean differences in RLU with statistical 
significance.  (b) Cells extracts were prepared and analysed by immunoblotting using anti-HA 
or anti-tubulin Abs.  Molecular size markers indicate mass in kDa. 
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Fig. 5-9.  Effect of v-slfn on m-slfn3 and m-slfn8 induced changes in cyclin D1 up-
regulation and E2F activity. 
RAW264.7 cells were seeded at a density of 2.5 × 104 cells/well in 24-well plates. Cells were 
transfected with a total of 400 ng of expression plasmids (200 ng pCI, pCI-m-slfn1-CHA, pCI-
m-slfn3-CHA, pCI-m-slfn8-CHA or pCI-v-slfn-CHA) and reporter plasmids (120 ng -
1745CD1LUC or pE2F-luc and 30 ng pTK-Renilla-luc) and stimulated with 100 ng/ml 
Pam3Cys.  (a) Cells were harvested 16 h later and assayed for luciferase activity.  Data are 
presented in RLU ± SD (calculated from triplicate samples) relative to pCI-transfected cells, 
which have been normalised to 1. Results are representative of three separate experiments.  
(b) Cells extracts were prepared and analysed by immunoblotting using anti-HA or anti-tubulin 
Abs.  Molecular size markers indicate mass in kDa. 
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5.4.3 Effect of m-slfn1 and v-slfn on cyclin D1 when up-regulated by 
various intracellular stimuli 
 
Fig. 5-10.  Transcription factor binding sites in the human cyclin D1 promoter. 
Schematic representation of the relative positions of transcription factor binding sites in the 
cyclin D1 promoter (not to scale).  Binding sites are shown with their position underneath. 
 
It is still unclear how m-slfn1 affects cyclin D1 transcription.  To narrow down the 
causes of the transcriptional inhibition by m-slfn1, plasmids expressing proteins that 
regulate cyclin D1 transcription (Fig. 5-10) (Albanese et al., 2003; Labalette et al., 
2008; Leslie et al., 2006; Matsumura et al., 1999; Roche et al., 2004; Watanabe et 
al., 1998) were transfected into RAW cells.  Fig. 5-11 shows that constitutively active 
STAT5a-N642H and STAT5bCA (Wang & Jiang, 2005), STAT3-C (Shen et al., 2001), 
VP16-CREB (Barco et al., 2002), RasV12 (Hirai et al., 1994) and overexpressed p65 
and c-myc increased cyclin D1 promoter activity. 
 
Fig. 5-11.  Ability of selected proteins to stimulate cyclin D1 promoter activity. 
RAW264.7 cells were seeded at a density of 2.5 × 104 cells/well in 24-well plates. Cells were 
transfected with a total of 200 ng of empty vector (pCI) or expression plasmids (expressing 
STAT5a-N642H, STAT5bCA, p65, STAT3-C, VP16-CREB, c-myc or RasV12) and reporter 
plasmids (120 ng -1745CD1LUC and 30 ng pTK-Renilla-luc).  Cells were harvested 16 h later 
and assayed for luciferase activity.  Data are presented in RLU ± SD (calculated from triplicate 
samples) relative to pCI-transfected cells, which have been normalised to 1. Results are 
representative of three separate experiments. 
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As the data from Fig. 5-11 have shown that various stimuli can activate cyclin D1 
transcription, the ability of m-slfn1 to repress these increases and of v-slfn to reverse 
this was studied next.  Plasmids expressing the various activators were co-
transfected with m-slfn1, v-slfn or both together and the relative luciferase activity 
was determined. 
 
pCI only
v-slfn
m-slfn1
v-slfn + m-slfn1
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
pCI only STAT5a STAT5b
p65 STAT3 CREB
c-myc RasV12
R
el
at
iv
e 
Li
gh
t U
ni
ts
R
el
at
iv
e 
Li
gh
t U
ni
ts
R
el
at
iv
e 
Li
gh
t U
ni
ts
p<0.05 p<0.005 p<0.05 p<0.05
p<0.05 p<0.05 p<0.001 p<0.005
p<0.005
 
Fig. 5-12.  Effect of v-slfn and m-slfn1 on the ability of selected proteins to stimulate 
cyclin D1 promoter activity. 
RAW264.7 cells were seeded at a density of 2.5 × 104 cells/well in 24-well plates. Cells were 
transfected with a total of 200 ng of empty vector (pCI) or expression plasmids (expressing 
STAT5a-N642H, STAT5bCA, p65, STAT3-C, VP16-CREB, c-myc or RasV12), 200 ng of slfn 
plasmids (pCI-m-slfn1-CHA or pCI-v-slfn-CHA) and reporter plasmids (120 ng -1745CD1LUC 
and 30 ng pTK-Renilla-luc).  Cells were harvested 16 h later and assayed for luciferase 
activity.  Data are presented in RLU ± SD (calculated from triplicate samples) relative to pCI-
transfected cells, which have been normalised to 1. Results are representative of three 
separate experiments. 
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m-slfn1 reduces the transcription of cyclin D1 that is upregulated by STAT5a, 
STAT5b, STAT3, CREB and Ras (Fig. 5-12).  None of the samples were treated with 
the TLR2 ligand Pam3Cys as in previous experiments (Fig. 5-8) and in the absence of 
any stimulus m-slfn1 had no effect (Fig. 5-12, first panel).  c-myc was unable to 
dramatically increase cyclin D1 transcription (Fig. 5-11), and this may be the reason 
for the lack of any effect of m-slfn1 on cyclin D1 activity (Fig. 5-12).  It is unclear why 
the response to m-slfn1 following p65 overexpression is so small (12 % reduction), 
since the upregulation caused by p65 was the highest of all transfected proteins (Fig. 
5-11).  Based on the fact that m-slfn1 reduced the transcriptional activity of most of 
the tested proteins, despite the fact that they signal through different pathways and 
activate the promoter through different transcription factor binding sites, it is likely that 
any effect that m-slfn1 has is at the level of the promoter itself.  The localisation of m-
slfn1 to the nucleus (section 3.3.7) supports this hypothesis. 
5.4.4 Analysis of the effect of v-slfn and m-slfn1 on specific promoter 
elements within the cyclin D1 promoter 
Previous work on the effect of m-slfn1 on the cyclin D1 promoter showed that 
although the activity was reduced by deletions from the 5’ end of the promoter, m-
slfn1 could further reduce the activity when the promoter was truncated up to 
nucleotide -271 (Brady et al., 2005).  Within the remaining region of the promoter 
after this truncation there are binding sites for STAT3, E2F, Sp1, TCF, CREB and 
NF-κB (Fig. 5-10).  Previous studies attempting to narrow down the effect of a 
regulator of cyclin transcription have focused on individual transcription factors using 
artificially produced promoters with individual transcription factor binding sites in a 
reporter plasmid (James et al., 2006). 
Reporter plasmids with binding sites for NF-κB (pNF-κB-luc), TCF (pTOPFLASH) and 
CREB (pCRE-luc) were used to determine whether expression from them was 
affected by m-slfn1 and v-slfn in a manner comparable to that seen in the cyclin D1 
luciferase assay.  Similar to the cyclin D1 promoter, m-slfn1 had no effect on 
expression of luciferase from pCRE-luc, pTOPFLASH or pNF-κB-luc in the absence 
of an activating stimulus (data not shown).  pCRE-luc was therefore activated by 
transfection of the plasmid expressing VP16-CREB, pTOPFLASH by adding lithium 
chloride to the growth medium and pNF-κB-luc by adding Pam3Cys to the growth 
medium (Fig. 5-13).  Expression of luciferase from pCRE-luc was down-regulated by 
m-slfn1 in a manner similar to expression from -1745CD1LUC in the presence of a 
stimulus (Fig. 5-13).  However, v-slfn also appears to down-regulate expression from 
this promoter.  Interestingly, m-slfn1 had no effect on the expression of luciferase 
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from pNF-κB-luc, which is consistent with previous reports (Brady et al., 2005), but v-
slfn had an opposite effect to that seen with -1745CD1LUC and reduced expression 
from this promoter.  From these results, the elements within cyclin D1 promoter that 
m-slfn1 affects is still unclear.  A promoter with a CRE element would have to be 
studied to determine whether slfns had a specific effect on this binding site. 
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Fig. 5-13.  Effect of v-slfn and m-slfn1 on specific elements of the cyclin D1 promoter. 
RAW264.7 cells were seeded at a density of 2.5 × 104 cells/well in 24-well plates. Cells were 
transfected with a total of 400 ng of empty vector (pCI) or expression plasmids (pCI-v-slfn-
CHA or pCI-m-slfn1-CHA) and reporter plasmids (120 ng -1745CD1LUC or pE2F-luc and 30 
ng TK-Renilla luciferase). Cells transfected with -1745CD1LUC or pNF-κB-luc were stimulated 
with 100 ng/ml Pam3Cys, cells transfected with pCRE-luc were co-transfected with pVP16-
CREB and cells transfected with pTOPFLASH were stimulated with 15 mM LiCl.  Cells were 
harvested 16 h later and assayed for luciferase activity.  Data are presented in RLU ± SD 
(calculated from triplicate samples) relative to pCI-transfected cells, which have been 
normalised to 1. Results are representative of three separate experiments. 
5.5 Determination of the effect of m-slfn1 and v-slfn on histone deacetylases 
m-slfn1 interacts with DnaJB6 (Zhang et al., 2008), an uncharacterised member of 
the HSP40 family of proteins (Ohtsuka & Hata, 2000).  DnaJB6 interacts with 
NFATc3 and prevent its function as a transcription factor by the recruitment of 
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HDACs (Dai et al., 2005).  Recruitment of HDACs causes transcriptional repression 
by removing the acetyl groups from lysine residues in the N termini of histones, 
allowing them to interact with the phosphate groups of DNA and form condensed 
chromatin (Brownell et al., 1996; Emiliani et al., 1998; Taunton et al., 1996). 
5.5.1 Effect of histone deacetylase (HDAC) inhibition on m-slfn1 induced 
cyclin D1 repression 
To determine whether the repression of cyclin D1 transcription by m-slfn1 could be 
altered by inhibition of histone deacteylase activity, reporter assays were repeated in 
the presence of a broad range histone deacetylase inhibitor, trichostatin A (TSA).  
The decrease in cyclin D1 promoter activity as a result of m-slfn1 expression is 
reversed in the presence of TSA (Fig. 5-14), showing that the effect of m-slfn1 on the 
cyclin D1 promoter is a result of HDAC recruitment. 
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Fig. 5-14.  Effect of TSA on m-slfn1 induced inhibition of cyclin D1 
RAW264.7 cells were seeded at a density of 2.5 × 104 cells/well in 24-well plates. Cells were 
transfected with a total of 400 ng of empty vector (pCI) or expression plasmids (200 ng pCI-m-
slfn1-CHA or pCI-v-slfn-CHA) and reporter plasmids (120 ng -1745CD1LUC and 30 ng pTK-
Renilla-luc).  Samples were stimulated with 100 ng/ml Trichostatin A (TSA) or with 100 ng/ml 
Pam3Cys where indicated.  Cells were harvested 16 h later and assayed for luciferase activity.  
Data are presented in RLU ± SD (calculated from triplicate samples) relative to pCI-
transfected cells, which have been normalised to 1. Results are representative of three 
separate experiments.  P values were determined using the Student’s t test and indicate the 
mean differences in RLU with statistical significance. 
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5.5.2 Localisation of DnaJB6 in the presence of m-slfn1 and v-slfn 
The study showing the interaction between m-slfn1 and DnaJB6 also showed that the 
nuclear localisation of m-slfn1 was critical for its function (Zhang et al., 2008).  v-slfn 
is predominantly located in the cytoplasm and it was therefore hypothesised that v-
slfn may interact with DnaJB6 and sequester it in the cytoplasm. This would prevent 
recruitment of HDACs to the cyclin D1 promoter, resulting in reversal of the effect 
observed on cells that express m-slfn1.  Zhang et al. showed that some cell types 
express low levels of DnaJB6, and so the endogenous levels of DnaJB6 was 
investigated by immunoblotting in HeLa cells using an anti-DnaJB6 polyclonal Ab 
(Proteintech Group) (Fig. 5-15, top panel).  The protein was expressed at a high 
enough level to be detected by this Ab.  Expression of v-slfn and m-slfn1 from 
transfected plasmids was also confirmed (Fig. 5-15, middle panel). 
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Fig. 5-15.  Expression of DnaJB6 in HeLa cells in the presence of m-slfn and v-slfn. 
HeLa cells were transfected with empty vector (pCI), pCI-v-slfn-CHA or pCI-m-slfn1-CHA, as 
indicated.  Cells extracts were prepared 16 h post-transfection and analysed by 
immunoblotting using anti-DnaJB6, anti-HA or anti-tubulin Abs.  Molecular size markers 
indicate mass in kDa. 
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Fig. 5-16.  Subcellular localisation of DnaJB6 in the presence of m-slfn1 and v-slfn. 
HeLa cells were transfected with (a) pCI only or with plasmids expressing (b) v-slfn-CHA (c) 
m-slfn1-CHA (d) v-slfn-CHA and untagged m-slfn1 (e) m-slfn1-CHA and untagged v-slfn.  
Cells were fixed 16 h post-transfection and stained with anti-DnaJB6 and anti-HA Abs, and 
fluorescent secondary Abs were viewed by confocal microscopy.  Scale bars, 20 µm. 
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HeLa cells were transfected with plasmids expressing m-slfn1 or v-slfn alone or both 
together.  It was not possible using the reagents available to view the localisation of 
both m-slfn1 and v-slfn simultaneously while also viewing the localisation of DnaJB6, 
as both the anti-v-slfn and anti-DnaJB6 Abs were raised in rabbits.  Co-transfection of 
plasmids expressing v-slfn and m-slfn1 was carried out twice, using tagged v-slfn and 
untagged m-slfn1, and vice versa.  Endogenous levels of DnaJB6 could be detected, 
and the localisation remained predominantly nuclear in the presence of either v-slfn 
or m-slfn1, or in the presence of both together (Fig. 5-16).  Therefore, expression of 
v-slfn does not alter the subcellular localisation of DnaJB6, and any effect that it has 
on the reduction in cyclin D1 transcription is a result of a different mechanism. 
5.6 Effect of m-slfns and v-slfn in the context of a virus infection 
5.6.1 Effect of VACV infection on cyclin D1 and E2F-dependent 
transcription 
To determine the effect of virus infection on cyclin D1 and E2F-dependent 
transcription, RAW264.7 cells were transfected with the -1745CD1LUC or pE2F-luc 
reporter plasmids and mock-infected or infected with VACVs 16 h post-transfection.  
Three different viruses based on a TK- parental virus were used, expressing nothing 
from the TK locus (v∆B8), expressing HA from influenza A/PR/8/34 (vH1) or 
expressing v-slfn (v176) ((Gubser et al., 2007) and described in more detail in 
chapter 6).  Virus infection increased transcription from the cyclin D1 promoter by 
approximately 60 %, in the presence and in the absence of Pam3Cys stimulation (Fig. 
5-17a).  Expression of v-slfn from the virus did not alter the activity of the cyclin D1 
promoter (Fig. 5-17a), which is contrary to what would be expected based on 
previous reporter assays (Fig. 5-6a).  However, the level of E2F-dependent 
transcription was increased more than 50 fold over uninfected cells following VACV 
infection (Fig. 5-17b).  This was further increased by 10-15 % by the expression of v-
slfn from VACV, and this increase was statistically significant in Pam3Cys-treated 
cells.  This is consistent with the observations that E2F activity is increased in 
poxvirus infected cells because pRb is sequestered and prevented from acting as a 
repressor (Yoo et al., 2008). 
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Fig. 5-17.  Effect of VACV with and without v-slfn on cyclin D1 transcription and E2F-
dependent transcription. 
RAW264.7 cells were seeded at a density of 2.5 × 104 cells/well in 24-well plates. Cells were 
transfected with reporter plasmids (120 ng (a) -1745CD1LUC or (b) pE2F-luc and 30 ng pTK-
Renilla-luc) and incubated for 16 h.  Samples were stimulated with 100 ng/ml Pam3Cys where 
indicated.  Cells were infected with the indicated viruses at 5 PFU/cell, harvested 6 h later and 
assayed for luciferase activity. Data are presented in RLU ± SD (calculated from triplicate 
samples) relative to uninfected cells, which have been normalised to 1. Results are 
representative of three separate experiments.  P values were determined using the Student’s t 
test and indicate the mean differences in RLU with statistical significance 
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5.6.2 Effect of m-slfns on VACV-induced up-regulation of E2F activity 
To determine whether overexpression of m-slfns had any effect on the large increase 
in E2F activity, the transfection and infection was repeated, with the addition of 
plasmids expressing m-slfns 1, 3 or 8.  E2F-dependent transcription was focused on 
for these experiments, owing to the drastic increase in reporter activity caused by 
VACV infection (Fig. 5-17b).  The expression plasmids were transfected 16 h prior to 
infection to ensure that the proteins were expressed at a sufficient level. 
In the absence of infection, there was a decrease in promoter activity in response to 
m-slfn1 expression comparable to previous experiments, but there was no decrease 
in promoter activity in the presence of m-slfns 3 or 8 (Fig. 5-18).  In fact, there is a 
slight increase in promoter activity with expression of m-slfn3, which is consistent with 
previous assays (Fig. 5-9)  However, expression of all m-slfns decreased E2F activity 
in cells infected with VACV (Fig. 5-18). 
m-slfn1 expression had the greatest effect on E2F activity, with a reduction to 11-15 
% promoter activity as compared to uninfected samples.  m-slfns 3 and 8 did not 
have as large an effect (reduction to 25-51 % and 43-71 % promoter activity as 
compared to uninfected samples, respectively), but the differences observed were 
significant and different to the effect seen in the absence of infection.  Expression of 
v-slfn or the control influenza HA protein from the virus, however, did not have any 
effect on the reduction in E2F activity caused by VACV infection. 
These data show that although expression of m-slfns 3 or 8 increase E2F-dependent 
transcription in the absence of infection, they have a similar effect to m-slfn1 in the 
context of a virus infection and result in a decrease in E2F-dependent transcription. 
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Fig. 5-18.  Effect of m-slfns on E2F-dependent transcription in the context of a virus 
infection, with and without v-slfn expression. 
RAW264.7 cells were seeded at a density of 2.5 × 104 cells/well in 24-well plates. Cells were 
transfected with reporter plasmids (120 ng pE2F-luc and 30 ng pTK-Renilla-luc) and empty 
vector (pCI) or expression plasmids (pCI-v-slfn-CHA or pCI-m-slfn-1, 3 or 8) and incubated for 
16 h.  Cells were mock infected or infected with the indicated viruses at 5 PFU/cell, harvested 
6 h later and assayed for luciferase activity.  Data are presented in RLU ± SD (calculated from 
triplicate samples) relative to pCI-transfected cells, which have been normalised to 1. Results 
are representative of three separate experiments.  P values were determined using the 
Student’s t test and indicate the mean differences in RLU with statistical significance. 
5.7 Analysis of potential binding partners of v-slfn and m-slfn1 
Previous work on v-slfn and m-slfn1 identified several potential binding partners 
through a yeast-2-hybrid screen (Brady, 2004).  Of these, the most interesting was a 
fragment of a human orthologue of the Drosophila melanogaster MESR6 protein (h-
MESR6).  D. melanogaster MESR6 was identified through its ability to suppress Ras 
signalling (Huang & Rubin, 2000).  v-slfn and m-slfn1 bound this protein in the yeast-
2-hybrid system, and this was verified for v-slfn by GST-pulldown (Brady, 2004). 
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Fig. 5-19.  Expression of murine and human MESR6 orthologues. 
Empty vector or plasmids expressing the indicated proteins were transfected into HeLa cells.  
Cell extracts were prepared 16 h post-transfection and analysed by immunoblotting using an 
anti-HA Ab. Molecular size markers indicate mass in kDa. 
 
Full length m-MESR6 was cloned from mouse spleen RNA and h-MESR6 was cloned 
from HeLa cell RNA (methods, section 2.3.4), and both were inserted into the pCI 
vector with a C-terminal HA tag.  To extract RNA from the spleen, the organ was 
homogenised and   Fig. 5-19 shows expression of the expressed proteins, as 
detected with an anti-HA Ab.  
To confirm the interaction between v-slfn and MESR6, a series of co-IP experiments 
were performed.  Although a number of conditions were used using several different 
lysis buffers (methods), the two proteins were not co-immunoprecipitated under the 
conditions tested.  Fig. 5-20 shows that anti-v-slfn Ab can pull down v-slfn (lower left 
panel, fourth lane) and anti-HA Ab can pull down HA-tagged h-MESR6 (lower right 
panel, fourth lane).  The upper left panel was blotted for HA following a v-slfn 
pulldown, but although present in the input, there was no protein present following 
pulldown at the size expected for m-MESR6.  Similarly, the blot shown in the upper 
right panel was probed for v-slfn following a HA pulldown, and although it was 
present in the input there was no band present following pulldown for v-slfn. 
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Fig. 5-20.  Immunoprecipitation of v-slfn and h-MESR6. 
HeLa cells were co-transfected with plasmids expressing the indicated proteins and harvested 
16 h post-transfection.  Proteins were pulled down with anti-v-slfn (left panels) or anti-HA 
(right panels), resolved by SDS-PAGE and detected by immunoblotting using anti-v-slfn or 
anti-HA Abs.  Molecular size markers indicate mass in kDa. 
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To determine whether v-slfn and MESR6 co-localised, HeLa cells were transfected 
with plasmids expressing v-slfn, m-MESR6 or h-MESR6 and protein localisation was 
viewed by immunofluorescence with anti-v-slfn and anti-HA Abs.  Murine and human 
MESR6 were predominantly nuclear, although some was present in the cytoplasm. 
Co-expression of v-slfn did not change the localisation of the proteins (Fig. 5-21). The 
MESR6 proteins were therefore not studied any further, as there is a possibility that 
that interaction between v-slfn and the h-MESR6 fragment was an artefact of the 
yeast-2-hybrid screen. 
 
Fig. 5-21.  Sub-cellular localisation of v-slfn and h-MESR6. 
HeLa cells were transfected with pCI vector expressing un-tagged v-slfn and either m-
MESR6-HA or h-MESR6-HA.  Cells were fixed 16 h post-transfection and stained with anti-v-
slfn and anti-HA Abs, followed by secondary Abs and viewed by immunofluorescent 
microscopy.  Scale bars, 20 µm. 
5.8 Generation of TAP-tagged proteins for identification of binding partners 
For identification of binding partners for v-slfn and related proteins a number of 
expression plasmids were made for generation of stable cell lines using the T-Rex 
tetracycline-inducible system (Invitrogen).  A modified version of the pcDNA4/TO 
vector with a tandem affinity purification (TAP) tag inserted after the multiple cloning 
site was generated by Dr Brian Ferguson (Imperial College London).  The TAP tag 
contains two streptavidin tags and a FLAG tag and is used for isolation of highly 
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purified tagged proteins and their binding partners (Gloeckner et al., 2007), which can 
be identified by mass spectrometry.  Plasmids encoding v-slfn, its two domains (p26 
and core), m-slfn1 and the VACV B2 and B3 proteins were generated with a C-
terminal TAP tag.  Expression of v-slfn-TAP, p26-TAP and B2-TAP was detected 
following transient expression using the anti-FLAG or anti-v-slfn Abs (Fig. 5-22) and 
these plasmids are being used to generate stable cell lines.  It is possible that the 
other proteins will express at levels that can be detected following generation of 
stable cell lines.  These cell lines will be used in the future for binding partner 
identification. 
 
 
75
37
50
25
75
37
50
25
α-FLAG
v-slfn
B2
B2
p26
α-v-slfn
v-slfn
p26
α-tubulin
50
m-
slf
n1
-TA
P
v-s
lfn
-TA
P
Co
re-
TA
P
p2
6-T
AP
B2
-TA
P
B3
-TA
P
 
Fig. 5-22.  Transient expression of TAP-tagged proteins. 
HeLa cells were seeded in a 6-well plate. Cells were transfected with 2 µg of plasmids 
expressing the proteins indicated above.  Cells extracts were prepared 16 h post-transfection 
and analysed by immunoblotting using anti-FLAG, anti-HA or anti-tubulin Abs.  Molecular size 
markers indicate mass in kDa. 
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5.9 Conclusions 
In this chapter, the effect of v-slfn alone and in the presence of over-expressed m-
slfn1 has been studied.  As predicted from the fact that m-slfns are regulated by NF-
κB and AP-1 and the fact that VACV infection up-regulates NF-κB activity early in 
infection, VACV infection increased m-slfn levels in both in vivo and in vitro models.  
Consistent with previous studies, it has been shown that m-slfn1 causes cell cycle 
arrest, and consistent with the hypothesis that v-slfn is a negative regulator of m-slfn1 
activity, it has been shown that v-slfn can reverse this.  Neither VACV B2 nor B3 were 
capable of reversing the effects of m-slfn1, and only the schlafen core region of v-slfn 
was capable of doing so, but not the p26-like domain. 
Interestingly, although m-slfn8 was up-regulated in the in vivo intranasal model of 
infection, it did not have the same effect as m-slfn1 in reporter assays in the absence 
of infection.  This might be because it has different targets within the cell or it could 
act as an antagonist for m-slfn1. 
m-slfn1 was capable of reducing the activity of the cyclin D1 promoter when it was 
activated with several different constitutively activated proteins.  This suggests that it 
acts at the level of the promoter, either binding directly to the promoter itself or by 
interfering with the activity of a required transcription factor or co-factor.  Studying the 
different transcription factor binding sites within the cyclin D1 promoter in more detail 
revealed that a similar profile of transcriptional inhibition was observed in CREB 
luciferase reporter assays with m-slfn1 and v-slfn, but this was reversed with NF-κB 
luciferase.  This could be the result of m-slfn and v-slfn interactions with a protein that 
stimulates the activity of one but inhibits the other, such as protein kinase A. 
m-slfn1 interacts with DnaJB6, which itself recruits HDACs.  The hypothesis that the 
effect of m-slfn1 is a result of HDAC recruitment is promising, and this chapter shows 
that a HDAC inhibitor reverses the effect of m-slfn1. 
Although v-slfn has been shown in this chapter to reverse the effects of m-slfn1 in 
transfected cells, it does not appear to have a noticeable effect on cyclin D1 
transcription in infected cells.  However, the m-slfns have a strong effect on E2F 
activity in infected cells, dramatically reducing E2F activity. 
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6 Chapter 6
Production and Characterisation of Recombinant VACV 
6.1 Introduction 
Recombinant VACV expressing CMLV v-slfn was generated previously (Gubser et 
al., 2007), section 6.2.1).  Because of the potential risks of introducing a CMLV gene 
into VACV (Gubser & Smith, 2002), these viruses were made by insertion of v-slfn 
into the TK locus (Davison & Moss, 1990; Mackett et al., 1984) of the ∆B8R virus, 
which is predicted to be highly attenuated in humans but remains virulent in mice 
(Alcami & Smith, 1995).  Analysis of these recombinant viruses determined that 
expression of CMLV v-slfn from VACV reduced rather than increased virulence, and, 
given this phenotype, a new set of recombinant viruses was constructed in which v-
slfn was expressed from its natural promoter without the added attenuation of the TK-
negative parental virus.  The region of the VACV genome corresponding to CMLV 
176R was removed and replaced with CMLV 176R.  This region of VACV contains 
two ORFs, B2R and B3R, and therefore viruses were constructed lacking each of 
these ORFs individually.  Revertant viruses were constructed for all deletion viruses, 
in which the regions of the genome removed to create the deletion viruses were re-
inserted.  All viruses were analysed in vitro to determine whether any phenotype 
could be observed as a result of the removal or insertion of ORFs. 
6.2 Previous work on recombinant viruses expressing v-slfn from the TK 
locus 
Generation and characterisation of the viruses described in this sub-section was 
carried out by Dr. Caroline Gubser and Miss Andrea Ecker. 
6.2.1 Generation of recombinant viruses using TK- selection 
The viruses were made by cloning the genes coding for v-slfn or HA from influenza 
A/PR/8/34 (Bennink et al., 1986) into the pMJ601 vector (Davison & Moss, 1990), 
transfecting these plasmids into cells infected with v∆B8R (Alcami & Smith, 1995) 
and selecting TK- viruses as described (Mackett et al., 1984). Briefly, this was 
achieved by adding bromodeoxyuridine (BrdU) to the culture medium, which when 
phosphorylated by thymidine kinase can be utilised by DNA polymerase and 
incorporated into DNA (Bessman et al., 1958).  BrdU exists more frequently than 
thymine in its ionised or enol forms, which results in base-pairing with G rather than 
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A, and leads to DNA mutations (Lasken & Goodman, 1984; Yu et al., 1993). In TK- 
cells infected with TK- viruses, BrdU is not phosphorylated and can not integrate into 
nascent virus DNA. 
TKL TKRJ2R
TKL TKRΒ-gal
multiple cloning site
sE/L sp7.5(a)
(b)
pMJ601
Parental virus
TKL TKRΒ-galv-slfn
Insertion plasmid
TKL TKRΒ-galv-slfn
Insertion virus
 
Fig. 6-1.  Generation of recombinant viruses using TK- selection. 
(a) pMJ601 plasmid is shown, with a multiple cloning site downstream of a synthetic early/late 
VACV promoter and the gene coding for β-galactosidase downstream of a shortened version 
of the p7.5 promoter in between the left and right flanking regions of J2R.  (b) Generation of 
recombinant VACV using TK- selection.  TKL and TKR represent the left and right flanking 
regions of the J2R ORF (encoding TK), respectively. 
 
Fig. 6-1 shows the strategy used for cloning and subsequent virus construction, using 
insertion of v-slfn as an example.  The virus lacking the J2R ORF in TK locus but 
expressing no exogenous genes is referred to in these experiments as v∆B8R, the 
virus expressing influenza H1 is vH1 and the viruses expressing untagged v-slfn and 
v-slfn tagged at the N or C termini are known as v176-WT, v176-NHA and v176-CHA, 
respectively. 
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6.2.2 Growth kinetics in BS-C-1 cells 
To determine the effect of v-slfn expression on virus replication, the virus titres 
recovered from infected BS-C-1 cells was determined after an infection with 10 
PFU/cell (Fig. 6-2).  At the indicated times pi cells were scraped from the flask and 
collected by centrifugation, and the virus titre was determined by plaque assay on 
BS-C-1 cells.  Fig. 6-2 shows that there was no difference in virus replication when 
either v-slfn or the control H1 proteins are expressed from the TK locus. 
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Fig. 6-2.  Growth kinetics of TK recombinant viruses in BS-C-1 cells. 
BS-C-1 cells were infected with 10 PFU per cell. At the indicated time pi, cells were scraped 
into the medium and the total infectivity was determined by plaque assay. Data points are the 
mean titre from triplicate samples ± SD.  Data are representative of two separate experiments. 
6.2.3 Effect of v-slfn on mice infected intranasally 
Groups of groups of female BALB/c mice (6–8 weeks old) were infected intranasally 
with 4 × 106 or 1 × 107 PFU of sucrose-purified virus, and their weight and signs of 
disease were scored daily (Alcami & Smith, 1992).  Mice showed weight loss and 
signs of illness from day 4 pi onwards (Fig. 6-3).  However, from day 4 pi there was a 
significant attenuation (p<0.05) of v176-WT and v176-CHA compared with vH1 and 
v176-NHA.  In addition, mice infected with v176-WT or v176-CHA started to recover 
sooner after infection (day 6) compared with mice infected with vH1 and v176-NHA.  
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This showed that expression of v-slfn attenuated VACV in this model, and the 
function of v-slfn was affected by the HA tag at the N terminus. The expression of the 
influenza virus H1 HA did not alter VACV virulence in this model. 
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Fig. 6-3.  Weight change and signs of illness in mice infected intranasally. 
Groups of five BALB/c mice were mock-infected or infected with (a) 107 or (b) 4x106 PFU of 
the indicated purified viruses. Mice were weighed daily, and results are the mean percentage 
weight change of each group ± SD compared to the weight on the day of infection (upper 
panels). Animals were monitored daily for signs of illness, scored 1 to 4 (Alcami & Smith, 
1992) (lower panels). Data are expressed as the mean ± SD. P values were determined using 
the Student's t-test and indicate the significantly different mean percentage weight changes or 
signs of illness. 
 
The lungs and spleens of mice infected with 4 × 106 PFU were extracted at days 3, 5 
and 7 pi and virus titres were determined in the lungs and spleens (Fig. 6-4).  At day 
3 pi, the virus titres were comparable in the lungs of mice infected with all three 
viruses.  However, by day 5 pi there was a reduction in virus titre after infection with 
v176-WT compared to v176-NHA and vH1.  This difference was significant at day 7 pi 
for both control groups.  In the spleen, the v176R-WT titre was below the level of 
detection at days 3 and 7 p.i., unlike vH1 and v176-NHA, indicating that v176R-WT 
spread to this organ later and was cleared earlier than control viruses. 
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Fig. 6-4.  Virus titres in the lungs and spleens of infected mice. 
Groups of five mice were infected intranasally with 4x106 PFU of the indicated virus, and the 
lungs (a) and spleen (b) were harvested at days 3, 5 and 7 pi.  Virus titres were determined by 
plaque assay on TK–143 cells. Virus titres are expressed as the mean log10 PFU per organ ± 
SD from groups of five mice. P values were determined using Student's t-test and indicate the 
mean virus titres that were significantly different between mice infected with v176-WT and 
v176-NHA and vH1.  The dashed line indicates the lower limit of detection for this assay. 
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6.3 Further characterisation of previously constructed recombinant viruses 
Further characterisation of the recombinant viruses described in section 6.2 was 
undertaken to examine the function of v-slfn.  Expression of v-slfn from these viruses 
and sub-cellular localisation was described in sections 3.3.3 and 3.3.4, respectively.   
6.3.1 Plaque morphology of cells infected with recombinant VACV 
expressing v-slfn from the TK locus 
The plaque morphology of the v-slfn recombinant viruses was compared to that of 
wild-type and control viruses in infected BS-C-1 cells.  Virus stocks were diluted to 
give individual plaques and infected cells were overlaid with semi-solid medium to 
prevent secondary plaques forming.  After 72 h, infected cells were stained with 
crystal violet, photographed and the diameter of individual plaques was determined 
using ImageJ v1.41 software. 
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Fig. 6-5.  Comparison of the relative plaque sizes of recombinant VACV. 
(a) Plaque morphology of recombinant VACV. BS-C-1 cell monolayers were infected with the 
indicated viruses, overlaid with DMEM/2.5 % FBS/1.5 % carboxymethylcellulose and 
incubated for 3 days at 37 °C. Cells were then stained with 0.1 % (w/v) crystal violet in 15 % 
(v/v) ethanol.  (b) The diameters of 12 isolated plaques were measured using the ImageJ 
measuring tool. Data are expressed as individual plaque sizes relative to the mean size of the 
plaques formed by infection with v∆B8R, which has been set to 100 %, with a line showing the 
mean size for each group. 
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Fig. 6-5 shows that infection with all viruses resulted in comparable plaque sizes in 
BS-C-1 cells.  All virus infections resulted in a range of plaque diameters, ranging 
from 85 % of the v∆B8R mean to 111 %.  These data are further evidence that the 
viruses replicate at a similar rate and are capable of cell to cell spread with 
comparable kinetics to parental virus. 
6.3.2 Growth kinetics in RAW264.7 cells 
As discussed in section 6.2, RAW264.7 cells were chosen for detailed studies of v-
slfn function because in these cells m-slfns are up-regulated in response to 
stimulation with TLR ligands and their expression of short m-slfns.  To determine 
whether v-slfn has an effect on the replication of VACV in these cells, RAW264.7 
cells were infected with 5 PFU/cell, and the virus titre was determined by plaque 
assay at different times pi (Fig. 6-6a).  Unlike infection in BS-C-1 cells, expression of 
v-slfn resulted in a significant reduction in the level of virus recovery 12 h (31, 59 and 
54 % for v176-WT, v176-CHA and v176-NHA, respectively) and 24 h (64, 59 and 24 
% for v176-WT, v176-CHA and v176-NHA, respectively) pi compared to infection with 
v∆B8R. 
Infection with a lower MOI shows both virus replication and cell to cell spread, and 
small variations in replication can be more evident.  Like the high MOI infection, 
expression of v-slfn results in significant reduction in virus recovery 24 h (33, 41 and 
38 % for v176-WT, v176-CHA and v176-NHA, respectively), 48 h (70 and 31 % for 
v176-WT and v176-CHA, respectively) and 72 h (75 and 72 % for v176-WT and 
v176-CHA, respectively) pi compared to infection with v∆B8R (Fig. 6-6b). 
The differences in virus recovered from cells infected with viruses expressing v-slfn 
after both low and high moi was repeatable (n = 4) and may account for the reduction 
in virus recovery from the lungs and spleens of infected mice (section 6.2.3).  The 
mechanism through which v-slfn expression reduces the level of virus recovery 
remains unclear, as do the reasons why poxviruses would express a protein with this 
function. 
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Fig. 6-6.  Growth kinetics of TK recombinant viruses in RAW264.7 cells. 
RAW264.7 cells were infected with (a) 5 PFU per cell or (b) 0.01 PFU per cell. At indicated 
time pi, cells were scraped into the medium and the total infectivity was determined by plaque 
assay. Data points are the mean titre from triplicate samples ± SD. 
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6.4 Construction of recombinant viruses 
To study the effect of v-slfn from its natural promoter in VACV, a new set of viruses 
was constructed in which the corresponding region of the VACV genome was 
removed and replaced with CMLV 176R.  To rule out the possibility of any observed 
effects being a result of the removal of the VACV ORFs in this region (B2R and B3R), 
knockout viruses where also constructed that lack these ORFs.  Revertant viruses 
were made from all knockout viruses, in which the deleted regions of the genome 
were re-inserted. 
6.4.1 Strategy for construction of B2R and B3R knock-out viruses 
B2R and B3R knockout viruses were generated by transient dominant selection 
(Falkner & Moss, 1990), using expression of XGPRT (xanthine-guanine 
phosphoribosyl transferase) from the E. coli GPT gene as a selection marker 
(Falkner & Moss, 1988).  The protein expressed from EcoGPT is fused to eGFP to 
aid in visualisation of recombinant virus plaques.   
The mammalian HGPRT enzyme (hypoxanthine-guanine phosphoribosyl 
transferase), which does not use 2,6-dihydroxypurine (xanthine) efficiently (Mulligan 
& Berg, 1981), is involved in generation of guanosine monophosphate (GMP) and 
adenosine monophosphate (AMP) via the conversion of 6-hydroxypurine 
(hypoxanthine) into inosine monophosphate (IMP) (Mulligan & Berg, 1981).  IMP is 
then converted into xanthine monophosphate (XMP) by inosine monophosphate 
dehydrogenase (IMPDH) (Jackson et al., 1975; Weber et al., 1976).  DNA replication 
therefore does not occur in the presence of MPA, a noncompetitive inhibitor of 
IMPDH, in cells that rely on de novo purine biosynthesis. 
XGPRT converts xanthine into XMP directly, thereby side-stepping the inhibition 
caused by MPA and allowing recombinant viruses that express it to replicate. 
Plasmids were constructed containing the left and right flanking regions of B2R 
(p25N1, Fig. 6-7b) or the left flank of B3R and the right flank of the region 
corresponding to CMLV 176R (p26N2, Fig. 6-7c) with EcoGPT-eGFP at a site distal 
to the flanking regions.  A plasmid was also created to knock out both ORFs 
simultaneously, with the left flank of B2R and the right flank of the region 
corresponding to CMLV 176R (p21N1, Fig. 6-7a). 
A final plasmid was constructed with the full region corresponding to CMLV 176R and 
its flanks (p7N3), which was used to generate the revertant viruses. 
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BS-C-1 cells that had been infected with plaque purified v∆B8R (the parental virus for 
all recombinants discussed in this section) at an MOI of 0.05 were transfected with 
p21N1, p25N1 or p26N2.  Virus was harvested from this transfection/infection, diluted 
serially and used to infect fresh monolayers of BS-C-1 cells that had been treated 
with MPA.  These cells were then overlaid with 1 % low melting point (LMP) agarose 
and incubated for 2-3 days before plaque picking.  The resulting recombinant virus 
was created by a single recombination event, which incorporated the entire plasmid 
including the EcoGPT-eGFP cassette (Fig. 6-7d).  The inserted plasmid can be 
ejected by either a second recombination between the same flanks that inserted it or 
between the other pair of flanks (Fig. 6-7e), and is therefore referred to at this stage 
as an intermediate virus.  The intermediate virus was plaque purified four times with 
MPA selection, and expression of XGPRT-eGFP (from EcoGPT-eGFP) was 
confirmed by fluorescent microscopy.  The presence of both the parental and deletion 
DNA sequences was confirmed by PCR. 
Due to the presence of repeated sequences of the left and right flanking regions of 
the intermediate virus, the inserted plasmid can be excised by a second 
recombination between either pair of repeats. This can occur if the selective pressure 
for XGPRT expression (MPA) is removed, or if viruses are grown on HGPRT- cells in 
the presence of 6-thioguanine (6-TG) (Fig. 6-7e).  Both HGPRT and XGPRT can 
convert guanine into GMP, and can process 6-TG in a similar manner (Drake et al., 
1983; Isaacs et al., 1990).  When integrated into DNA, the thiol group can be 
methylated by thiopurine S-methyltransferase (TPMT) (Krynetski et al., 1995).  This 
results in either mismatches in replicating DNA or abortion of replication (Swann et 
al., 1996).  Expression of XGPRT is therefore inhibitory to virus replication in the 
presence of 6-TG selection and only viruses that have undergone recombination to 
remove the EcoGPT gene can replicate.  After one round of amplification in D98OR 
cells in the presence of 6-TG selection, resolved viruses were plaque purified once 
and tested by PCR to determine whether the isolated virus clones had resolved 
towards deletion or parental virus.  Isolated clones of deletion viruses were plaque 
purified twice more, and amplified.  The resultant B2R and B3R knockout viruses 
were named v∆B2R and v∆B3R. 
B2R and B3R revertant viruses were generated in a similar manner by transfecting 
cells infected with v∆B2R and v∆B3R, respectively, with p7N3.  The intermediate 
viruses were resolved and screened for re-insertion of the ORFs.  The resultant 
revertant viruses for B2R and B3R were named vB2Rrev and vB3Rrev, respectively. 
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Fig. 6-7.  Strategy for generation of recombinant viruses using transient dominant 
selection. 
 (a) p21N1, the plasmid designed for simultaneous deletion of both B2R and B3R.  (b) p25N1, 
the plasmid designed for deletion of B2R.  (c) p26N2, the plasmid designed for deletion of 
B3R.  (d) The two possible single homologous recombinations between the left and right 
flanks, using p21N1 as an example.  (e) Intermediate viruses generated by both F1/F1 
recombination or F2/F2 recombination and the second recombination events that can occur in 
both.  Single asterisks indicate a reversion to parental virus, double asterisk indicate 
resolution to deletion virus. 
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Despite the construction of B2R and B3R knockout viruses and their revertants by 
transient dominant selection, attempts to make a knockout of both ORFs 
simultaneously using this strategy was unsuccessful.  Although intermediate viruses 
were isolated, these all resolved back to parental virus, rather than to deletion 
mutant.  A second attempt to generate the double knockout was attempted by 
transient dominant selection, using v∆B2R and v∆B3R as parental viruses.  Infected 
cells were transfected with p21N1 and intermediate viruses were resolved.  However, 
this method also resulted in resolution of the virus back to parental following 6-TG 
selection, despite the large numbers of resolved virus clones analysed.  The reasons 
for this were not obvious, but in view of the difficulty an alternative strategy was used. 
6.4.2 Construction of recombinant virus stably expressing EcoGPT-
eGFP from the v-slfn locus 
To generate B2R/B3R double deletion viruses a stable intermediate virus was made 
first by double homologous recombination with EcoGPT-eGFP between the flanking 
regions corresponding to CMLV 176R.  This method was used before transient 
dominant selection was first described (Isaacs et al., 1990).  Use of eGFP as an 
indicator of recombination has been described for this method (Fahy et al., 2008). 
BsiWI and ApaI restriction sites were inserted between the flanks of the p21N1 
plasmid by overlap PCR (Fig. 6-8a) to create the pKIVEC plasmid.  This vector was 
designed for insertion of genes for generation of knock-in viruses, but was suitable for 
insertion of EcoGPT-eGFP.  The EcoGPT-eGFP gene was excised from the pAFB 
(Fahy et al., 2008) using SmaI, and ligated into blunted ends of BsiWI- and ApaI-
digested pKIVEC to create the pKIE/E plasmid (Fig. 6-8b). 
The pKIE/E plasmid was linearised by digestion with BamHI and purified by agarose 
gel electrophoresis.  The linearised DNA was transfected into cells that had been 
infected with the v∆B8R parental virus.  The linearisation of the plasmid meant that 
single recombinations were not possible for integration of the selection cassette, so 
any resulting recombinant virus had to occur through double homologous 
recombination between the left and right flanks of the linearised plasmid and the virus 
(Fig. 6-8d).  The virus harvested from this transfection/infection was plaque purified 
three times in the presence of MPA and twice in the absence of MPA and analysed 
by PCR to confirm replacement of the region between the two flanks with EcoGPT-
eGFP.  This stable intermediate, which is a “dirty” B2R/B3R double knockout, was 
named vRGKI.  The isolation of this virus confirmed that the combination of the B2 
and B3 ORFS were not essential for virus replication. 
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Fig. 6-8.  Construction of recombinant virus with EcoGPT-eGFP in place of B2R and 
B3R. 
Schematic representation of the strategy used to create a stable intermediate virus expressing 
EcoGPT-eGFP.  (a) Insertion of BsiWI and ApaI restriction sites between F1 and F2 in p21N1 
to create pKIVEC.  (b, c) Insertion of EcoGPT-eGFP and 176R into pKIVEC to create pKIE/E 
and pKICHA.  (d) Simultaneous double homologous recombination between linearised vector 
and parental virus.  Recombination between VACV DNA and pKIE/E is shown, a similar 
recombination would occur between VACV DNA and linearised pKICHA. 
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6.4.3 Strategy for construction of B2R/B3R double knock-out viruses 
and v-slfn knock-in virus 
For generation of a clean knockout virus from vRGKI p21N1 was used.  To generate 
a v-slfn knock-in virus, a plasmid was made with CMLV 176R in between the left and 
right flanks of the region into which it was going to be inserted.  176R was cloned into 
pKIVEC using the BsiWI and ApaI restriction sites to create the pKICHA plasmid (Fig. 
6-8c). 
p21N1 and pKICHA were linearised with XmaI and NotI and the linear DNA was 
purified and transfected into cells infected with vRGKI.  Harvested virus was amplified 
in D98OR cells in the presence of 6-TG but no resolved virus was recovered.  
Although similar intermediate viruses have been resolved using this method (Isaacs 
et al., 1990), in this instance it was not successful. 
It was decided to generate the resolved viruses using single homologous 
recombination of a circular plasmid, which meant that the EcoGPT-eGFP cassette 
had to be removed from p21N1 and pKICHA.  To do this, a sequence coding for the 
cherry fluorescent protein was used to replace EcoGPT-eGFP, keeping the same 
synthetic early late promoter driving its expression.  The resulting plasmids based on 
p21N1 and pKICHA were renamed p21N1-Ch (Fig. 6-9a) and pKICHA-Ch (Fig. 6-9b), 
respectively.  This system had the added advantage of allowing amplification of 
recombinant virus in a similar manner to that used for transient dominant selection 
(Fig. 6-7), based on expression of fluorescent protein rather than on drug resistance 
(Fig. 6-9c,d).  However, a major difference between this method and transient 
dominant selection is that XGPRT is expressed from a sequence between the two 
flanks, meaning that the only resolved viruses that can replicate in the presence of 6-
TG in D98 cells are deletion viruses, which have recombined to remove the EcoGPT-
eGFP cassette (Fig. 6-9d). 
Cells infected with vRGKI were transfected with p21N1-Ch or pKICHA-Ch.  
Harvested virus was plaque purified four times in BS-C-1 cells, picking only plaques 
that express the cherry protein as determined by fluorescent microscopy.  Purified 
intermediate virus was amplified on D98OR cells in the presence of 6-TG and the 
resolved virus was plaque purified.  Removal of EcoGPT-eGFP was confirmed by 
PCR.  The resulting deletion and v-slfn insertion viruses were named v∆B2R∆B3R 
and vSlfnCHA-KI, respectively. 
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Fig. 6-9.  Construction of vectors for replacement of EcoGPT/eGFP in recombinant 
viruses and strategy for generation of viruses using fluorescent selection. 
(a, b) Schematic representation of the replacement of EcoGPT-eGFP in both p21N1 and 
pKICHA with a sequence coding for the cherry protein. (c) The two possible single 
homologous recombinations between the left and right flanks, using p21N1-Ch as an 
example.  (d) Intermediate viruses generated by both F1/F1 recombination or F2/F2 
recombination and the second recombination events that can occur in both.  Single asterisks 
indicate a reversion to parental virus, double asterisk indicate resolution to deletion/insertion 
virus.   
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6.4.4 Analysis of viruses to confirm recombination 
In the initial stages of purification, insertion of the EcoGPT-eGFP cassette was 
determined by fluorescent microscopy.  Fig. 6-10 shows two plaques viewed by 
fluorescent microscopy, demonstrating the difference between viruses that do or do 
not express XGPRT-eGFP (from EcoGPT-eGFP).   
 
 
Fig. 6-10.  Visualisation of green plaques in cells infected with recombinant virus. 
A monolayer of D98OR cells was infected with vRGKI at an MOI of 0.05 in the presence of 6-
TG.  Virus was harvested 72 hpi, diluted serially and used to infect confluent monolayers of 
BS-C-1 cells.  Plaques were viewed by fluorescent microscopy 48 hpi.  A mixed population of 
plaques not expressing (left plaque) and expressing (right plaque) eGFP were observed.  
Scale bars 500 µm. 
 
To confirm deletion or insertion of sequences in VACV, PCR analysis was carried 
out.  Fig. 6-11 shows the results from four sets of PCR carried out on recombinant 
viruses.  This confirmed that the desired DNA sequences had been removed from the 
relevant viruses, or inserted into the revertant and knock-in viruses. 
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Fig. 6-11.  Analysis of recombinant viruses by PCR. 
(a) Predicted size of PCR products obtained from the indicated reactions using DNA extracted 
from cells infected with the indicated viruses.  (b) PCR analysis of DNA extracted from cells 
infected with the indicated viruses to determine deletions and insertions, using the primers 
detailed in (a).  (c) Schematic representation of the region of VACV WR corresponding to 
CMLV 176R and the left and right flanking regions (L and R, respectively). Single ended 
arrows represent primer annealing sites for the specified reaction and double ended arrows 
indicate the positions of B2R and B3R. 
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6.5 In vitro characterisation of recombinant viruses 
6.5.1 Level of expression of v-slfn from knock-in viruses 
The level of v-slfn expressed from vSlfnCHA-KI was compared to the level expressed 
from v176-CHA.  BS-C-1 cells were mock infected or infected with the parental 
v∆B8R virus, vSlfnCHA-KI or v176-CHA.  The level of v-slfn expressed from its 
natural promoter was considerably lower than the protein expressed from the strong 
synthetic early late promoter in the TK locus (Fig. 6-12).  Levels of F13 were also 
determined as an internal control for levels of viral protein expression, and it was 
found that levels were comparable in all three infections, as were levels of tubulin. 
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Fig. 6-12.  Expression of v-slfn from new and old recombinant viruses. 
BS-C-1 cells were mock infected or infected with the indicated viruses with 5 PFU/cell.  Cell 
extracts were prepared 16 hpi and analysed by immunoblotting using anti-HA, anti-F13 or 
anti-tubulin Abs.  Molecular size markers indicate mass in kDa. 
6.5.2 Expression of v-slfn and B2 proteins in recombinant viruses 
To determine the levels of B2 and v-slfn expression in the recombinant viruses, 
monolayers of BS-C-1 cells were infected with each of the new viruses, CMLV CMS 
and v176-CHA and cell extracts were analysed by immunoblotting (Fig. 6-13).  A 
protein of approximately 25 kDa was detected in extracts from cells infected with 
parental virus, all of the revertants and v∆B3R.  However, it was absent in the 
extracts from cells infected with v∆B2R, v∆B2R∆B3R and vSlfnCHA-KI, confirming 
that this protein is B2.  A band approximately the same size as the predicted 57 kDa 
of v-slfn was detected in the extract from cells infected with vSlfnCHA-KI, and the 
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levels are comparable to those from cells infected with CMLV CMS (Fig. 6-13).  The 
considerably higher levels of v-slfn observed in extracts from cells infected with v176-
CHA (Fig. 6-12) can also be seen here.  Interestingly, the levels of B2 expressed by 
v176-CHA are higher than those expressed from any other viruses, despite the level 
of expressed F13 being at a comparable level, as seen previously (Fig. 3-19).  A 
possible reason for this is that some full length v-slfn is proteolytically cleaved 
between the p26 and slfn domains, generating a protein similar in size to B2.  
However, this 25-kDa protein is not seen in CMLV-infected cells, making stabilisation 
of B2 by v-slfn a more likely explanation, possibly as a result of protein dimerisation 
(section 4.4.1). 
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Fig. 6-13.  Detection of v-slfn and B2 proteins in recombinant VACV and CMLV. 
BS-C-1 cells were mock infected or infected with the indicated viruses with 5 PFU/cell.  Cell 
extracts were prepared 16 hpi and analysed by immunoblotting using anti-HA, anti-F13 or 
anti-tubulin Abs.  Molecular size markers indicate mass in kDa. 
6.5.3 Kinetics of expression of v-slfn in cells infected with v-slfn knock-
in virus 
To determine whether the kinetics of v-slfn expression from vSlfnCHA-KI was 
comparable to v-slfn expression of v-slfn from CMLV CMS and B2 from VACV WR 
(section 3.4.2), BS-C-1 cells were infected with vSlfnCHA-KI at 10 PFU/cell and cell 
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lysates were prepared at the indicated times pi (Fig. 6-14).  v-slfn can be detected 
from 2 hpi, and continued to be expressed up to 16 hpi.  Similar to the expression of 
v-slfn from CMLV and B2 from VACV (Fig. 3-18), expression was reduced 16 hpi in 
cells treated with AraC, showing that expression is both early and late. 
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Fig. 6-14.  Kinetics of expression of v-slfn in cells infected with v-slfn knock-in virus. 
BS-C-1 cells were infected with vSlfnCHA-KI at 10 PFU/cell in the presence (+) or absence (-) 
or 40 µg/ml cytosine arabinoside (AraC).  At the indicated time pi, cells were lysed and 
resolved by SDS-PAGE.  Protein was detected using the anti-HA, anti-F13 or anti-tubulin Abs.  
Molecular size markers indicate mass in kDa. 
6.5.4 Sub-cellular localisation of B2 and v-slfn in cells infected with 
recombinant viruses 
To determine the sub-cellular localisation of v-slfn and B2 in cells infected with the 
new recombinant viruses, HeLa cells were infected and visualised by confocal 
microscopy (Fig. 6-15).  No fluorescence was detected in mock-infected cells (Fig. 
6-15a).  A protein with similar sub-cellular localisation to v-slfn (section 3.3.4) was 
detected in cells infected with v∆B8R parental virus and v∆B3R (Fig. 6-15 b,d) but 
not in cell infected with v∆B2R or v∆B2R∆B3R (Fig. 6-15 c,e).  v-slfn expressed from 
vSlfnCHA-KI is located predominantly in the cytoplasm, with some protein in the 
nucleus (Fig. 6-15f).  This is similar to the localisation of v-slfn in CMLV and v176-
CHA infected cells (Fig. 3-11), 
These data indicate that the diffuse cytoplasmic protein detected previously using the 
anti-v-slfn Ab in cells infected with VACV WR was in fact B2 (Fig. 3-11).  The 
localisation of B2 to actin filaments observed in transfection models (Fig. 3-13) does 
not occur following infection.  This suggests that the localisation in transfection 
models is an artefact of the transfection model. 
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Fig. 6-15.  Subcellular localisation of B2 and v-slfn proteins in HeLa cells infected with 
recombinant VACV. 
HeLa cells were mock infected or infected with 5 PFU/cell of the indicated viruses. 
Cells were fixed 6 hpi and stained with anti-v-slfn and anti-HA Abs, and fluorescent secondary 
Abs were viewed using a confocal microscope.  Scale bars, 20 µm. 
 
The subcellular localisation of B2 in cells infected with the three revertant viruses was 
also examined, and it was found to be comparable to the localisation observed 
following an infection with parental virus (data not shown). 
6.5.5 Growth kinetics of recombinant viruses 
To determine the kinetics of replication and spread of the knockout and knock-in 
recombinant viruses, RAW264.7 cells were infected at a high MOI (Fig. 6-16a) or a 
low MOI (Fig. 6-16b) and virus titres were determined at the indicated times pi. 
Unlike the small reduction in virus titres observed in cells infected with virus 
expressing v-slfn from the TK locus (Fig. 6-6), the virus expressing v-slfn from its 
natural locus (vSlfnCHA-KI) had indistuinguishable titres after either low or high MOI.  
There were also no differences in the levels of virus recovered from cells infected 
with v∆B2R, v∆B3R or v∆B2R∆B3R after either low or high MOI. (Fig. 6-16).  This 
shows that expression of v-slfn from its natural promoter does not affect replication or 
spread of the virus, and the differences observed previously may have been an 
artefact of over-expression.  These data also show neither B2 nor B3 are required for 
efficient replication or spread of the virus in vitro. 
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Fig. 6-16.  Growth kinetics of recombinant viruses in BS-C-1 cells. 
RAW264.7 cells were infected with (a) 5 PFU per cell or (b) 0.01 PFU per cell. At indicated 
time pi, cells were scraped into the medium and the total infectivity was determined by plaque 
assay. Data points are the mean titre from triplicate samples ± SD. 
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6.5.6 Plaque morphology of cells infected with recombinant VACV 
expressing v-slfn from its natural promoter 
The plaque morphology of the new v-slfn recombinant viruses was compared to that 
of parental virus in infected BS-C-1 cells.  Virus stocks were diluted to a titre from 
which individual plaques could be isolated following infection.  Infected cells were 
overlaid with semi-solid medium to prevent secondary plaque formation from 
extracellular virus in the medium.  After 72 h, infected cells were stained with crystal 
violet, photographed and the diameter of individual plaques was determined using 
ImageJ v1.41.  Infection with all viruses resulted in comparable plaque sizes in BS-C-
1 cells (Fig. 6-17), confirming that insertion of v-slfn or deletion of B2R or B3R does 
not have any effect on virus replication or spread in vitro. 
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Fig. 6-17.  Comparison of the relative plaque sizes of recombinant VACV. 
Plaque sizes in cells infected with recombinant VACV. BS-C-1 cell monolayers were infected 
with parental v∆B8R, v∆B2R, vB2Rrev, v∆B3R, vB3Rrev, v∆B2R∆B3R, vB2RB3Rrev or 
vSlfnCHA-KI and overlaid with DMEM/2.5 % FBS/1.5 % carboxymethylcellulose and 
incubated for 3 days at 37 °C. Cells were then stained with 0.1 % (w/v) crystal violet in 15 % 
(v/v) ethanol. The diameters of 12 isolated plaques were measured using the ImageJ 
measuring tool.  Data are expressed as individual plaque sizes relative to the mean size of the 
plaques formed by infection with v∆B8R, which has been set to 100 %, with a line showing the 
mean size for each group. 
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6.6 Conclusions 
Previous studies have shown that exogenous expression of v-slfn from the TK locus 
in VACV resulted in no differences in any of the in vitro models, but resulted in 
reduced virulence in the intranasal model of infection (Gubser et al., 2007).  Further 
analysis of these viruses showed that there was a small difference in titre after both 
high and low MOI in RAW264.7 cells, in contrast to the comparable virus recovery 
from infected BS-C-1 cells.  However, although statistically significant, this difference 
was small and does not suggest a change in virus replication or morphogenesis.  The 
cause of the altered phenotype of the viruses expressing v-slfn in the intranasal 
model of infection is therefore still unclear. 
The expression of v-slfn from the TK locus was very high, and it is possible that any 
effect observed may have been a result of the overexpression of the protein.  For this 
reason, the set of viruses made that lack either B2R or B3R, or both, or have 176R 
inserted, will be invaluable tools for the elucidation of the function of v-slfn.  The level 
of v-slfn expressed from the knock-in virus is indistinguishable from the level 
expressed from CMLV, and will therefore be less likely to provide us with false 
results. 
While the tools have been created to perform further analyses, the function of v-slfn  
cannot be deduced from the in vitro data presented in this chapter and in vivo 
analyses are required.  As predicted from the fact that there are no differences in the 
in vitro models of infection when using the TK viruses, none of the in vitro assays 
revealed a function for v-slfn.  Equally no role for B2 or B3 was found.  It is also not 
possible to determine from these assays whether expression of v-slfn or deletion of 
B2R and B3R from these new viruses will have any effect on the intranasal or 
intradermal models of infection in vivo.  Further analysis of the viruses will be 
required to answer these questions. 
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Discussion 
The function of CMLV v-slfn as a negative regulator of m-slfn function and possible 
mechanisms for this function has been described in this thesis.  In addition, a set of 
reagents have been constructed for future analysis of both the protein structure and 
its affect on virulence using in vivo models. 
7.1 Mammalian slfn proteins 
The number of slfn proteins varies amongst mammals, with all sequenced species, 
other than rodents, expressing only intermediate and long slfns.  The prototypic slfn 
protein, m-slfn1, is the most studied mammalian slfn despite only being expressed in 
rodents, and acts as a negative regulator of cyclin D1 expression (Brady et al., 2005).  
Recently, the intermediate m-slfn3 was shown to reduce transcription of cyclin D1 in 
a similar manner to m-slfn1 (Patel et al., 2009).  Long m-slfns (5, 8, 9 and 10) do not 
have an anti-proliferative effect when overexpressed in fibroblasts (Geserick et al., 
2004), although m-slfn8 decreased thymic cellularity when consitutively expressed 
under the control of the CD2 promoter (Geserick et al., 2004).  These data suggest 
that all m-slfn proteins might have an effect on cell proliferation, but their activity 
depends on the cell type and expression profile.  A mechanism for this function 
remains to be elucidated.  An interaction between m-slfn1 and DnaJB6 was 
demonstrated (Zhang et al., 2008), which may cause growth arrest by recruiting 
HDACs, resulting in chromatin condensation. 
Poxvirus proteins with sequence similarity to mammalian proteins controlling the 
immune response to infection or cell proliferation are well documented.  These 
proteins may either mimic the function of their host counterparts, for example the 
stimulation of cell growth by VGF (Buller et al., 1988a; Buller et al., 1988b), or they 
may inhibit function by mopping up effector proteins, for example the inhibition of IFN-
γ by the soluble viral IFN-γ receptor (Alcami & Smith, 1995; Mossman et al., 1995; 
Puehler et al., 1998; Symons et al., 2002b). 
7.2 Expression viral slfn-like proteins 
This project started with a bioinformatic analysis of viral slfns and their relationship to 
mammalian slfns.  The gene encoding v-slfn is present near the right hand end of the 
CMLV genome and is predicted to encode a protein of 57.1 kDa, with no predicted 
sub-cellular localisation signals.  Orthologues between 502 and 505 aa long and with 
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87 to 98 % aa identity to CMLV v-slfn are encoded by CPXV, ECTV, MPXV, HSPV 
and GBLV.  Intriguingly, the full length slfn protein is absent in all sequenced VACV 
and VARV strains and only gene fragments remain (www.poxvirus.org).  Analysis of 
the genomic sequence of several OPVs revealed that the ancestral virus(es) from 
which both VACV and VARV evolved probably expressed full length v-slfn proteins at 
some point, but independently acquired mutations have resulted in fragmentation of 
the ORF.  The expression of v-slfn was confirmed for CMLV and CPXV by 
immunoblotting, and similarly the lack of expression of full-length v-slfn from several 
strains of VACV was demonstrated.  Although it is not possible to test expression 
from VARV experimentally, bioinformatic analysis revealed that two identical 
frameshift mutations are present at the beginning of the ORF in all 47 VARV strains 
for which the genomic sequence is available (www.poxvirus.org).  Together, these 
data show that v-slfn is not required for VACV or VARV replication or virulence.  The 
reasons for conservation in most OPVs but not in VACV or VARV are unclear. 
The function of the baculovirus p26 proteins, which have 34-38% aa similarity to the 
N-terminal domain of v-slfn, is currently unknown, although it is established that p26 
is non-essential for baculovirus replication (Goenka & Weaver, 2008; Simon et al., 
2008).  Some entomopoxviruses, such as MSEV, also express p26-like proteins 
(Afonso et al., 1999), but the function of these insect poxvirus proteins is also 
unknown.  The fact that some sequenced strains of entomopoxvirus, such as AMEV, 
do not express a p26-like protein (Bawden et al., 2000) shows that, similar to 
baculoviruses, p26-like proteins are not essential in entomopoxviruses.  The 
fragmentation of the VACV strain WR slfn gene has split the p26-like domain and the 
slfn-like domain being separated into two genes, and these are called genes B2R and 
B3R.  If this was a single gene originally, as seems likely, and there is no internal 
promoter to initiate transcription near the 5’ end of the B3R ORF, only the B2 protein 
is likely to be expressed.  Indeed, a p26-like protein (B2) was shown to be expressed 
from most strains of VACV.  Removal of the gene coding for this p26-like protein from 
VACV did not alter replication. 
CMLV v-slfn and VACV B2 are expressed both early and late in infection, as 
predicted by transcriptome analysis (Assarsson et al., 2008) and by bioinformatic 
analysis of promoter regions.  During SDS-PAGE v-slfn migrates at the size of a 
protein of approximately 57 kDa, the size predicted by its sequence.  In addition to 
the 57-kDa protein, a 37-kDa protein was observed in lysates from cells transfected 
with plasmids expressing v-slfn.  This might be produced by proteolytic cleavage 
between the two domains of v-slfn because the size corresponds to the size of the 
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slfn core domain alone.  However, this protein fragment was not detected by the anti-
HA mAb when v-slfn was tagged either the N or C terminus.  If this is indeed the slfn 
core domain, one would expect the HA Ab to detect it when v-slfn was C-terminally 
tagged.  Perhaps the HA-tag was masked or removed by proteolytic cleavage. 
The anti-HA mAb detected the full length v-slfn tagged at the C terminus better than 
the N-terminally tagged v-slfn, and this was true whether the protein was expressed 
following infection or transfection.  The two tagged proteins express at a comparable 
level, as detected by the anti-v-slfn Ab.  The reduction in detection of the N-terminal 
tag could be a result of either reduced stability of the N-terminal tag or reduced 
accessibility to the tag, or both.  Recombinant VACV expressing v-slfn with an N-
terminal tag has a different phenotype to virus expressing untagged or C-terminally 
tagged v-slfn in the intranasal model of infection (Gubser et al., 2007), suggesting 
that the tag somehow alters the function of the protein.  It is possible that the N 
terminus is internal to the protein and addition of the tag results in a structural 
alteration of the protein, thereby affecting its function. 
Immunofluorescent analysis of v-slfn subcellular localisation showed that v-slfn is 
predominantly cytoplasmic.  This contrasts with m-slfn1, which is predominantly 
nuclear.  This difference in localisation makes it unlikely that v-slfn exerts its effect on 
m-slfn1 directly.  It is possible that v-slfn sequesters a binding partner for m-slfn1, 
preventing it from exerting its function.  The localisation of the proteins did not change 
when co-expressed following transfection, or following a co-infection of the 
transfected cells with VACV.  Interestingly, while the slfn core domain of v-slfn has 
comparable sub-cellular localisation to full length v-slfn, both the p26 domain of v-slfn 
and VACV B2 (which comprises a p26 domain without the slfn core domain) appear 
to localise to f-actin when expressed from transfected plasmids.  However, B2 does 
not localise to actin in VACV-infected cells, and has similar diffuse cytoplasmic 
localisation to full length v-slfn.  Thus, the localisation to actin is most likely to be an 
artefact of overexpression in the transfection model. 
7.3 Purification of recombinant v-slfn protein 
Recombinant v-slfn and m-slfn1 were expressed in both E. coli and recombinant 
baculovirus-infected Sf9 insect cells.  The protein expressed in E. coli was mostly 
insoluble and was sequestered within inclusion bodies.  Attempts to obtain soluble 
protein following denaturation and refolding or by purification of the small amount of 
soluble protein present gave very low yields.  As an alternative, v-slfn was expressed 
in Sf9 cells infected with recombinant baculovirus and this gave soluble v-slfn, which 
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could be readily purified by affinity and size exclusion chromatography.  The purified 
protein was sent to collaborators at Oxford University, Dr Mohammad Bahar and Prof 
David Stuart, and different conditions for crystallisation of the protein were trialled.  
These studies suggested that v-slfn was dimeric when expressed from this system. 
Future structural studies will require more soluble protein for more extensive protein 
crystallisation trials.  Selenomethionine (SeMet)-labelled protein will also need to be 
produced and crystallised, and diffraction patterns for the unlabelled and SeMet-
labelled protein will be needed to determine the 3D structure of the protein.  SeMet 
labelling overcomes what is known as the ‘phase problem’, which stems from the fact 
that X-ray diffraction measures the amplitude of the diffracted rays (which is related to 
intensity) but fails to measure the phase (reviewed in Taylor, 2003).  Diffraction of X-
rays from SeMet-labelled crystals can be compared to diffraction of unlabelled 
crystals.  The relative position of methionines can then be determined, allowing 
determination of phase and subsequent determination of protein structure (Yang et 
al., 1990).  A crystal structure of v-slfn will be the first 3D structure of a slfn protein. 
7.4 The role of v-slfn as a cell cycle regulator 
During infection by VACV the levels of D-type cyclins are reduced, which would 
normally lead to a decrease in both E2F activity and transcription of tRNA and small 
rRNA (Yoo et al., 2008).  Although poxviruses encode much of the machinery 
necessary for replication, they are reliant on host translation machinery, including 
tRNA, and recruit it to the viral factories (Katsafanas & Moss, 2007).  During VACV 
infection, expression of TFIIIB and TFIIIC is increased (Yoo et al., 2008).  Firstly, this 
leads to an increase in tRNA synthesis, and secondly, the Brf1 subunit of TFIIIB 
sequesters the pRb protein, which under normal circumstances inhibits E2F (Yoo et 
al., 2008). 
It is conceivable that poxviruses may have multiple mechanisms for controlling D-type 
cyclins and the proteins downstream of their activation.  The upregulation of TFIII 
subunits and subsequent sequestration of pRb proteins (Yoo et al., 2008) suggests 
that these transcription factors and/or E2F activation may be important for poxvirus 
replication.  The recruitment of HDACs by pRb and pocket proteins (Hurford et al., 
1997; Zhang et al., 2000) would, however, decrease the efficiency of tRNA 
transcription by TFIII.  A viral mechanism to inhibit the block in D-type cyclin 
transcription would result in hyperphosphorylation of pRb and would therefore result 
in increased efficiency of tRNA transcription. 
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To validate previous experiments and to investigate the theory that v-slfn reversed 
the effect of m-slfn1, a system was devised in which the effect of v-slfn on m-slfn1 
inducibly-expressed from stable cell lines (18-9 cells) was observed.  Changes in 
total cellular proliferation as a result of transfected plasmids would normally be 
difficult to see clearly because not all cells receive a copy of the transfected plasmid 
(approximately 30 % of the cells were transfected, as determined by co-expression of 
eGFP).  However, the complete halt in cell division resulting from m-slfn1 expression 
(Brady et al., 2005) made it possible to clearly observe the increase in cell division in 
cells expressing v-slfn, through a relative increase in total cell number.  This effect 
was even more evident when the percentage of eGFP-positive cells co-expressing v-
slfn (as compared to total cell number) was determined by flow cytometry and 
compared to cells expressing eGFP but not v-slfn.  This directly measured the 
relative number of transfected cells without the background of untransfected cells.  It 
was clear from these results that v-slfn reverses the anti-proliferative effect of m-slfn1 
in these cells.  An immunoblot of protein extracts from these cells showed that v-slfn 
increased the level of cyclin D1 expression over that of cells transfected with empty 
vector, and this is consistent with the hypothesis that v-slfn reverses the inhibition of 
cyclin D1 expression caused by m-slfn1. 
The fragments of v-slfn expressed from VACV were also tested to see if they could 
reverse the effect of m-slfn in a comparable manner.  However, neither B2 nor B3 
reversed the effect in this transfection model.  Futher analysis of v-slfn showed that 
the p26-like domain of v-slfn had no effect in this system, but the slfn core domain 
could reverse the effect in a comparable manner to full length v-slfn. 
To determine the effect of v-slfn on the level of transcription from the cyclin D1 
promoter, a number of luciferase reporter assays were performed using both 18-9 
cells and RAW264.7 murine macrophages.  Previous assays induced m-slfn1 
expression 24 h prior to reporter plasmid transfection (Brady et al., 2005), resulting in 
very high expression and a complete halt in cell proliferation.  This meant that the 
activity of the cyclin D1 promoter was reduced to approximately 5 % of that of 
uninduced cells.  In contrast, the assays presented in this thesis using 18-9 cells 
always were performed in cells induced to express m-slfn1 at the same time as 
transfection of reporter and expression plasmids.  The level of inhibition of activity of 
the cyclin D1 promoter from expression of m-slfn1 in this system was approximately 
40 %, which is comparable to a transfection model reported previously in CHO cells 
(Brady et al., 2005).  The effect on transcription from the cyclin D1 promoter was 
complemented by a comparable reduction in E2F-dependent promoter activity, as 
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measured by luciferase, activation of which is downstream of cyclin D1 activation.  
These data are consistent with the data showing a reversal of the effect of m-slfn1 
when v-slfn is co-expressed, further supporting the model that v-slfn reverses the 
effect of m-slfn1. 
Previous studies have shown that m-slfns are upregulated in response to various 
stimuli or infections (Eskra et al., 2003; Froese et al., 2006; Geserick et al., 2004; 
Rodenburg et al., 2007; Schurr et al., 2005) and the m-slfn2 promoter contains NF-κB 
and AP-1 binding sites (Sohn et al., 2007).  Collectively, this suggests that most, if 
not all, m-slfns are upregulated in response to TLR stimulation.  Consistent with the 
other models of infection that resulted in increased expression of m-slfns, intranasal 
infection of mice with VACV also resulted in upregulation of m-slfn1 and m-slfn8 
mRNA.  The upregulation of expression of a representative short and long m-slfn (m-
slfn1 and m-slfn8, respectively), but not the tested intermediate m-slfn (m-slfn3) is 
consistent with a previous study, which showed that all m-slfns are upregulated in 
bone marrow macrophages when stimulated with either IFNγ or LPS, with the 
exception of the intermediate m-slfn3 (Geserick et al., 2004).  To establish an in vitro 
system in which this upregulation of m-slfns could be repeated easily, RAW264.7 
cells were stimulated with TLR ligands (Pam3Cys, poly(I:C) and LPS).  This resulted 
in an upregulation in m-slfn1 expression in all cases.  This provided an environment 
for in vitro studies in which m-slfns are upregulated naturally. 
The effect of both m-slfn1 and v-slfn on the cyclin D1 and E2F-dependent promoters 
was then studied in RAW264.7 cells.  Initial experiments followed a similar protocol to 
the assays in 18-9 cells, but with m-slfn1 expressed from transfected plasmids rather 
than from induction of a stably-expressed gene.  However, very little difference was 
observed in cyclin D1 or E2F-dependent luciferase expression when m-slfn1 or v-slfn 
were expressed.  An effect on the activity of these promoters was only observed 
when these cells were stimulated with a TLR ligand.  Pam3Cys was used for these 
experiments, as it only activates the MyD88-dependent pathway via TLR2.  This 
requirement for TLR stimulation may be a result of upregulation of proteins required 
for m-slfn function following activation of the MyD88-dependent pathway.  Equally, it 
could be the result of NF-κB-induced upregulation of cyclin D1 transcription, making 
any effects on the promoter activity more noticeable.  Similar to the 18-9 cells, m-
slfn1 caused a reduction in the activity of both the cyclin D1 and E2F-dependent 
promoters, which was reversed by expression of v-slfn. 
The effect of the intermediate and long m-slfns on cyclin D1 transcription has not 
been reported previously.  Similar luciferase assays to those used to study the 
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function of m-slfn1 were performed using m-slfns 3 and 8.  Interestingly, both of these 
proteins increased the level of luciferase expressed from the cyclin D1 and E2F-
dependent promoters, and v-slfn expression further increased this.  In previous 
reports, m-slfn3 decreased cellular proliferation by 30 to 40 % when expressed in a 
transfection model in a colon cancer cell line, and m-slfn8 had no effect on fibroblasts 
when transduced using a lentivirus expression system.  The inconsistencies between 
previous reports and the results presented in this thesis may be a result of cell type 
differences, although further work would be required to fully determine this, including 
a repeat of the assays performed in previous studies. 
Infection of RAW264.7 cells with VACV appeared to increase cyclin D1 expression 
slightly.  However, this is most likely to be a result of slightly decreased levels of 
transcription of the internal control rather than an increase in cyclin D1 transcription.  
Expression of v-slfn from a recombinant virus did not increase the level of cyclin D1 
transcription above that of parental or control virus-infected cells.  However, VACV 
infection dramatically increased the activity of the E2F-dependent promoter.  This 
effect has been attributed to sequestration of the inhibitory pRb protein by Brf1 (Yoo 
et al., 2008), resulting in activation of E2F.  Following Pam3Cys stimulation, the 
activity of this promoter is significantly increased by the expression of v-slfn from a 
recombinant virus over the activity of the promoter in the absence of v-slfn 
expression. 
In the context of a VACV infection, exogenous expression of m-slfns 1, 3 and 8 all 
reduced the activity of the E2F-dependent promoter.  This result is interesting 
considering the observed upregulation of this promoter’s activity by m-slfns 3 and 8 in 
the absence of infection.  It is possible that infection induced expression of proteins 
required for this function of m-slfns 3 and 8 in a similar manner to the observed effect 
of m-slfn1 in RAW264.7 cells in the presence of TLR stimulation only.  More intriguing 
is the inability of v-slfn expression from VACV to counteract the effect of any of the m-
slfns.  One would expect, based on results obtained in the absence of a virus 
infection, that v-slfn expression would increase the level of E2F activity.  Further 
investigation into the effects of VACV on E2F activity, the contribution of cyclin D1 
and the overall contribution of m-slfns and v-slfn will be required. 
Investigation of the effect of m-slfn1 and v-slfn on individual elements from the cyclin 
D1 promoter showed that it has a similar effect on the cyclic AMP response element 
(CRE).  This is one of the elements present in the -271 cyclin D1 promoter, which 
lacks the majority of the promoter sequence but can still be repressed by m-slfn1 
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expression (Brady et al., 2005).  Analysis of other promoters containing the CRE will 
be required to determine if m-slfn1 affects these promoters in a similar manner. 
One hypothesis regarding the mechanism of m-slfn1 action is based on its interaction 
with DnaJB6 (Zhang et al., 2008), which itself interacts with HDACs (Dai et al., 2005).  
Recruitment of HDACs to the cyclin D1 promoter would result in chromatin 
condensation and a subsequent reduction in the activity of the promoter.  Equally, 
sequestration of DnaJB6 in the cytoplasm by v-slfn would prevent this from occurring, 
restoring the activity of the promoter.  However, immunofluorescence showed that 
expression of v-slfn does not sequester DnaJB6, and co-IPs failed to pull down v-slfn 
and DnaJB6 under the conditions tested.  However, the co-IPs did not replicate the 
results shown previously by other groups (Zhang et al., 2008).  Further investigation 
will be required to determine what the effect of v-slfn on these interactions is.  v-slfn 
may disrupt the interaction between m-slfn1 and DnaJB6 without markedly altering its 
subcellular localisation.  To determine this, the co-IPs performed showing the 
interaction between the two proteins will need to be repeated and the results verified, 
and then the effect of v-slfn on this interaction can be determined. 
The potential interaction between v-slfn and MESR6 proteins (Brady, 2004) was 
promising, because the initial characterisation of MESR6 was based on its ability to 
interfere with Ras signalling.  However, neither v-slfn nor m-slfn1 could be co-
immunoprecipitated with h- or m-MESR6 and data presented in this thesis suggest 
that m-slfns act downstream of any of the proteins that MESR6 might affect.   
7.5 Exogenous expression of v-slfn from VACV 
Exogenous expression of v-slfn from the TK locus of VACV resulted in decreased 
virulence in the intranasal model of infection (Gubser et al., 2007).  It is unclear why 
poxviruses would express a protein that decreases virulence, although it could be to 
reduce the effects on the host and thus allow for prolonged survival of the host and 
therefore of the virus.  Otherwise, this effect could be secondary to another function 
of v-slfn, for which a reduction in virulence was an acceptable side-effect.  It is also 
possible that expression from the synthetic early/late promoter resulted in this 
phenotype as an artefact of overexpression. 
The phenotype in vivo could not be attributed to replication efficiency or kinetics of 
virus spread in the initial in vitro experiments performed by Dr Caroline Gubser, 
because viruses expressing v-slfn had similar growth kinetics and formed plaques 
with a comparable size to control and parental viruses.  The only observed difference 
in any in vitro model was in growth kinetics in RAW264.7 cells.  Recovery of viruses 
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expressing either untagged or C-terminally tagged v-slfn following infection at high or 
low multiplicity was approximately half of that recovered from control viruses.  The 
reason for repeating the assay in these cells was that upregulation of m-slfns was 
observed in these cells in response to stimulus with TLR ligands, but a similar 
upregulation was not observed in BS-C-1 cells.  If this reduced level of virus 
replication was replicated in the in vivo models, it could account for the lower levels of 
virus observed in both the primary and secondary sites of infection and the more 
rapid clearance of the virus (Gubser et al., 2007). 
One reason for insertion of v-slfn into the TK locus for the initial studies was that TK 
negative viruses have reduced virulence (Buller et al., 1985) and it was not known 
whether expression of v-slfn would make the virus more virulent.  CMLV is the most 
closely related virus in sequence to VARV (Gubser & Smith, 2002), and so the 
outcome of introduction of CMLV genes into VACV was uncertain.  The attenuation of 
VACV in the system used for these viruses is two-fold.  Firstly, the parental virus 
lacks the soluble human IFNγ receptor, coded for by B8R.  Deletion of this ORF does 
not affect the virulence of the virus in murine models of infection but is predicted, 
based on the species-specificity of the IFNγ receptor, to reduce virulence in human 
infections.  Secondly, deletion of VACV TK, coded for by J2R, also reduces virulence 
(Buller et al., 1985). 
After the demonstration that expression of v-slfn from VACV did not pose a risk, a 
new set of viruses was constructed.  These viruses still lack B8R but express TK.  In 
these viruses, the region corresponding to CMLV 176R (genes B2R and B3R) was 
deleted from VACV and replaced with 176R.  In addition, B2R and B3R were 
removed individually and together. 
Mutants lacking either ORF separately were isolated easily but the double deletion 
was problematic.  However, a modification in strategy resulted in generation of 
double deletion virus.  The replication of these single and double deletion mutants 
showed no differences in plaque size or replication in RAW264.7 cells infected with 
high or low MOIs, unlike the recombinant viruses expressing v-slfn from the synthetic 
early/late promoter, and there was no difference in plaque size. 
The knock-in virus, with 176R under the control of its natural promoter, expressed v-
slfn at a comparable level to that expressed from a CMLV infection, but the TK 
recombinant virus expressed a much higher amount.  This overexpression of the 
protein may have had an effect which led to the phenotype in the in vivo models.  A 
repeat of the in vivo characterisation will be required to determine the effect of v-slfn 
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is when expressed at its natural levels from VACV, and this must be compared to 
viruses either expressing or lacking B2R and/or B3R. 
7.6 Future work 
A critical aspect of the determination of the function of v-slfn and m-slfns will be 
identification and verification of binding partners.  This has already been performed, 
to an extent, for m-slfn1 with the identification of DnaJB6 as a binding partner (Zhang 
et al., 2008).  However, the consequences of this interaction have not been explored, 
and an interaction with other slfns has not been reported.  Data have been presented 
in this thesis showing that inhibitors of HDACs reverse the effect of m-slfn1, which 
was based on the recruitment of HDACs by DnaJB6.  Determining whether v-slfn has 
any effect on this m-slfn1/DnaJB6 interaction and whether v-slfn itself interacts with 
DnaJB6 will be key to understanding the function of both viral and mammalian slfns.  
It will also be important to confirm the effect of m-slfn1 on the acetylation of histones.  
This could be accomplished by performing a chromatin immunoprecipitation in 18-9 
cells using an antibody against acetylated histones, and comparing the amount of 
cyclin D1 promoter pulled down in m-slfn1-positive vs. m-slfn1-negative cells. 
A screen of potential interacting partners will also be performed, not only for v-slfn, 
but for the p26 and slfn core domains of v-slfn and VACV B2 and B3.  This will be 
achieved through tandem affinity purification (TAP)-tagging each of the proteins and 
purifying the tagged proteins.  Any co-purified proteins can then be identified by mass 
spectrometry analysis.  The plasmids for generation of the required stable cell lines 
have been made and tested for expression. 
An analysis of the effect of v-slfn on the cell cycle profile will be required.  Since 
generation of a double-inducible cell line was unsuccessful, a model in which the 
effect on the cell cycle can be determined by transfection will be used.  This has the 
added benefit of being able to use multiple cell lines, such as those expressing low 
levels of DnaJB6 (Zhang et al., 2008).  This will be achieved by co-transfection of 
plasmids expressing v-slfn, m-slfns and membrane-bound GFP (Kalejta et al., 1999), 
which is not lost if cells are permeablised for DNA staining.  Transfected cells can 
then be gated by flow cytometry and their DNA profile can be analysed. 
Further purification of v-slfn for crystallisation and structure determination will also be 
performed, which will include expression and purification of selenomethionine-
labelled protein.  This will be the first structural determination of a slfn protein. 
Analysis of the newly-constructed viruses will also be important to determine whether 
natural levels of v-slfn expression from VACV results in a similar phenotype to the 
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viruses expressing v-slfn from the TK locus.  Studies in vitro have not shown any 
differences between the new recombinant viruses and controls.  However, similar 
studies using the viruses expressing v-slfn from the TK locus showed no differences 
in most models, and only modest differences in growth kinetics in RAW264.7 cells.  In 
vivo analysis will be required to make any comparison, and will focus initially on the 
intranasal model of infection. 
7.7 Final conclusions 
This thesis describes the expression and characterisation of the v-slfn protein, which 
is expressed as a 57-kDa protein from CMLV.  Orthologues are expressed from many 
OPVs but not from VACV or VARV.  It is expressed early and late in infection, and 
localises predominantly to the cytoplasm of infected or transfected cells. 
Expression of v-slfn in cells expressing m-slfn1 results in a reversal of the inhibition of 
cyclin D1 expression.  The mechanism of the inhibition of cyclin D1 expression by m-
slfn1 and the subsequent reversal of this by v-slfn has yet to be elucidated.  
Identification of binding partners for both proteins and determination of the effect of 
each protein on the binding potential of the other will be important for this. 
Several recombinant viruses have been constructed, which will be very important for 
determination of the function of v-slfn in vivo.  These viruses have shown no 
difference in growth kinetics or cell to cell spread in the in vitro models used in this 
study.  Comparison of the phenotype of these viruses and viruses overexpressing v-
slfn from the TK locus will be required. 
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Camelpox virus (CMLV) gene 176R encodes a protein with sequence similarity to murine schlafen
(m-slfn) proteins. In vivo, short and long members of the m-slfn family inhibited T-cell
development, whereas in vitro, only short m-slfns caused arrest of fibroblast growth. CMLV 176
protein (v-slfn) is most closely related to short m-slfns; however, when expressed stably in
mammalian cells, v-slfn did not inhibit cell growth. v-slfn is a predominantly cytoplasmic 57 kDa
protein that is expressed throughout infection. Several other orthopoxviruses encode v-slfn
proteins, but the v-slfn gene is fragmented in all sequenced variola virus and vaccinia virus
(VACV) strains. Consistent with this, all 16 VACV strains tested do not express a v-slfn detected
by polyclonal serum raised against the CMLV protein. In the absence of a small animal model to
study CMLV pathogenesis, the contribution of CMLV v-slfn to orthopoxvirus virulence was
studied via its expression in an attenuated strain of VACV. Recombinant viruses expressing
wild-type v-slfn or v-slfn tagged at its C terminus with a haemagglutinin (HA) epitope were less
virulent than control viruses. However, a virus expressing v-slfn tagged with the HA epitope at its
N terminus had similar virulence to controls, implying that the N terminus has an important
function. A greater recruitment of lymphocytes into infected lung tissue was observed in the
presence of wild-type v-slfn but, interestingly, these cells were less activated. Thus, v-slfn is an
orthopoxvirus virulence factor that affects the host immune response to infection.
INTRODUCTION
Camelpox virus (CMLV) is a member of the genus Ortho-
poxvirus (OPV) of the family Poxviridae, a group of
large double-stranded DNA viruses that replicate in the
cytoplasm (Moss, 2001). Compared with other OPVs,
CMLV is poorly characterized. The genomes of CMLV
strains CMS (Gubser & Smith, 2002) and M-96 (Afonso
et al., 2002) were sequenced and revealed that CMLV is
genetically closely related to variola virus (VARV), the
cause of smallpox (Gubser & Smith, 2002). Like other
OPVs, the CMLV genome has a highly conserved central
region of about 100 kb encoding genes that are mostly
essential for virus replication. In contrast, the genome
termini encode proteins known or predicted to affect virus
virulence or modulation of the host’s immune response.
Among these terminal genes, CMLV strain CMS 176R
encodes a protein with sequence similarity to mammalian
schlafens (slfn) (Gubser & Smith, 2002).
The prototypic member of the slfn family, murine (m-)
slfn1, was discovered by a subtractive hybridization be-
tween transgenic mice in which T-cell maturation was
halted at the CD4+8+ double-positive stage and mice in
which maturation was skewed toward CD4 single-positive
selection (Schwarz et al., 1998). BLAST searches identified a
further eight related mouse genes that are classified as short
(slfn1 and 2), intermediate (slfn3 and 4) or long (slfn5, 8, 9,
10 and 14) m-slfns, depending on their size (Schwarz et al.,
1998; Geserick et al., 2004) (Fig. 1). All m-slfns share a
conserved region that contains a putative divergent ATPase
associated with the cellular activities (AAA) domain (Lupas
& Martin, 2002; Frickey & Lupas, 2004), whereas inter-
mediate and long m-slfns have additional C-terminal
sequences. In vivo, short and long m-slfns inhibit T-cell
development (Schwarz et al., 1998; Geserick et al., 2004),
whereas in vitro, only m-slfn1 caused arrest of fibroblast
growth by inhibition of cyclin D1 (Schwarz et al., 1998;
Geserick et al., 2004; Brady et al., 2005). Additionally, the
expression level of m-slfns is regulated differentially after
3Present address: Division of Cell and Molecular Biology, Faculty of
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London, South Kensington Campus, Exhibition Road, London SW7 2AZ,
UK.
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infection with the intracellular pathogens Brucella (Eskra
et al., 2003) and Listeria (Geserick et al., 2004), suggesting a
role in host defence against pathogens.
This study describes the characterization of CMLV strain
CMS slfn-like protein 176 (v-slfn). Bioinformatic analyses
showed that v-slfn is most closely related to short m-slfns.
However, unlike m-slfn1, v-slfn did not inhibit cell growth
when expressed stably in mammalian cells. Using specific
antiserum, we showed that v-slfn is a predominantly cyto-
plasmic 57 kDa protein that is expressed throughout
infection. Screening of 18 OPVs showed that immunologi-
cally related proteins of similar sizes are expressed by two
cowpox virus (CPXV) strains but not by any of the 16
vaccinia virus (VACV) strains tested. To address whether
v-slfn affected OPV virulence, CMLV v-slfn was expressed
from the thymidine kinase (TK) locus of an attenuated
VACV strain. In vivo, this recombinant virus was attenuated
further compared with controls, and induced different
recruitment of lymphocytes to the site of infection.
METHODS
Cells and viruses. BS-C-1, TK2143 and HeLa cells were grown at
37 uC in a 5% CO2 atmosphere in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Gibco), 100 U penicillin ml21 (Gibco) and
100 mg streptomycin ml21 (Gibco). The source of VACV strain
Western Reserve (WR) vDB8R and CMLV strain CMS was described
previously (Gubser & Smith, 2002; Symons et al., 2002).
Viral growth curves. The one-step growth kinetics of VACV strains
were determined as described previously (Pires de Miranda et al.,
2003).
Plasmids. CMLV strain CMS genomic DNA was used for PCR-
mediated amplification of the v-slfn gene. For construction of recom-
binant viruses, haemagglutinin (HA)-tagged or wild-type (WT) v-slfn
were cloned into pMJ601 (Davison & Moss, 1990) to create plasmids
pMJ601-176RWT, pMJ601-176RNHA and pMJ601-176RCHA. Oligo-
nucleotide primers were forward primers 176FW (59-CCCCCG-
CTCGAGGCCGCCACCATGGCGATGTTTTACGCACACGC-39)
and 176FH (59-CCCCCGCTCGAGGCCGCCACCATGTACCCATA-
CGATGTTCCAGATTACGCTGCGATGTTTTACGCACACGC-39),
Fig. 1. CMLV v-slfn is related to members of
the mammalian slfn family. (a) Diagrammatic
representation of CMLV strain CMS v-slfn
(GenBank accession no. AAG37679), VACV-
WR B2 (YP_233066) and B3 (YP_233067),
and murine slfns m-slfn1 (AAH52869),
m-slfn3 (NP_035539) and m-slfn8 (NP_
853523). Protein sizes (number of aa) are
shown on the right. (b) CLUSTAL W (Thompson
et al., 1994) alignment of the m-slfn1, 3 and 8
conserved region with the C terminus of v-slfn.
Identical residues are shown in black and
residues conserved in two or three out of four
sequences are shown in light or dark grey,
respectively. Amino acid co-ordinates are
indicated. (c) Unrooted phylogenetic tree
showing the relationship of v-slfn from camel-
pox virus (CMLV), cowpox virus (CPXV),
monkeypox virus (MPXV), ectromelia virus
(ECTV), taterapox virus (GBLV) and m-slfns.
Protein sequences were aligned using CLUSTAL
W and an unrooted tree was generated based
on this alignment using PHYLIP on the European
Bioinformatic Institute website (http://www.e-
bi.ac.uk/clustalw/). Bootstrap values from
1000 replica samplings and the divergence
scale (substitutions per site) are indicated.
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and reverse primers 176RW (59-CGCCGCCCCGGGTTAAAATT-
TTATAGATGACACCC-39) and 176RH (59-CGCCGCCCCGGGTT-
AAGCGTAATCTGGAACATCGTATGGGTAAAATTTTATAGATG-
ACACCC-39); restriction sites for XhoI and SmaI, respectively, are
underlined. The influenza virus A/34/PR/8 HA gene was subcloned
from plasmid pGS63 (Smith et al., 1987) into pMJ601 to create
plasmid pMJ601-H1. For bacterial expression, the v-slfn gene was
cloned into the pET28a vector (Novagen) without the stop codon to
obtain a C-terminal histidine (His) tag, creating pET28-176CHis.
Oligonucleotide primers were 176FB (59-CCCCCCCATGGCGATG-
TTTTACGCACACGC-39) and 176RB (59-CCCCCCTCGAGAAAT-
TTTATAGATGACACCC-39); restriction sites for NcoI and XhoI,
respectively, are underlined. For production of stable cell lines, the v-
slfn gene encoding a C-terminal FLAG tag was cloned into the T-REx
tetracycline-inducible expression vector pcDNA4/TO (Invitrogen)
creating pcDNA4/TO-v-slfn-FLAG. Oligonucleotide primers were
CMLV176 forward (59-CGCTCTAGAATGGCGATGTTTTACGCA-
39) and CMLV176 reverse (5-CCCAAGCTTTTACTTGTCGTCGTC-
GTCCTTGTAGTCAAATTTTATAGATGACAC-39). Underlined and
bold nucleotides represent the restriction site for HindIII and FLAG
tag, respectively. The fidelity of all PCR-generated DNA sequences was
confirmed by sequencing.
Generation of v-slfn tetracycline-inducible stable cells. NIH3T3
murine fibroblasts were transfected with linearized pcDNA4/TO-v-
slfn-FLAG and pcDNA6/TR vectors (Invitrogen) and cell lines were
selected under antibiotic selection with 3 mg blasticidin ml21 and
750 mg zeocin ml21 for 3 weeks. Clone B7 was selected as the line
exhibiting no basal v-slfn expression and the highest tetracycline
inducibility.
Production of rabbit polyclonal antiserum to v-slfn. Plasmid
pET28-176CHis was transformed into Rosetta-gami Escherichia coli
cells (Novagen) and cultured in Luria–Bertani (LB) medium at 37 uC
until the OD600 reached 0.6. Protein expression was induced by the
addition of 1 mM IPTG for 3 h at 37 uC. Cells were lysed in
BugBuster protein extraction reagent (Novagen) containing protease
inhibitor cocktail set III (Calbiochem). The bacterial lysates were
sonicated and the insoluble material was removed by centrifuga-
tion at 10 000 g for 10 min. v-slfn was purified from insoluble
inclusion bodies by washing four times in wash buffer (20 mM
Tris pH 7.5, 10 mM EDTA, 1% Triton X-100). SDS-PAGE and
Coomassie blue staining confirmed that v-slfn was the major
protein present (data not shown). A polyclonal rabbit antiserum
was raised against v-slfn by Harlan Seralabs. To reduce cross-
reactivity of the antiserum with denatured mammalian proteins,
the antiserum was incubated with HeLa cell proteins. HeLa cells
(36108) were lysed using acetone and proteins were collected by
centrifugation and dried overnight at room temperature. Antiserum
diluted 1 : 10 in PBS was added to the precipitate and incubated
with shaking for 48 h. The protein precipitate was removed by
centrifugation and filtration, and the supernatant was used for
immunoblotting.
Immunoblotting. BS-C-1 cells were mock-infected or infected at
5 p.f.u. per cell for the indicated time and lysed in radioimmuno-
precipitation assay (RIPA) buffer. Protein samples were resolved by
SDS-PAGE, transferred to a nitrocellulose membrane and probed
with a-v-slfn polyclonal rabbit antiserum (1 : 100), rat monoclonal
antibody (mAb) 15B6 against the VACV F13 protein (1 : 100; Schmelz
et al., 1994), mouse a-FLAG M2 mAb (1 : 1000; Sigma-Aldrich) or
mouse a-HA mAb (1 : 1000; Covance). Secondary antibodies were
horseradish peroxidase (HRP)-conjugated goat anti-rabbit, anti-rat
and anti-mouse IgG (1 : 2000; Sigma-Aldrich). Bound Ab was
detected using Enhanced Chemiluminescence Plus Western blotting
detection reagents (Amersham Biosciences).
Immunofluorescence. HeLa cells were grown on sterile glass
coverslips (borosilicate glass; BDH) in six-well plates and intracellular
proteins were stained as described previously (Law et al., 2004).
Samples were examined with a Zeiss LSM 510 laser scanning confocal
microscope. Images were captured and processed using Zeiss LSM
Image Browser version 3.2. Primary Abs used were a-v-slfn polyclonal
antiserum (1 : 200) and a-HA mAb (1 : 500).
Construction of recombinant viruses. VACV vDB8R was used as
the parental virus for construction of recombinant VACV expressing
WT v-slfn, HA-tagged v-slfn or influenza virus HA from the TK locus.
CV-1 cells were infected with vDB8R at 0.1 p.f.u. per cell for 1 h and
then transfected with pMJ601, pMJ601-176RWT, pMJ601-176RNHA,
pMJ601-176RCHA or pMJ601-H1. Virus was harvested from infected
cells 3 days later and recombinant TK2 viruses were selected by
growth on TK2143 cells in the presence of 25 mg 5-bromodeoxy-
uridine (BUdR) ml21 and chromogenic substrate X-Gal, as described
previously (Chakrabarti et al., 1985). Blue plaques were picked,
plaque purified and the presence of v-slfn was confirmed by PCR and
immunoblotting. Resulting viruses were named vDB8R, v176-WT,
v176-NHA, v176-CHA and vH1, respectively.
Mouse intradermal and intranasal model of infection. The
intradermal inoculations were carried out as described previously
(Tscharke & Smith, 1999). For the intranasal model, groups of female
BALB/c mice (6–8 weeks old) were infected intranasally with 46106
or 107 p.f.u. sucrose-purified virus in 20 ml PBS, and their weight and
signs of disease were scored daily as described previously (Alcami &
Smith, 1992). Mice infected with 46106 p.f.u. vH1, v176-WT or
v176-NHA were sacrificed at 3, 5 and 7 days post-infection (p.i.).
Cells present in the alveoli were removed by bronchoalveolar lavage
(BAL) using BAL solution (12 mM lidocaine and 5 mM EDTA in
Earl’s balanced salt solution), centrifuged at 800 g, resuspended in
erythrocyte lysis buffer (0.829% NH4Cl, 0.1% KHCO3, 0.0372%
Na2EDTA) for 3 min and kept on ice in RPMI/10% FBS. Lung cells
were obtained from lung homogenates by enzymic digestion, lysis of
erythrocytes and centrifugation through 20% Percoll (Sigma-
Aldrich), as described previously (Clark et al., 2006). Live cells in
BAL and lung single-cell suspensions were counted, blocked and
stained with appropriate combinations of fluorescein isothiocyanate-,
phycoerythrin- or tricolour-labelled a-CD25, a-CD69, a-CD3, a-CD8,
a-CD4, B220 or a-DX5 and the relevant isotype mAb controls (BD
Biosciences) as described previously (Clark et al., 2006). The distri-
bution of cell-surface markers was determined on a FACScan flow
cytometer with CellQUEST software (BD Biosciences). A lymphocyte
gate was used to analyse data from at least 20 000 events. The titres of
virus in tissues were determined as described previously by plaque
assay on duplicate monolayers of TK2143 cells (Reading & Smith,
2003).
Statistical analysis. Student’s t-test (two-tailed) was used to test the
significance of the results.
RESULTS
CMLV protein 176 (v-slfn) is related to members of
the slfn family
The characterization of murine slfn1 (m-slfn1), the
prototype of the slfn protein family, led to the identifica-
tion of related sequences in several OPVs (Schwarz et al.,
1998). Subsequent sequencing of CMLV identified another
v-slfn orthologue (protein 176, called v-slfn hereafter)
(Gubser & Smith, 2002). CMLV v-slfn was predicted to
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encode a 502 aa protein with an N-terminal domain that
has 22% amino acid identity (approx. 41% similarity) to
an uncharacterized family of baculovirus proteins, collec-
tively known as p26 (Liu et al., 1986), and a C-terminal
domain related to the conserved region of m-slfns (Fig. 1).
v-slfn is poorly conserved amongst chordopoxviruses, with
only members of the OPV genus encoding putative v-slfn
counterparts; however, a p26-like domain is present in
certain entomopoxvirus proteins. Melanoplus sanguinipes
entomopoxvirus (MSEV) ORF 237 encodes a protein with
43% identity and 61% similarity to the first 197 aa of
CMLV v-slfn, although this sequence is absent in Amsacta
moorei entomopoxvirus (AMEV) (Afonso et al., 1999;
Bawden et al., 2000; Tulman et al., 2006).
Other OPVs predicted to encode full-length v-slfns are
CPXV, ectromelia virus (ECTV), monkeypox virus (MP-
XV) and taterapox virus (GBLV) (http://www.poxvirus.
org), whereas in VACV and VARV, the corresponding gene
is broken into fragments. All full-length OPV v-slfns share
between 84 and 100% amino acid identity (93–100%
amino acid similarity) with CMLV strain CMS v-slfn.
Fig. 1(a) shows a depiction of CMLV v-slfn protein and its
relationship with the v-slfn fragments from VACV strain
Western Reserve (WR) and a representative member of
each of the m-slfn subgroups. Altogether, CMLV v-slfn is
most similar to mammalian short m-slfns (m-slfn1 and 2),
lacking the C-terminal extensions of intermediate (m-slfn3
and 4) and long (m-slfn5, 8, 9, 10 and 14) m-slfns. Fig. 1(b)
shows an alignment of the conserved region of m-slfns with
the C terminus of v-slfn. In this region, v-slfn shares
between 24 and 30% identity (42–60% similarity) with m-
slfns. Notably, v-slfn lacks similarity to the first 27 aa of m-
slfn1, which are essential for m-slfn1-mediated inhibition
of cell growth of fibroblasts (Fig. 1b; Geserick et al., 2004).
The unrooted tree in Fig. 1(c) shows the phylogenetic
relationships of OPV v-slfn proteins with their mammalian
counterparts. Due to their high sequence similarity, all
OPV v-slfns group closely together. Compared to mam-
malian counterparts, v-slfns are most closely related to
short m-slfns (m-slfn1 and 2) and least related to long m-
slfns (m-slfn5, 8, 9, 10 and 14), due to their lack of C-
terminal extension and also because of a lower degree of
similarity within the m-slfn conserved region (Fig. 1b).
Fig. 1(c) also highlights the reported divergence of m-slfn5
protein sequence (Geserick et al., 2004) and that of the
newly identified m-slfn14 (GenBank accession no. XP_
899217) to other long m-slfns.
Expression of v-slfn in fibroblasts
v-slfn is most similar to short m-slfns, of which m-slfn1
inhibits fibroblast cell growth in vitro (Schwarz et al., 1998;
Brady et al., 2005). To investigate whether v-slfn had a
similar effect on cell growth, a C-terminally FLAG-tagged
v-slfn was expressed stably in NIH3T3 cells using the T-
REx inducible system (Methods). Two independent clones
(clone B7; Fig. 2 and data not shown) were induced for
expression of v-slfn and after 24, 48 and 72 h the number
of viable cells was assessed (Fig. 2a). Although v-slfn was
expressed after addition of tetracycline (Fig. 2b, arrow),
there was no difference in cell proliferation between cells
that did or did not express v-slfn, showing that unlike
m-slfn1, but like intermediate long m-slfns (Schwarz et al.,
1998; Geserick et al., 2004; Brady et al., 2005), v-slfn does
not affect fibroblast cell growth in vitro.
Detection and characterization of v-slfn
To characterize v-slfn, the CMLV 176R gene was expressed
in E. coli with a C-terminal His tag, and the recombinant
protein was purified from inclusion bodies and used to
raise a rabbit a-v-slfn polyclonal Ab (Methods). In
immunoblots, the a-v-slfn Ab detected an approximately
57 kDa protein in cells infected with CMLV (Fig. 3a, b) or
with a recombinant VACV expressing CMLV v-slfn with or
without an HA tag (Fig. 3b, c). v-slfn was not present in
mock-infected cells.
The time of expression of the v-slfn protein during
infection was investigated in CMLV-infected cells
(Fig. 3a). v-slfn was expressed from 2 h p.i. and its
expression levels increased until 16 h p.i. The protein was
also detected at 16 h p.i. in cells in the presence of cytosine
arabinoside (AraC), an inhibitor of DNA replication and
thereby of virus intermediate and late gene expression,
indicating that v-slfn was expressed early during infection.
Fig. 2. v-slfn effect on NIH3T3 cell growth. (a) NIH3T3 cell line
(B7) expressing v-slfn stably upon tetracycline induction was
seeded at a density of 5105 cells per 100 mm dish in triplicate
and, after 24 h, expression of v-slfn was induced or not by addition
of tetracycline (0.5 mg ml”1). Cells were cultured over 72 h,
harvested by trypsinization and counted in duplicate. (b) Cell
lysates from (a) were analysed for expression of v-slfn using an a-
FLAG mAb (arrow). Data are representative of three independent
experiments. Positions of molecular size markers (kDa) are
indicated.
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The higher level of expression of v-slfn in the absence of
AraC indicates that the protein continues to be made after
DNA replication has started. In contrast, a 37 kDa protein,
which is the orthologue of VACV late protein F13, was not
expressed in the presence of AraC (Fig. 3a).
Sequence data predict that a v-slfn is expressed by some
OPVs; however, the v-slfn ORF is broken in sequenced
VACV and VARV strains (http://www.poxvirus.org). To
analyse whether other VACV and CPXV strains express a
full-length v-slfn, BS-C-1 cells were infected with 16 strains
of VACV and two strains of CPXV, and cell extracts were
analysed by immunoblotting (Fig. 3b). This showed that
none of the VACV strains examined expressed a protein
detected by the a-v-slfn Ab. However, in accord with
available sequence data, v-slfn was detected in cells infected
with CPXV strain Brighton Red (BR). Similarly, elephant-
pox virus (EP2), another CPXV strain, also expressed a
v-slfn counterpart. For both CPXV strains, the proteins
migrated slightly faster than CMLV v-slfn, despite having
a comparable predicted molecular mass (CPXV strain BR;
http://www.poxvirus.org). Both CPXV v-slfns were
detected at lower levels (Fig. 3b); however, this might be
due to a-v-slfn Ab specificity. The recognition of a 37 kDa
protein (VACV F13 orthologue) by an F13-specific mAb
confirmed that all cells had been infected (Fig. 3b, lower
panels). Note that the F13 orthologue in buffalopox virus
(BPXV)-infected cells was only detected at later times p.i.
(data not shown) and that a non-specific doublet is present
in mock-infected and infected cells. Thus, v-slfn is an early
and late protein that is encoded by a full-length ORF in
several OPVs, but is not expressed by any of the 16 VACV
strains tested, suggesting that it is either absent or broken
into smaller ORFs, as is the case for VACV strains
Copenhagen (COP) and WR.
Construction of recombinant VACV expressing
CMLV v-slfn
A VACV strain expressing full-length v-slfn was not
identified, therefore the function of v-slfn was studied
using a recombinant VACV expressing the CMLV v-slfn.
An attenuated VACV strain lacking the B8R gene encoding
the gamma interferon-binding protein (vDB8R) (Symons
et al., 2002) was selected as the parent virus to meet
biosafety concerns that insertion of the CMLV 176R gene
into VACV might increase virulence. In addition, the
CMLV 176R gene was inserted into the TK locus of vDB8R
to provide a second attenuating mutation (Buller et al.,
1985). v-slfn was expressed either without (v176-WT) or
with an N- or C-terminal HA tag (v176-NHA and v176-
CHA, respectively) under the control of a synthetic early
and late promoter. v-slfn expression by these viruses was
observed from 2 h p.i., similar to the expression pattern
seen in CMLV-infected cells (Fig. 3a and data not shown).
A control virus expressing the HA from influenza A/PR/8/
34 (Bennink et al., 1986) from the same locus and using the
same promoter was also constructed (vH1). The genotype
Fig. 3. Characterization of v-slfn by immunoblotting. (a) HeLa cells
were either mock-infected (M) or infected with CMLV strain CMS
at 5 p.f.u per cell and harvested when indicated. + indicates that
AraC was present throughout infection. Cell extracts were
analysed by immunoblotting using either a-v-slfn or a-F13 Abs.
(b) Expression of v-slfn protein in OPVs. Monolayers of BS-C-1
cells were mock-infected or infected with 5 p.f.u. of the indicated
virus per cell, harvested at 6 h p.i. and cell extracts were analysed
by immunoblotting using either a-v-slfn or a-F13 Abs. CMLV,
camelpox virus; VACV, vaccinia virus; WR, Western Reserve;
Patw, Patwadangar; King’s Ins, King’s Institute; Tashk, Tashkent;
COP, Copenhagen; CPXV, cowpox virus; EP2, elephantpox virus-
2; BPXV, buffalopox virus; RPXV, rabbitpox virus. (c) HeLa cells
were either mock-infected or infected with 10 p.f.u. of the
indicated VACV per cell, harvested 16 h p.i. and cell extracts
were analysed by immunoblotting. In all panels, the positions of
molecular size markers (kDa) are indicated.
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of recombinant viruses was confirmed by PCR (data not
shown). HeLa cells were mock-infected or infected with
vDB8R, vH1, v176-WT, v176-NHA or v176-CHA, and
expression of v-slfn was detected using a-v-slfn Ab. Fig. 3(c)
shows that v176-WT, v176-CHA and v176-NHA express v-
slfn whereas, vDB8R and vH1 do not (top panel). Infection
was confirmed by detection of the VACV F13 orthologue in
all samples in parallel blots (Fig. 3c, bottom panel). The blots
were then stripped and reprobed with an a-HAmAb (Fig. 3c,
middle panel). This detected the HA-tagged protein
expressed by v176-CHA and 176-NHA. There was, however,
a reproducible large difference in level of detection between
the two samples, suggesting that the N terminus of N-
terminally tagged v-slfn is removed by proteolytic cleavage.
To determine whether expression of v-slfn altered virus
replication, the growth properties of vDB8R, vH1, v176-
WT, v176-NHA and v176-CHA were analysed. After
infection of BS-C-1 cells at 10 p.f.u. per cell for 24 or
48 h, the total virus yield of all recombinant viruses was
indistinguishable (Supplementary Fig. S1, available in JGV
Online). Similarly, VACV plaque morphology and size
were unaltered by expression of v-slfn in BS-C-1 (Supple-
mentary Fig. S2), RK13 and TK
2143 cells (data not shown).
Therefore, v-slfn does not affect virus growth or plaque size
when expressed by recombinant VACV under the condi-
tions tested.
Subcellular localization of v-slfn
To investigate the subcellular localization of v-slfn, HeLa
cells were either mock-infected or infected with CMLV
strain CMS, VACVWR or v176-CHA for 6 h (Fig. 4). v-slfn
was detected as a predominantly cytoplasmic protein with
no obvious localization to any organelles (Fig. 4c–e) and
similar localization was detected at later time points (data
not shown). No signal was present in mock-infected cells
(Fig. 4a), and only a weak background was present in cells
infected with VACV WR (Fig. 4b). The specificity of the v-
slfn antiserum was confirmed by co-staining cells infected
with v176-CHA with a-v-slfn Ab (Fig. 4d) and a-HA mAb
(Fig. 4e) and merging the images (Fig. 4f), showing co-
staining with these two Abs. v-slfn localization was also
analysed in NIH3T3 cell lines expressing v-slfn using an a-
FLAG mAb (data not shown), and after transient transfec-
tion of HeLa cells with the mammalian expression vector
pCI alone or pCI expressing v-slfn with or without an HA
tag. v-slfn was visualized with either a-v-slfn antiserum or a-
HA mAb. All approaches showed the same predominantly
cytoplasmic localization for v-slfn, ruling out the possibility
that other factors associated with virus infection contributed
to v-slfn localization (data not shown).
Expression of v-slfn attenuates VACV in the
murine intranasal model
The virulence of recombinant VACV that does or does not
express v-slfn was examined in the murine intradermal and
intranasal models of infection. In the intradermal model,
no difference in lesion size was observed between recom-
binant VACV expressing v-slfn or not (Supplementary
Fig. S3, available in JGV Online). In the murine intranasal
model of infection, mice infected with 107 p.f.u. vH1, v176-
WT, v176-NHA or v176-CHA all showed loss of body
weight (Fig. 5a, upper panel) and signs of illness (Fig. 5a
lower panel); however, from day 4 p.i. there was a
significant attenuation (P,0.05) of v176-WT and v176-
CHA compared with vH1 and v176-NHA. In addition,
mice infected with v176-WT or v176-CHA started to
recover sooner after infection (day 6, Fig. 5a) compared
with mice infected with vH1 and v176-NHA. This showed
that (i) expression of v-slfn attenuated VACV in this
model, and (ii) the function of v-slfn was affected by the
HA tag at the N terminus. The expression of the influenza
virus H1 HA from the TK locus did not alter VACV
virulence in this model (data not shown).
Fig. 4. Subcellular localization of v-slfn. HeLa cells were either (a)
mock-infected or infected with 5 p.f.u. per cell of (b) VACVWR, (c)
CMLV-CMS or (d–f) v176-CHA for 6 h and were analysed by
immunofluorescence using a-v-slfn (a–d) or a-HA (e) Abs. (f)
Shows a merged image of (d) and (e). Bars, 20 mm.
C. Gubser and others
1672 Journal of General Virology 88
To study v-slfn-mediated virus attenuation, recombinant
VACV expressing an irrelevant protein (vH1) or non-
attenuating v-slfn (v-176NHA) were used as controls. Mice
were infected with 46106 p.f.u. vH1, v176-WT or v176-
NHA (Fig. 5b) and virus titres were measured in lungs
(Fig. 6a) and spleens (Fig. 6b) of infected animals. Initially,
all viruses replicated similarly in the lungs (day 3), but from
day 5 there was a reduction in virus titre after infection with
v176-WT, compared with v176-NHA and vH1. This differ-
ence was significant at day 7 p.i. for both control groups
(Fig. 6a). In the spleen, the v176R-WT titre was below the
level of detection at days 3 and 7 p.i., unlike vH1 and v176-
NHA, indicating that v176R-WT spread to this organ later
and was cleared earlier than control viruses (Fig. 6b).
The early clearance of virus after infection with v176-WT
compared with control groups suggested a more effective
antiviral host response, and therefore the cellular inflam-
matory response in lungs was analysed by flow cytometry
(Fig. 7). At days 3, 5 and 7 p.i., cells recovered from BALs
and lung cells from mice infected with v176-WT contained
an increased number of lymphoid cells compared with
mice infected with control viruses, and this difference was
significant at day 7 p.i. in BALs (Fig. 7a) and lungs (Fig. 7b).
To test whether this increase in lymphoid cells was due to
an enhanced recruitment of a particular lymphoid subset,
the percentage of CD4+ and CD8+ T lymphocytes, B220+
B lymphocytes and DX5+ natural killer (NK) cells present
in lungs was analysed, but no significant difference between
groups of mice was found (data not shown). Next, the
activation of CD3+ T cells was investigated using the
activation marker CD69+. This showed that although on
day 7 p.i. there were more lymphocytes recruited to lungs
infected with v-176WT compared with infection with vH1
or v176-NHA, CD3+ T cells were less activated (Fig. 7c,
left panel), and this was reflected by a lower level of the
activation marker CD69+ on both CD4+ and CD8+
lymphocytes (Fig. 7c, right panel). There was no difference
between groups in CD3+ CD69+ lymphocytes at days 3
and 5 p.i. (data not shown). Another activation marker,
Fig. 5. Virulence assay using the intranasal model of infection.
Groups of five BALB/c mice were mock-infected or infected with
(a) 107 or (b) 4106 p.f.u. of the indicated purified viruses. Mice
were weighed daily, and results are the mean percentage weight
change of each group ± SEM compared to the weight on the day
of infection (upper panels). Animals were monitored daily for signs
of illness, scored 1 to 4 (Alcami & Smith, 1992) (lower panels).
Data are expressed as the mean± SEM. P values were determined
using the Student’s t-test and indicate the mean percentage
weight changes or signs of illness that were significantly different
between groups.
Fig. 6. Virus titres of vH1, v176-WT and v176-NHA in (a) lungs
and (b) spleens. Groups of five mice were infected intranasally with
4106 p.f.u. of the indicated virus, and the lungs and spleen were
harvested at days 3, 5 and 7 p.i. Virus titres were determined by
plaque assay on TK”143 cells. Virus titres are expressed as the
mean log10 p.f.u. per organ ± SEM. P values were determined
using Student’s t-test and indicate the mean virus titres that were
significantly different between mice infected with v176-WT and
mice infected with v176-NHA and vH1. Broken line indicates the
minimum detection limit of the plaque assay.
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CD25+, was used in a further experiment and showed that
at days 7 and 10 p.i. there were also less CD25+ CD4+ and
CD25+ CD8+ lymphocytes in BALs of mice infected with
v-176WT compared with control groups, although this
difference was only significant for CD8+ lymphocytes at
day 7 and CD4+ lymphocytes at day 10 (Fig. 7d).
DISCUSSION
This paper provides a characterization of the CMLV-CMS
176R gene, which is shown to encode a predominantly
cytoplasmic 57 kDa protein that is expressed both early and
late in infection. v-slfn shows sequence similarity to the
mammalian schlafen protein family and is most closely
related to the short members, m-slfn1 and 2. Construction
of an inducible cell line that expresses v-slfn showed that,
unlike m-slfn1, v-slfn did not inhibit NIH3T3 cell growth.
This is probably due to v-slfn lacking a region with
sequence similarity to m-slfn1 aa 1–27 that is essential for
m-slfn1-mediated inhibition of fibroblast cell growth
(Geserick et al., 2004).
The m-slfn proteins are expressed differentially in activated
T cells and macrophages, and regulate T-cell development
and differentiation (Schwarz et al., 1998; Geserick et al.,
2004). Since there is no established small animal model for
studying CMLV pathogenesis, we screened several VACV
strains, hoping to identify a strain that expresses a full-
length v-slfn. However, none of the 16 strains examined
expressed a v-slfn orthologue suggesting that, like VACV
strain COP, the v-slfn ORF is broken into smaller fragment
in these viruses. Sequence data from VACV strains WR,
MVA and Lister are consistent with these observations.
Therefore, the function of v-slfn in vivo was investigated
using a recombinant VACV expressing untagged v-slfn
(v176WT) or v-slfn with a C-terminal (v176-CHA) or N-
terminal (v176-NHA) HA tag. Expression of WT or tagged
v-slfn by recombinant VACV did not affect virus virulence
in the intradermal model of infection. However, expression
of WT v-slfn or C-terminally tagged v-slfn attenuated
VACV in a murine intranasal model, resulting in reduced
weight loss and more rapid recovery compared with
control groups. In contrast, N-terminally tagged v-slfn
did not attenuate VACV in this model, showing that v-slfn
function was affected by addition of an HA tag on the N
terminus, and suggesting that this part of the protein is
important for function. The altered function of N-
terminally tagged v-slfn is possibly due to cleavage of a
small part of the N terminus of the protein after addition of
the HA tag, as shown by immunoblotting (Fig. 3c). v-slfn-
mediated attenuation in vivo was characterized by a
significantly reduced virus titre in lungs at day 7 p.i.
compared with vH1 and v-176NHA, although at day 3 the
titres were equivalent. This shows that expression of
v-slfn did not prevent establishment of infection or virus
replication, but probably accelerated virus clearance by the
immune system. Consistently, v176-WT spread to the
spleen was delayed and v176-WT was cleared more rapidly
from this organ compared with control groups.
Characterization of the cellular inflammatory response in
the lungs showed that v176-WT infection was characterized
by a more pronounced recruitment of lymphocytes that
was most striking at day 7 p.i. However, in lung cells, no
particular lymphoid subset (CD4+ or CD8+ T cells, B cells
or NK cells) was solely responsible for this increase. The
mechanism by which v-slfn promotes such vigorous
lymphocyte recruitment is under investigation. At day
7 p.i., when mice infected with v176-WT had almost
recovered, but mice infected with vH1 and v176-NHA were
Fig. 7. Analysis of cellular inflammatory response by flow cyto-
metry. (a, c and d) BAL and (b) lung cells were recovered on the
indicated day (a, b and d) or at day 7 (c) p.i. (a, b) Lymphoid
population was determined by its characteristic forward and side
scatter profiles. (c, d) Percentage of cells expressing activation
markers CD69+ or CD25+ in CD3+, CD4+ and CD8+ cell
populations. Data shown are the mean percentage from five or six
mice± SEM. P values were determined using Student’s t-test and
indicate the mean data that were significantly different between
mice infected with v176-WT, mice infected with v176-NHA and
mice infected with vH1. To obtain sufficient cells in BALs, cells
from two mice were pooled.
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still getting sicker, the CD3+ lymphocytes present in the
BALs of mice infected with v176-WT showed a reduced
expression of activation markers CD69 and CD25, com-
pared with control groups. This was consistent with the
greater and earlier recruitment of lymphocytes, so that the
immune response was already declining by day 7.
It is unclear why a poxvirus would encode a protein that
decreases virus virulence. One possibility is to prevent the
virus from overwhelming its host too quickly. Another is
that the v-slfn protein affects virus virulence differently in
other models of infection and, consistent with this, v-slfn
did not affect virulence in the intradermal model (Supple-
mentary Fig. S3, available in JGV Online). VACV WR gene
B15R, which encodes a soluble interleukin-1b receptor, is
another example of a gene that decreases viral virulence in
one model but not others (Alcami & Smith, 1992, 1996;
Spriggs et al., 1992; Tscharke et al., 2002; Staib et al., 2005).
In summary, we have identified and characterized CMLV
strain CMS 176R and shown that it encodes an intracellular
protein, which attenuates VACV in vivo but does not affect
virus replication or plaque morphology in vitro. v-slfn
shares sequence similarity with members of the m-slfn
family of mammalian proteins, and recent reports suggest
that these play a role in the modulation of the innate and
adaptive immune responses against pathogens (Schwarz et
al., 1998; Eskra et al., 2003; Geserick et al., 2004). The exact
role of v-slfn within the context of a viral infection remains
to be elucidated.
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